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1. Aim of the review 
This review focuses on the pharmacokinetics, safety and effectiveness of adjusted-dose 
protease inhibitors with rifampicin. 
2. Introduction 
Globally Sub-Saharan Africa carries the biggest burden of patients infected with human 
immunodeficiency virus (HIV).(l) Tuberculosis is the most common opportunistic infection 
in patients infected with HIV.(2) Although antiretroviral therapy (ART) has decreased the 
burden of tuberculosis in HIV-infected patients, the incidence of tuberculosis remains higher 
than in the general population.(3) HIV-tuberculosis co-infection requires dual treatment 
with ART and tuberculosis treatment, exposing patients to multiple drug-drug interactions. 
As ART programs mature, more patients will be changed from first-line to second-line ART. 
In South Africa, the adult second-line ART consists of the protease inhibitor (PI) 
lopinavirfritonavir (LPV fr) and 2 nucleoside reverse transcriptase inhibitors (NRTls). This 
review will focus on the data of the drug-drug interactions between the Pis and rifampicin, 
with an emphasis on LPV fr. 
3. Protease inhibitor-rifampicin interaction 
Rifampicin is a potent inducer of several drug metabolizing enzymes, particularly of the 
cytochrome P450 (CYP) 3A4 enzyme.(4) The rifampicin mediated increase in CYP450 enzyme 
protein synthesis is a complex process that is mediated by the pregnane X nuclear receptor 
(PXR). Rifampicin binds to PXR forming a rifampicin-PXR complex, which in turns forms a 
complex with the retinoid X receptor (RXR). The rifampicin-PXR-RXR complex binds to a 
deoxyribonucleic acid (DNA) upstream promoter element, recruits a co-activator that binds 
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to the TATA box binding protein (TBP); and ultimately enhances CYP3A4 DNA 
transcription.(4) The potent induction effect of rifampicin is not confined to CYP450 
enzymes, but also increases the expression of transporter proteins, such as p-glycoprotein 
(p-gp). P-gp is a transmembrane efflux protein that is expressed in the liver, small intestine 
and other organs that actively transport xenobiotics out of the organ cells.(5) Pis are 
substrates of both CYP3A4 and p-gp. Rifampicin induction of CYP3A4 and p-gp reduces 
plasma PI trough concentrations by more than 90%, reducing PI efficacy.(6) 
The PI-rifampicin interaction can be avoided by replacing rifampicin with the rifamycin 
rifabutin, which has a minimal inducing effect on CYP3A4.(6) High-income countries 
therefore replace rifampicin with rifabutin in patients on PI-based ART who have 
tuberculosis. However, rifabutin is not currently used in developing countries for several 
reasons. First, Pis inhibit the metabolism of rifabutin resulting in a marked increase in the 
area under the plasma concentration-time curve (AUC) of rifabutin and its metabolite 25-0-
des-acetyl rifabutin.(6) Rifabutin therefore requires a dose reduction and a decrease in 
dosing frequency from daily to 3 times a week, which will be difficult to implement in clinics 
where standard tuberculosis drugs are administered daily. Second, current tuberculosis 
treatment programs dose standardized tuberculosis treatment regimens in fixed-dosed 
tablets and rifabutin dosing will require separate dosing of individual anti-tuberculosis 
drugs. Last, rifabutin is priced out of range for use in most developing countries. Therefore 
developing countries are currently compelled to use rifampicin-based tuberculosis 
treatment. 
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4. Adjusted doses of protease inhibitors in adults when dosed with 
rifampicin 
In order to compensate for the induction of PI metabolism by rifampicin, two dosing 
strategies have been explored. The dose of the PI can be increased or alternatively the dose 
of co-administered ritonavir (RTV), used for its "boosting" effect on other Pis, can be 
increased. RTV is a potent inhibitor of CYP450 enzymes, including CYP3A4, and can produce 
substantial increases in the plasma concentrations of other Pis that are CYP3A4 
substrates.(7) 
5. Objectives of literature review 
The primary objective of this review is to review the literature of dose adjusted Pis with 
rifampicin, focusing on the pharmacokinetics, safety and effectiveness of the PI. The 
secondary objective is to determine the gaps in current knowledge and the contribution the 
study will make to existing knowledge. 
6. Literature review methodology 
6.1. Search strategy 
The electronic journal database PubMed, Cochrane Database of Systematic Reviews and 
Google Scholar was searched from 1994 onwards, to capture all studies from 1995 when the 
Pis were approved by the United States Food and Drug Agency (FDA). We also searched the 
electronic conference databases of the International Workshop on Clinical Pharmacology of 
HIV Therapy, Conferences on Retroviruses and Opportunistic Infections and International 
AIDS Conference. Our search strategy included the following medical subject heading 
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(MeSH) terms: protease inhibitors, lopinavir, atazanavir, saquinavir, nelfinavir, indinavir, 
darunavir, amprenavir tipranavir and rifampin. We included all fields in our search but 
limited our search to humans older than 18 years. The search command was "HIV Protease 
Inhibitors"[Mesh] OR "lopinavir"[Mesh] OR "atazanavir"[Supplementary Concept] OR 
"saquinavir"[Mesh] OR "nelfinavir"[Mesh] OR "indinavir"[Mesh] OR 
"darunavir"[Supplementary Concept] OR "amprenavir"[Supplementary Concept] OR 
"fosamprenavir"[Supplementary Concept] OR "tipranavir"[Supplementary Concept] AND 
"rifampin"[Mesh] AND ("humans"[MeSH Terms] AND "adult"[MeSH Terms)). We also 
scrutinized the citations of reviewed articles for any references not identified in our search. 
6.2 Eligibility criteria 
6.2.1 Types of studies 
Clinical trials, randomized or non-randomized trials, as well as observational studies were 
included. 
6.2.2 Types of participants 
Studies of healthy volunteers or HIV-infected patients were included. HIV-infected patients 
could be ART-naive or ART-experienced. 
6.2.3 Exposure of interest 
The exposure of interest was rifampicin co-administered with a PI. Rifampicin could be part 
of rifampicin-based tuberculosis therapy or be administered on its own. The PI could be part 
of an ART-regimen or administered on its own. 
6.2.4 Outcome measures 
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Key plasma pharmacokinetic parameters of the PI administered with and without rifampicin 
were extracted. The key pharmacokinetic parameters included trough concentrations and 
AUC. All adverse events that occurred in participants on the rifampicin-PI were reviewed, 
but the focus was on hepatotoxicity. 
6.3 Quality criteria 
Sixteen studies met the inclusion criteria. Fourteen studies were prospective clinical trials, 
of which 8 were performed in healthy volunteers; and 2 were retrospective studies. All the 
prospective clinical trials were open-label studies and some of the treatment arms were 
randomized to different dosing approaches. Methods were clearly stated and included the 
inclusion criteria, drug interventions and pharmacokinetic sampling schedule. All the trials 
reported that ethical approval was granted before any study procedures were performed. 
No formal sample size calculation was done in any of the trials and sample sizes varied 
between 2 and 30 participants. 
7. Literature summary 
Patient data of adjusted dose PI-based ART regimens with rifampicin-based tuberculosis 
treatment is scarce. Most studies were conducted in healthy normal volunteers and 
hepatotoxicity occurred frequently. The different Pis dosed with rifampicin will be discussed 
next. 
7.1 Lopinavir 
In South Africa LPV /r is part of the second-line ART regimen. Before the publication of our 
study, dosing recommendations were based on a healthy volunteer study done in the 
Netherlands.(8) The study demonstrated that lopinavir (LPV) trough concentrations similar 
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to those without rifampicin can be achieved, either by adding RTV to give a LPV: RTV ratio of 
1:1, or by doubling the dose of the capsule formulation of LPV /r when dosed with 
rifampicin. From days 1 to 10 all volunteers received LPV /r dosed at 400/100 mg 12 hourly, 
followed by the same dose of LPV/r but with rifampicin 600 mg daily added from days 11 to 
15. After day 15, volunteers were randomized to rifampicin with either double doses of 
LPV /r 800/200 mg (arm 1) 12 hourly or additional RTV (LPV /r 400/400 mg) (arm 2). Intensive 
pharmacokinetic sampling was performed on days 10 and 24. Thirty-two volunteers were 
included in the study and 19 volunteers completed the pharmacokinetic sampling on day 24. 
Thirteen volunteers prematurely discontinued the study due to adverse events or laboratory 
abnormalities. Table 1 summarizes the LPV pharmacokinetic data. Both approaches 
achieved mean LPV trough concentrations (Cmin) above the recommended minimum target 
concentration of 1 mg/L for PI-na"ive patients.(9) In the two arms 37% (7/19) of the 
volunteers developed asymptomatic transaminitis. More volunteers discontinued study 
treatment in the LPV/r 400/400 mg arm compared to the LPV/r 800/200 mg arm (5/9 
compared to 2/10). 
Subsequent to this study, a LPV /r tablet formulation with reduced pharmacokinetic 
variability and higher bioavailability unrelated to meals became available; and rifampicin in 
combination with adjusted doses of the LPV /r tablet formulation in healthy normal 
volunteers was studied.(10) The volunteers received 600 mg rifampicin daily on days 1 to 5, 
foHowed by LPV /r dosed at 600/150 mg or 800/200 mg 12 hourly on days 6 to 15. 
Unexpected high rates of hepatotoxicity occurred with 8 of 11 volunteers developing 
symptomatic grade 3 or 4 transaminitis. The study was prematurely discontinued. 
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The treatment of co-infected HIV-tuberculosis patients on LPV /r-based ART was described in 
a small retrospective observational study in the Netherlands.(ll} The study included 34 
patients, 26 of whom started concomitant treatment after the recommendation of LPV /r 
dose adjustment was in the public domain. Only 5/26 patients were dosed correctly with 
adjusted dose LPV /r. Plasma LPV trough concentrations were measured in 6 patients 
receiving unadjusted or incorrectly adjusted LPV /r doses and in 2 patients receiving the 
recommended adjusted LPV /r dose. The LPV trough concentration was therapeutic in 2/6 
patients with unadjusted or incorrectly adjusted LPV /r doses, compared to 2/2 patients with 
correctly adjusted LPV/r doses. In the patients in whom a viral load was measured, more 
patients in the unadjusted or incorrectly adjusted LPV /r groups had unsuppressed viral loads 
compared to the correctly adjusted LPV/r patient group (5/8 compared to 3/3). Within 4 
weeks of starting the combination treatment, 7 of the 34 patients prematurely stopped the 
combination because of unspecified acute adverse effects; of whom 2 were on the correctly 
adjusted dose of LPV /r. 
7.2 Saquinavir 
The FDA and Roche Pharmaceuticals contraindicated the combination of 
saquinavir/ritonavir (SQV /r) with rifampicin because of high rates of hepatotoxicity in 
healthy normal volunteers.(12-14} Twenty-eight healthy normal volunteers were 
randomized to either receive SQV /r 1000/100 mg 12 hourly for 14 days, followed by 
concomitant rifampicin for 14 days; or in arm two, rifampicin for 14 days followed by 
concomitant SQV/r 1000/100 mg 12 hourly for 14 days.(12,15} The study was stopped after 
11 volunteers on the SQV /r-rifampicin combination developed hepatotoxicity. The drug 
initiation sequence was an important predictor of hepatotoxicity, as more hepatotoxicity 
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occurred in the arm where rifampicin was initiated first (9/9 compared with 2/8). Possible 
explanations for this will be discussed in more detail in section 7.6 below. 
Apart from tolerability concerns, dosing SQV /r to get adequate SQV exposure in the 
presence of rifampicin was challenging. Unboosted SQV 1200 mg 8 hourly with rifampicin 
decreased the SQV AUC exposure by 70% and 46% in healthy normal volunteers and HIV-
infected patients respectively.(16) Boosted SQV were subsequently studied at different 
doses and dosing intervals. A retrospective study compared HIV-tuberculosis co-infected 
patients receiving SQV/r-based ART dosed at 1000/100 mg 12 hourly (n=14) with 18 patients 
receiving triple NRTls (n=18).(17) Pharmacokinetic data was not recorded, but based on the 
observation that the virological response in the triple-NRTI group was inferior to the SQV /r-
based ART treated group, the authors suggested that the latter combination may be more 
effective when dosed with rifampicin-based tuberculosis treatment. Once daily SQV /r 
1600/200 mg studied in HIV-infected patients on tuberculosis treatment was inadequate to 
compensate for the rifampicin induction: SQV AUC and trough concentrations were reduced 
by 39.5% and 48.7% respectively.(14) A third of patients (6/18) had unsuppressed viral loads 
after completing tuberculosis treatment, and 1 of 18 patients developed asymptomatic 
grade 3 hepatitis. Reassuring virological outcomes in HIV-tuberculosis co-infected patients 
treated with the SQV /r 400/400 mg 12 hourly dosing approach, was reported in 2 small 
prospective studies (n=2 and n=20 respectively).(18,19) Tolerability was acceptable: no 
hepatotoxicity occurred in the 2-patient study and 4/20 patients developed symptomatic 
hepatotoxicity in the other study.(19) 
Health care workers from developing countries questioned the FDA's safety 
recommendation based on limited healthy normal volunteer and published patient 
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data.(12-14) The health care workers argued that SQV/r- based ART (400/400 mg) has been 
dosed safely and effectively for years with tuberculosis treatment in their countries. The 
current US Centers for Disease Control and Prevention (CDC} recommendation is that 
although the SQV /r-rifampicin combination should preferably be avoided, the 
recommended SQV /r dose in the presence of rifampicin is 400/400 mg 12 hourly.(6) 
7.3 Indinavir 
Although indinavir (lDV) initially inhibit the metabolism of rifampicin, the induction effect of 
rifampicin on IDV is much more pronounced.(20) Low-dose rifampicin (300 mg daily) 
resulted in an 87% reduction of IDV trough concentrations in HIV-infected patients receiving 
indivavir/ritonavir (lDV/r)-based ART dosed 800/100 mg 12 hourly.(21) This dramatic 
reduction in IDV trough concentrations was seen with half the normal dose of rifampicin 
after only 4 days of treatment, probably underestimating the true effect of rifampicin 
treatment. This is because rifampicin induction only approaches maximum after at least 10 
days of rifampicin administration.(22) No hepatotoxicity occurred after the short duration of 
rifampicin administration. 
7.4 Amprenavir 
In healthy normal volunteers standard doses of rifampicin dosed with unboosted 
amprenavir (APV) 1200 mg 12 hourly, decreased APV AUC exposure by 82% and trough 
concentrations by 92%.(23) The combination was well tolerated despite rifampicin being 
dosed before APV. APV production was discontinued and replaced with the pro-drug 
fosamprenavir that has an improved bioavailability. 
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7.5 Atazanavir 
A healthy normal volunteer study showed that daily dosing of atazanavir/ritonavir (ATV/r) 
400/200 mg was inadequate to compensate for the inducing effect of rifampicin.(24) ATV 
trough concentrations were decreased by 59% when dosed with rifampicin. Increasing the 
dosing interval of unboosted ATV 300 mg or 400 mg to 12 hourly also failed to maintain 
adequate plasma exposure in healthy normal volunteers.(25) Once rifampicin was added, 
ATV trough concentrations decreased by more than 80%. In both studies, steady-state ATV 
was achieved before rifampicin was introduced. No hepatotoxicity occurred in either cohort. 
However, when RTV -boosted ATV (300/100 mg) was studied in combination with rifampicin 
in healthy normal volunteers, the study was discontinued due to hepatotoxicity.(26) The 
design differed from the previous healthy normal volunteer studies in the sequence of drug 
initiation: ATV/r was added after rifampicin induced hepatic and gut enzymes for 8 days. 
One can also not rule out the effect of RTV on the hepatotoxicity as demonstrated in the 
lopinavir study discussed earlier where more hepatotoxicity occurred in the additional 
ritonavir arm.(8) Although the study was discontinued before performing plasma ATV 
sampling, a study of the same dose ATV in 3 HIV-tuberculosis co-infected patients showed 
dramatic median decreases of 64% and 100% in AUC and trough concentrations 
respectively.(27) 
7.6 Patients different from healthy normal volunteers 
From the available PI-rifampicin literature, we know that dose adjusted Pis can compensate 
for the rifampicin induction effect. However, safety and tolerability concerns deter 
implementation of this strategy in clinical practice. Unacceptable tolerability was 
experienced in the healthy normal volunteer studies; but importantly, findings in healthy 
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normal volunteers may not necessarily be extrapolated to patients co-infected with HIV and 
tuberculosis. 
First, we observed from the healthy normal volunteer studies that volunteers who take the 
PI before rifampicin, less hepatotoxicity occurred.(8,12,15,25,26) It is speculated that prior 
induction of the liver enzymes by rifampicin, may give rise to high concentrations of toxic 
intermediate PI metabolites when the PI is introduced.(26) In high-burden countries 
rifampicin-based tuberculosis therapy will usually be commenced in patients established on 
the PI, given that Pis are mostly used in second-line ART regimens. Slower accumulation of 
metabolites without pre-induction by the rifampicin lead-in may allow tachyphylaxis to 
ameliorate toxicity.(26) Clinicians may be challenged to differentiate between and deal with 
tuberculosis- and PI-drug toxicity in the minority of patients who will be started on a PI-
based regimen while on tuberculosis treatment. 
Second, there may be differences in the risk of hepatotoxicity between healthy normal 
volunteers and HIV-infected patients. In a multi-national trial that studied the treatment of 
latent tuberculosis in HIV-infected patients, 12-month isoniazid (IN H) was compared with 2-
month rifampicin and pyrazinamide (RZ). In HIV-infected patients, allocation to the RZ arm 
was associated with a hepatotoxicity odds ratio of 4.20 (95% confidence interval of 1.43 to 
12.35), while allocation to the RZ arm in healthy normal volunteers was associated with a 
hepatotoxicity odds ratio of 8.46 (95% confidence interval of 1.9 to 76.5).(28,29) Similar 
rates of hepatotoxicity occurred in the HIV-infected and HIV-uninfected participants that 
received INH. The reason for the lower RZ-hepatotoxicity rate observed in HIV-infected 
patients is not clear, but the hypothesis is that hepatotoxicity is immune-mediated and 
immunosuppression protects against hepatotoxicity. In addition, active tuberculosis itself 
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may be immunosuppressive as it has been associated with reduced Thl lymphocyte 
counts.(30) 
Third, hepatotoxicity may be different in patients receiving combination tuberculosis 
treatment. Standard tuberculosis treatment consists of mUltiple drugs, including INH. INH is 
an inhibitor of CYP3A4 and may therefore theoretically attenuate the induction effect of 
rifampicin on LPV/r.(31,32) 
Lastly, HIV-infected patients with tuberculosis have 2 complex systemic diseases that may 
influence drug disposition. 
Although limited data exists, the use of adjusted dose Pis with rifampicin appears to be 
better tolerated in HIV-infected patients compared to healthy normal volunteers. See table 
2. 
7.7 Further research 
The proportion of patients on PI-based ART will increase in resource-limited countries as 
ART programmes mature and more patients move from first-line to second-line ART. 
Tuberculosis still remains the most common opportunistic infection in HIV-infected patients 
despite being treated with ART and in the medium-term future the standard of care will be 
rifampicin-based tuberculosis treatment. Relevant to our setting, the use of LPV/r-based 
ART in combination with rifampicin needs to be studied in HIV-infected African patients, as 
the existing evidence is based on small studies in healthy Caucasian male volunteers who 
are genetically and environmentally different. The LPV/r 400/400 mg dosing approach is 
complicated by the increased pill burden, complex dosing regimen and low temperature 
storage instructions. In addition, ritonavir is poorly tolerated in high doses. Furthermore, 
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there was a trend towards more toxicity in the LPV /r 400/400 mg dosing group compared to 
the LPV 800/200 mg group.(8) These factors favour the LPV/r 800/200 mg or double dose 
approach to be evaluated in a bigger study in the relevant patient population. 
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Rifampin coadministration dramatically reduces plasma lopinavir (LPV) concentrations. In healthy volun-
teers, doubling the dose of a lopinavir-ritonavir (LPV/r) capsule formulation overcame this interaction, but a 
subsequent study of double doses of the tablet formulation was stopped early owing to hepatotoxicity. However, 
healthy-volunteer study findings may not apply to HIV-infected adults. We evaluated the steady-state phar-
macokinetics of LPV in HIV-infected adults virologically suppressed on an LPV/r regimen who were given 
rifampin, and the dose of the LPV/r tablet formulation was gradually increased. The steady-state pharmaco-
kinetics of LPV/r were evaluated at baseline, a week after commencing rifampin, a week after the LPV/r dose 
was increased 1.5 times, and a week after the LPV/r dose was doubled. Twenty-one participants were enrolled. 
The median [interquartile range (IQR)] predose LPV concentrations (CO> were 8.1 (6.2 to 9.8) mg/liter at 
baseline, 1.7 (0.3 to 3.0) mg/liter after 7 days of rifampin, 5.9 (2.1 to 9.9) mg/liter with 1.5 times the dose of 
LPV/r, and 10.8 (7.0 to 13.1) mg/liter with double-dose LPV/r. There were no significant ditferences in the LPV 
area under the plasma concentration-time cu"e from 0 to 12 h (AUCo-u), C." Cu , maximum concentration of 
drug in serum (Cm ..,.), or half-Ilfe (tltZ> between the baseline and double-dose LPV/r time points. Treatment was 
generally well tolerated, with two participants developing asymptomatic grade 3/4 transaminitis. Doubling the 
dose of the tablet formulation of LPV/r overcomes induction by rifampin. Less hepatotoxicity occurred in our 
cohort of HIV-infected participants than was reported in healthy-volunteer studies. 
Rifampin is a key component of tuberculosis treatment but 
also a potent inducer of many cytochrome P450 enzymes and 
the efflux pump p-glycoprotein (15). Protease inhibitors are 
substrates of both CYP 3A4 andp-glycoprotein, and the trough 
concentrations of all ritonavir-boosted protease inhibitors are 
reduced by more than 90% when standard doses are coadmin-
istered with rifampin (2). A healthy-volunteer study demon-
strated that similar lopinavir (LPV) trough concentrations can 
be achieved either by adding ritonavir (RTV) to give a lopi-
navir/ritonavir ratio of 1:1 or by doubling the dose of the 
capsule formulation of lopinavir-ritonavir (LPV/r) (12). 
Subsequent healthy-volunteer studies of the interaction 
between rifampin and adjusted doses of ritonavir-boosted 
saquinavir, atazanavir, and lopinavir (tablet formulation) were 
prematurely terminated because of high incidences of hep-
atotoxicity (6, 7, 16). These high rates of hepatotoxicity in 
healthy volunteers might not apply to patients with tuberculo-
sis and HIV. First, in the healthy-volunteer studies, initiating 
rifampin prior to the protease inhibitor was associated with 
high rates of hepatotoxicity (6, 7, 16). In high-burden coun-
tries, protease inhibitors are used as part of the second-line 
antiretroviral treatment (ART) regimen; hence, most patients 
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are established on the protease inhibitor before rifampin is 
initiated. Second, HIV infection may lower the risk of hepa-
totoxicity, as illustrated by the experience with rifampin and 
pyrazinamide for latent tuberculosis, which was well tolerated 
in HIV-infected individuals but was associated with high rates 
of hepatotoxicity in non-HIV-infected individuals (5, 9, 20). 
We evaluated the steady-state pharmacokinetics of LPV and 
RTV in HIV-infected adults virologically suppressed on an 
LPV/r regimen who were given rifampin with the dose of 
LPV/r gradually increased to double the standard dose. 
MATERIALS AND MEmODS 
Study design. The study was an open-label, sequential, four-period, multiple-
dose trial in HIV -infected adults who were virologically suppressed (viral loads, 
<400 copies/ml) on LPV /r together with dual nucleoside reverse transcriptase 
inhibitors. We compared the steady-state pharmacokinetics of LPV and RTV 
using noncompartmental analysis under 4 sequential treatment conditions over a 
12-h dosing interval in HIV-infected participants: a standard dose of LPV/r (400 
mg/l00 mg) every 12 hours (study day 1). after which rifampin at 600 mg daily 
was commenced; LPV/r in standard doses every 12 hours with rifampin (study 
day 8); 1.5 times the standard dose of LPV/r (600 mg/150 mg) every 12 hours with 
rifampin (study day 15); and twice the standard dose of LPV/r (800 mgl200 mg) 
every 12 hours with rifampin (study day 22). Dual nucleoside reverse transcrip-
tase inhibitors were continued throughout with no dose adjustments. Treatment 
adherence was assessed by using a treatment diary and piu counts. 
Study participants. We recruited HIV-infected participants established on an 
LPV /r regimen (tablet formulation) from a South African antitretroviral clinic, 
the Hannan Crusaid Treatment Centre in Gugulethu, Cape Town, South Africa. 
We included medically stable HIV-infected adults older than 18 years with viral 
loads of <400 copies/mi. Exclusion criteria were abnormal creatinine, severe 
diarrhea, hepatic disease (defined as either alanine aminotransferase [ALT] at 
more than 1.5 times the upper limit of normal or a positive hepatitis B surface 
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antigen or hepatitis C antibody test result), grade 3 or higher raised fasting 
cholesterol (>7.77 rnrnoVliter) or triglycerides (>8.49 mmoVliter), random glu-
cose measurements of >11.1 mmollliter, excessive alcohol consumption (in ex-
cess of 2 units per day or 14 units per week), symptoms or signs of tuberculosis, 
taking drugs other than the study drugs known to alter the pharmacokinetics of 
LPV, and pregnancy. 
Pharmaeokinetic assessmenL Participants were admitted overnight and fasted 
from 22hOO. We observed the dose of LPV/r taken the evening before pharma-
cokinetic sampling and ensured it was 12 h before the predose sample the next 
morning. Intensive pharmacokinetic sampling was done predose and at 1.5 h, 2 h, 
2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, and 12 h after observed dosing. Standardized meals 
were given between the 2-h and 2.5-h, 5-h and 6-h, and 8-h and 12-h sampling 
times. 
We collected 4-ml blood samples in lithium heparin tubes that were kept on 
melting ice prior to separation. Within 1 h of sampling, the blood samples were 
centrifuged at 3,000 rpm for 10 min. Each plasma sample was aliquoted and 
stored at -8O"C until the drug concentration was determined. 
Safety monitoring. We monitored AL T and total serum bilirubin 3 times a 
week from the day before rifampin was started until the end of the study period 
(study days 1, 4, 6, 8, 11, 13, 15, 18,20,22, 25, and 28). Electrocardiograms were 
done at baseline and repeated at days 15 and 22 after the LPV/r dose increases. 
AU adverse events were recorded and graded according to the grading system of 
the Division of AIDS (4). Subjects were withdrawn from the study when they 
developed grade 3 or greater adverse events thought to be related to the study 
drugs. 
Drug assays. We used validated liquid chromatography tandem mass spec-
trometry (LCIMS-MS) to determine the LPV and RTV concentrations in the 
plasma samples. Lopinavir and ritonavir were assayed as previously described 
(17). The assay range for lopinavir was 0.05 to 20 IJ-g/ml, and for ritonavir it was 
0.025 to 5 ILg/m1.tnter- and intraday coefficients of variation were below 10% for 
both drugs. The laboratory participates in the International Interlaboratory Con-
trol Program of Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en 
Toxicologie (KKGT) (Hague, Netherlands). LPV and RTV concentrations re-
ported as below the limit of quantification (BLQ) were analyzed as the BLQ 
concentration divided by 2. 
Ethical approval. The study was approved by the University of Cape Town 
Human Research Ethics Committee. Each volunteer was informed of the objec-
tives, nature, and potential risks of the study. Written informed consent was 
obtained from every participant. 
Stadstical analyses. Stata version 11.0 (Stata Corporation, College Station, 
TX) was used to characterize the pharmacokinetic parameters of LPV and RTV 
using noncompartmental analyses. The area under the plasma concentration-
time curve from 0 to 12 h (AUCo..12) was calculated from a 12-h dosing interval 
using the linear trapezoidal rule. The predose (Co) and 12-h (CI2) LPV concen-
trations were determined directly from the concentration-time data. 
Normally distributed numerical data were described using means and standard 
deviations, and the t test for paired samples was used for hypothesis testing. The 
Fisher exact test was used for categorical data hypothesis testing. Numerical data 
that followed a nonnormal distribution were described using the median and 
interquartile range (IQR), and the Wilcoxon signed-rank test was used for 
hypothesis testing. Geometric mean ratios (90% confidence intervals [CIs]) were 
calculated to compare the AUC()'12 and the maximum concentration of drug in 
serum (Cm .. ) on study days 8, 15, and 22 to those on study day 1. 
RESULTS 
We enrolled 21 black African participants in the study, 18 of 
whom were female. The mean age ± standard deviation (SD) 
was 36.1 ± 7.1 years, the mean body mass index ±SD was 
26.2 ± 5.8 kg/m2, and the median (lOR) CD4+ cell count was 
564 (408 to 669) cells/mm3• 
Figure 1 shows the median steady-state LPV concentrations 
over time measured on study days 1, 8, 15, and 22, and the 
pharmacokinetic parameters are summarized in Table 1. 
LPV trough (Co) concentrations below the recommended 
lower limit for ART-naive patients (1 mg/liter) (1, 11) occurred 
in 0/21 study subjects on day 1, 10/21 (P < 0.01) on day 8, 2/20 
(P = 0.23) on day 15, and 0/18 on day 22. The proportion of 
participants with subtherapeutic LPV C 12 concentrations was 
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higher on all study days than the number of those with sub-
therapeutic LPV Co concentrations: 2/21 on day 1, 18/21 (P < 
0.01) on day 8,10/20 (P < 0.01) on day 15, and 4118 (P = 0.39) 
on day 22. 
Table 2 summarizes the steady-state ritonavir pharmacoki-
netic parameters. 
Nineteen of the 21 participants completed the study. Two 
participants were withdrawn from the study owing to grade 3/4 
asymptomatic transaminitis; one developed grade 3 transami-
nitis on the standard dose of LPV /r and rifampin, the other on 
1.5 times the standard dose of LPV/r and rifampin. In both 
participants, the transaminitis resolved after LPV/r and rifam-
pin were withdrawn. Another participant withdrew consent 
after developing grade 2 nausea on 1.5 times the standard dose 
of LPV/r and rifampin. Other adverse events were mild but 
frequent: 6 participants developed grade 1/2 transaminitis, 2 
grade 1 hyperbilirubinaemia, 8 grade 1/2 nausea, 2 grade 1/2 
diarrhea, and 1 PR interval prolongation (0.198 to 2.14 ms) on 
double the standard dose of LPV/r. All adverse events re-
solved. On routine viral-load measurement, all but 2 partici-
pants remained virologically suppressed. Adherence was mea-
sured at least 3 times a week during the study period by using 
participant questioning and correlating pill counts with re-
corded doses in the treatment diary. All participants had 100% 
adherence during the study period using these measures. Sub-
sequent to the pharmacokinetic study, 2 participants had de-
tectable viral loads measured at their routine clinic visits, which 
were ascribed to poor adherence. 
DISCUSSION 
This is the first study of the steady-state pharmacokinetics of 
adjusted doses of LPV/r with rifampin in HIV-infected adults. 
Therapeutic LPV Co trough concentrations were achieved in 
all participants by doubling the dose of the tablet formulation 
of LPV/r, although 18/20 participants achieved therapeutic 
LPV Co trough concentrations with 1.5 times the dose of LPV/r 
(600 mg/150 mg every 12 hours). In our cohort, we consistently 
found a higher proportion of participants with subtherapeutic 
C 12 trough concentrations than with subtherapeutic Co trough 
concentrations. Subtherapeutic LPV C12 trough concentra-
tions were noted on all study days. The combination of LPV/r 
and rifampin was relatively well tolerated in our cohort of 
HIV-infected individuals compared with previous healthy-vol-
unteer studies, but this cannot be extrapolated to treating 
patients with tuberculosis, as we have safety data for only 22 
days. 
LPV is a substrate of both CYP 3A4 and p-glycoprotein, 
which are inhibited by RTV (22). The increased dose of RTV 
partially offsets the induction effect of rifampin and, together 
with the increased dose of LPV, sufficiently overcomes induc-
tion by rifampin. However, we report pharmacokinetic mea-
surements only; the effect of the increased dose of LPV/r with 
rifampin on the virological response is unknown. 
Most patients achieved therapeutic LPV Co trough concen-
trations with 1.5 times the dose of LPV/r (600 mg/150 mg every 
12 hours), making a dose-down strategy with therapeutic drug 
monitoring of LPV an option in patients who do not tolerate 
double-dose LPV/r (800 mg/150 mg every 12 hours). 
For patients on protease inhibitors who have no other anti-
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a"oc;atod will1 a lower ri>k of ocp""'oxicit)', H;~b ,.to. of 
I"op-"'otoxidty occurred ;~ noo-HI \I,infe<tod individuals rom· 
parcd .,ith I-IIY·;nfc<tod indi>idua" II .tudic> 'l.,iIlg ribmpin 
, "d p)'razin.mkle tu lTeat lorent tuheTCu""i, (5. 9, 20), HJV· 
tubercuuis-coini<ctod ""',,,nlS I"kr.ted the combiMtion oJ 
ribmpin and .. qum .... ir-ritooavU- rolatiy<1y well ((4. 18). but 
hi~h ,"1o, ul hopalu<U'ici'), ""'''' "''''' in hcaltl,y ,'ul,mleer. 
,,,,.tod witb Ihi> c-urnbina';'Jn \6). The lo-..-or T~k ul hop.t(J-
toxicity in HIV-inf«ted pallen!> mi,!-Itt he oxplRined by an 
atte"ua'ed imrn\Jlle ""pt"''''. "hl<il j; 'oo",tll 10 pl.y.n im-
porMnt ",Ie in ><IiO:;yn<Tabc d,"~-indl!Ce~ ilepmocdklkor ",X-
1;0", (13), Se""ndl-,. we ,i<o.<-'Iy .",.I<lod Ill. (\(Jo¢ of LPV!r 
""er J ",'oeLs. Hiih Me, ui' hep-"wt~xi<i'y occurre6;" he.ilhy 
voluntee" who" d<>ul1ie oc..c, 01 iopilla- ir·riton""j, """0 ~vcn 
wilooul do". o""al, tio", in oombh"'""n wilh ,jf~mpjn (J6). 
'""~t;, we injt;~!Cd r;fampin in H(Y·i~f<c'od pMticipa"" 0 . ' 
tabli,hod on LPYir. High rato, d h<patotoxicit)' OC'Currro in 
the ocaltl1y.yolunteer >ludk> wll<re riIampin w .. introouced 
prioc to tl>o FnAo,,,,, inbibitur> (6, 7, (6), Rililmpin proindoc-
hon m~y rapidly gcoc,"to po'()tc~'" iniJibilc>r motabolito. that 
a ro hopato,mic (7). In 11igh.burocn COlHltri~ nfarnp;n.bll.'lCd 
.n,itubereulor tl>orap)' will ""O"lly be <'UItlIIlOIl<.-ro in P<'licnl' 
.l.-eady un prNeose inhil1i,,,,'. g;v<~ to.1 pr",e",o iniJ;O;I'-'" 
are ...,d in , ... oood_line ART regimo,", 
tJiumal "r; .. t;on of proto,"," inhibitors h", been roportcd 
preWlu>l:t (8. 10). Ahs""pl;on d,iJhe .... ,« d ... 10 \he .recl 01 
lood may ..x0!.lI1' fN lhe ~it"cronce8 i" 00 1' C" and C" (,ough 
moccntr .. tion •. Our cobon roceived a me.,] hefore 'ho ob-
.,,,"od C" do:>e w", ",!-.on, "bil . ,'''' uo'o",eJ C" dose wAA 
'.'en aflOl' , l(l_h laSi. 
Our ,"udy finding;< h",'c ""vcrol I""it~t ion •. Fin'- we .. ,. 
,o.",d tho of cct m: rllampin on LPVlr <oo<o]>lraool1.' only. 
Tube«"l",i. i. troated wilh combmahun o"'iluborrul""" 
drop. ]tI<.iudi!t~ i,.-,ni.<li'l. which j , on inhiNt~r ~I CYP .'M 
(3). Il<Hh LPYI, ph""'''''''''i''''''''' ao.,\ hepatotoxicity "'ay he 
dHforent whc~ adm;n"tor<d with r;f.mpin.oo iwnillZid. Sec-
ond, tocro may a l." oc a disc",o of""t m: lubercuto.is on both 
LPViT runcentratlU]lS .nd """"I"'oxicil)', Third, "''' "",loalod 
Il<patuiUJocily lor only 3 week>, I' i, p""iI:>l.lhol hi~iJ ,"Ie, of 
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SUMMARY 
There is an urgent need to investigate practical approaches to using antiretrovirals together 
with tuberculosis (TB) treatment. Administration of rifampicin with Kaletra® (Iopinavir 400 
mg/ritonavir 100 mg 12 hourly) reduces the lopinavir (LPV) pharmacokinetic parameters 
area under the curve and trough concentrations by approximately 75% and 99% 
respectively. A small study in healthy adults [La Porte 2004] found that doubling the dose of 
Kaletra® (LPV 800 mg/ritonavir[RTV] 200 mg), or giving additional RTV (LPV 400 mg/RTV 400 
mg 12 hourly), ameliorates the rifampicin-mediated decrease in LPV concentrations. There 
is an urgent need to investigate these approaches in South African patients requiring 
combined treatment for TB and HIV. 
We propose to study the steady state pharmacokinetics of LPV in 24 HIV-infected adult 
volunteers established on an antiretroviral regimen comprising LPV /RTV (in the film-coated 
tablet formulation Aluvia®) plus 2 NRTls. Intensive blood sampling will be employed over a 
single dosing interval (12 hours) to study the pharmacokinetics of LPV at baseline, after 
which rifampicin will be added. After steady state has been achieved on rifampicin intensive 
sampling will be repeated. The pharmacokinetics will then be evaluated after increasing in 
the dose of LPV /RTV to 1.5 and 2 times the standard dose, respectively. 
As multiple viral mutations are required to confer LPV resistance [Kempf 2001] and because 
we will only enroll participants who have virologic suppression, there should be no risk of 
resistance developing should the concentrations of LPV be low during the short period of 
the study. Participants will be carefully monitored for the development oftoxicity during the 
administration of rifampicin with the antiretroviral therapy, by means of frequent alanine 
aminotransferase (ALT) and total serum bilirubin measurements. 
Patients will be recruited at antiretroviral clinics in the Western Cape and admitted to the 
pharmacokinetic facility at the Division of Clinical Pharmacology, University of Cape Town 
and Groote Schuur Hospital for pharmacokinetic assessment. The study will be conducted in 
accordance with international (lCH) and local (National Department of Health) Good Clinical 
Practice Guidelines. The study is funded by the European and Developing Countries Clinical 
Trials Partnership. The University of Cape Town is the sponsor. 
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ABREVIATIONS 
AE 
All 
ART 
ARV 
AUC 
Cmax 
Cmin 
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CYP 
DSMB 
HAART 
HBVsAg 
HCVAb 
HIV 
IQR 
LPV 
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NNRTI 
NRTI 
PI 
PK 
RIF 
RTV 
SAE 
TB 
TSB 
UCT 
Adverse event 
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Antiretroviral treatment 
Antiretroviral 
Area under the drug concentration-time curve 
Maximum / peak concentration 
Minimum concentration 
C-reactive protein 
Cytochrome P450 enzyme 
Data safety and monitoring board 
Highly active antiretroviral treatment 
Hepatits B virus surface antigen 
Hepatits C virus antibody 
Human immunodeficiency virus 
Inter-quartile range 
Lopinavir 
Medicines Control Council of South Africa 
Noncompartmental analysis 
Nonnucleoside reverse transcriptase inhibitor 
Nucleoside reverse transcriptase inhibitor 
Protease inhibitor 
Pharmacokinetic(s) 
Rifampicin 
Ritonavir 
Serious adverse event 
Tuberculosis 
Total serum bilirubin 
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1. STUDY RATIONALE 
There is an urgent need to evaluate highly active antiretroviral (ARV) treatment regimens 
that are compatible with rifampicin-based antitubercular treatments. Combined treatment 
is life-saving for tuberculosis patients with advanced HIV-related immunosuppression. Co-
administration of ARV and antitubercular treatment regimens is occurring frequently in 
countries where the burdens of HIV and TB are high. However, major concerns of using HIV 
and TB treatments together include pharmacokinetic (PK) drug-drug interactions, combined 
regimen toxicity and the development of immunopathological reactions. The optimal 
approaches to co-administration of TB and HIV treatment regimens have not been 
adequately evaluated in patient populations. Moreover, the optimization of co-treatment 
strategies is all the more important where target drug concentration measurement is not 
generally available. 
Rifamycin-based regimens are recommended for the treatment of TB, especially in the 
presence of HIV-infection. Rifampicin is a potent inducer of cytochrome P450 (CYP) 
isoenzyme 3A and also causes several fold increases in the expression of CYP2B6, and p-
glycoprotein (an important transmembrane efflux protein and product of the MDR-l gene), 
amongst other enzymes of importance for PK [Rae 2001]. Thus rifampicin results in 
important reductions in the concentrations of protease inhibitors (Pis) and nonnucleoside 
reverse transcriptase inhibitors (NNRTls). Although rifabutin causes less enzyme induction 
(and some guidelines recommend that it should replace rifampicin in patients receiving 
concurrent LPV /RTV [US DHSS 2006]), it is expensive and its dosing is complex with Pis 
which inhibit rifabutin metabolism; it is currently not accommodated within the TB control 
programs of most countries with a high burden ofTB/HIV. 
Guidelines for managing the interactions between the rifamycins and antiretrovirals [US-
DHHS 2006; SA Dept. of Health National (2004)] are based primarily on drug interaction 
studies in healthy volunteers and expert opinion. Research is urgently needed to better 
characterize these interactions in the relevant patient populations with HIV-associated 
tuberculosis, and to understand the pharmacodynamic consequences of the resultant 
changes in serum concentrations of antiretroviral drugs. 
A small study [La Porte 2004] amongst adult healthy volunteers investigated the approach 
of adjusted doses of LPV /RTV to counteract the enzyme induction caused by concomitant 
rifampicin. Volunteers were established on twice daily LPV /RTV in doses of 400/100 mg for 
several days before the introduction of rifampicin and escalation of the PI doses to reach a 
steady state on dosing with rifampicin 600 mg once daily plus 12 hourly doses of RTV 400 
mg in conjunction with LPV 400 mg (arm 2), or double doses of Kaletrae : LPV /RTV 800/200 
mg (arm 1). As shown in the Table 1, both approaches offset the effect of rifampicin-
mediated induction of LPV (Table 1). 
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Table 1: The pharmacokinetic measures for lopinavir when given 12 hourly in combination 
with ritonavir and a daily dose of rifampicin 600 mg in healthy volunteers [La Porte 2004]. 
The point estimate (90% CI) of the geometric mean ratio (GMR) is also given for co-
administration of Kaletra GD and rifampicin ± ritonavir / standard doses of Kaletra e in the 
same subjects. 
LPV/RTV: N Cmax AUC Cmin 
800/200 mg 10 13.8±4.89 mg/L 104.5±46.86 mg.h/L 5.1±4.17 mg/L 
(arm 1) GMR: 1.02 (0.85-1.23) GMR: 0.84 (0.64-1.10) GMR: 0.43 (0.19-0.96) 
400/400 mg 9 1l.5±3.07 mg/L 100.7±26.81 mg.h/L 5.9±2.73 mg/L 
(arm 2) GMR: 0.93 (0.81-1.07) GMR: 0.98 (0.81-1.17) GMR: 1.03 (0.68-1.56) 
The study was underpowered to assess differences between the 2 dosing approaches in 
combination with rifampicin. Although the trough concentration (Cmin) for arm 1 was 
reduced in comparison to standard Kaletra GD doses without rifampicin, the difference 
between the mean Cmin for the 2 arms was less obvious (arm 1: 5.1 mg/L ± 4.17; vs. arm 2: 
5.9 mg/L ± 2.73 mg/L) and the trough concentrations were above the recommended 
minimum target concentration of 1 mg/L for protease inhibitor na'ive patients [La Porte 
2006]. The study was not designed to establish safety of the combinations. However, 28% of 
the volunteers discontinued due to liver enzyme abnormalities. The adverse events tended 
to be less frequent in the group given LPV /RTV 800/200 mg. Based on this study, dosing 
approaches have been recommended when it is necessary to use the combination of 
LPV/RTV and rifampicin-based TB treatment (with the caution that patients are closely 
monitored and that further evidence of the safety and efficacy of the approaches are 
required). 
The approach of using additional RTV with Kaletrae (LPV /RTV 400/400 mg) adds complexity 
to the combined dosing regimen; increasing the risk of errors in drug supply, prescribing and 
dispensing. Moreover, RTV is poorly tolerated in high doses. These factors favour the 
approach of increasing the dose of Kaletra GD (with LPV:RTV in a ratio of 4:1) without adding 
extra RTV separately. The approach needs to be evaluated in an adequately powered study 
amongst the relevant patient populations; the existing evidence is based on a small 
underpowered study in healthy Caucasian male volunteers who are genomically, 
environmentally and behaviorally different to their African counterparts. 
The film-coated tablet formulation of LPV/RTV (to be marketed as Aluvia GD in South Africa) is 
less susceptible than the capsule to food effects and results in more predictable systemic 
LPV concentrations [Kaletrae package insert 2007]. The film-coated tablet has replaced the 
capsule in many countries; and will shortly become available in South Africa. 
LPV /RTV is commonly associated with diarrhoea, nausea and vomiting; the lipodystrophy 
syndrome is less common; and pancreatitis, hyperglycaemia, ketoacidosis, diabetes and 
hepatitis are rare. Hypersensitivity reactions may also occur. 
Rifampicin administration is commonly associated with elevated serum transaminase 
concentrations. Progression to liver injury is unpredictable and clinical hepatitis is rare but 
may be fatal. The use of other potentially hepatotoxic drugs may enhance the risk of 
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hepatitis developing. Inhibition of bilirubin excretion may cause jaundice on initiation of 
rifampicin, but it usually clears with ongoing therapy. Gastrointestinal effects include nausea 
and vomiting, anorexia, mild abdominal discomfort and diarrhoea. Taking the drug with 
food may alleviate the symptoms, although administration on an empty stomach is 
recommended for optimal absorption. Hypersensitivity reactions are mainly associated with 
intermittent or discontinuous therapy and include a 'flu-like' syndrome with fever, urticaria, 
haemolysis, eosinophilia, thrombocytopenia, leucopenia, interstitial nephritis and acute 
tubular necrosis. CNS effects such as drowsiness, headache, mental confusion and muscular 
weakness are described. Rifampicin colours urine, tears and other body fluids reddish-
orange to reddish-brown; staining of contact lenses may occur. 
Concerns relating to toxicity of PI - rifampicin combinations arise largely from two recent 
studies in healthy volunteers [Grange 6th International Workshop on Clinical Pharmacology 
of HIV Therapy 2005; o. Burger, 8th International Workshop on Clinical Pharmacology of HIV 
Therapy 2007]. These 2 studies were terminated due to the high incidence of severe 
hepatoxicity in the participants who received increased doses of protease inhibitors 
(saquinavir with RTV, and LPV/RTV, respectively) after several daily doses of rifampicin. 
Participants who took LPV /RTV before rifampicin had less hepatotoxicity. It is not known 
why treatment sequence should be an important determinant of hepatic damage, but it is 
speculated that prior induction of the liver enzymes by rifampicin, may give rise to high 
concentrations of toxic intermediate metabolites when LPV /RTV is introduced. The use of 
adjusted dose protease inhibitors with rifampicin appears to be well tolerated in patients, 
but this has been poorly documented. 
These concerns, together with the fact that the reported trough concentrations of LPV are 
well above the lower limit of the recommended range, and wide variability in the LPV 
concentrations between subjects, support the approach of studying LPV concentrations 
using 1.5 X in addition to 2 X the usual dose of Kaletra· in patients receiving rifampicin, and 
frequent monitoring of transaminase concentrations during the period of rifampicin 
administration. 
Earlier this year, 6 April 2009, the FDA issued a warning that lopinavir/ritonavir prolongs the 
PR interval in some patients; and although causality of lopinavir/ritonavir could not be 
established, postmarketing cases of QT interval prolongation and torsade de pointes have 
. . been reported With Kaletra use. 
Pharmacokinetic evaluation: 
Intensive pharmacokinetic sampling will be used to characterize the pharmacokinetics using 
noncompartmental analysis (NCA). This approach allows characterization of the 
pharmacokinetic profiles of the drugs in a relatively small number of patients with rapid 
statistical analysis and reporting. 
Pharmacokinetics 0/ Kaletra· in standard recommended doses (400/100 mg) in HIV-in/ected 
patients: 
After multiple 12 hourly doses of the capsule form of Kaletra· a mean peak LPV 
concentration (Cmax) of 9.8 mg/L (SO: 3.7) was achieved approximately 4 hours after 
dOSing. The steady state trough concentration was 7.1 mg/L (SO: 2.9) and the AUC during a 
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dosing interval was 92.6 (SO: 36.7). Plasma concentrations of lPV and RTV after 
administration of two 200/50 mg tablets are similar to three 133.3/33.3 mg capsules under 
fed conditions, but with less pharmacokinetic variability (KaletraGD package insert). Unlike 
that following administration of the capsule, the bioavailability of lPV in the tablet 
formulation is not substantially altered by concomitant food ingestion: With a high fat 
("'56%) meal and a medium fat ("'25% fat) the AUC was increased by 19% and 27% 
respectively, in comparison to taking it under fasting conditions. The tablet formulation of 
lPV/RTV (AluviaGD) can therefore be taken with or without food. 
Proposed study: 
We propose to study the steady state pharmacokinetics of lPV in 24 HIV-infected adult 
volunteers established on an antiretroviral regimen comprising lPV/RTV plus 2 NRTls. 
Intensive blood sampling will be employed over a single dosing interval (12 hours) to study 
the pharmacokinetics of lPV on 4 sequential occasions: 
1) at baseline (lPV 400 mg/RTV 100 mg 12 hourly), 
2) after steady state has been achieved with the addition of rifampicin (600 mg daily for 6 
days), 
3) after steady state has been achieved with a dose of lPV /RTV 1.5 times the standard dose 
(600 mg/150 mg, 12 hourly) with rifampicin, and 
4) after steady state has been achieved with a dose of lPV/RTV 2 times the standard dose 
(800 mg/ 200 mg, 12 hourly) with rifampicin. 
Rifampicin will then be stopped and the dose of lPV /RTV returned to normal. The 
pharmacokinetics of lPV will be compared between the 4 sampling occasions. Trough 
concentrations of lPV will be compared to the recommended minimum target 
concentration (1 mg/l). 
Secondary objectives include the documentation of adverse events and laboratory 
abnormalities in enrolled patients. 
The study will be submitted to the South African Medicines Control Council and the 
Research Ethics Committee of the University of Cape Town for their approval, and will be 
conducted in accordance with ICH GCP (1997), South African regulatory requirements and 
the Declaration of Helsinki. 
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2. STUDY OBJECTIVES 
2.1 Using noncompartmental analysis (NCA), to describe the steady state 
pharmacokinetics of LPV and RTV over a 12 h dosing interval in 24 HIV-infected 
volunteers treated with: 
2.1.1 LPV/RTV in standard doses (400 mg LPV/100 mg RTV) 12 hourly together with 2 
NRTls (Baseline measurement; PK1) 
2.1.2 LPV/RTV in standard doses (400 mg LPV/100 mg RTV) 12 hourly together with 2 
NRTls and rifampicin 600 mg daily (PK2) 
2.1.3 LPV/RTV at 1.5 X the standard doses (600 mg LPV/1s0 mg RTV) with 2 NRTls AND 
rifampicin 600 mg daily (PK3) 
2.1.4 LPV/RTV at 2 X the standard doses (800 mg LPV/200 mg RTV) with 2 NRTls AND 
rifampicin 600 mg daily (PK4) 
2.2 To compare the pharmacokinetics of LPV and RTV between PK1, PK2, PK3 and PK4. 
2.3 To document and evaluate adverse events and laboratory abnormalities in all 
patients throughout the study period. 
47 
University of  Cape Town
3.1 STUDY DESIGN 
The steady state pharmacokinetics of lPV and RTV will be evaluated in a cohort of South 
African HIV-infected volunteers under 4 sequential treatment conditions in steady state: 
lPV /RTV in standard doses (400 mg/l00 mg) 12 hourly together with 2 ·NRTls (standard 2nd_ 
line ARV regimen) without rifampicin (PK1; DAY1); lPV/RTV in standard doses 12 hourly 
together with 2 NRTls AND rifampicin (PK2; DAY8); 1.5 X the usual dose of lPV/RTV (600 
mg/1S0 mg) 12 hourly together with 2 NRTls AND rifampicin (PK3; DAY1S); and 2 X the usual 
dose of lPV/RTV (800 mg/200 mg) 12 hourly together with 2 NRTls AND rifampicin (PK4; 
DAY22). 
3.2 STUDY METHODS 
3.2 1. Study participants: 
HIV-infected volunteers established on 400mg lPV /100 mg RTV plus 2 NRTls will be 
recruited from ARV clinics within the Western Cape province. 
3.2.1.1. Inclusion criteria: 
• HIV-infected adults (~18 yr) 
• Established on an antiretroviral regimen comprising lPV 400 mg/RTV 100 mg and 2 
NRTls > 6 months 
• Undetectable viral load « 50 viral copies/ml); confirmed by Vl test within 12 weeks 
of the study 
• Al T (within 1 week of enrolment) < 1.5 X the upper limit of normal 
• Recent (within 12 weeks of enrolment) Hepatitis B virus surface antigen negative and 
HCV Ab negative 
• Normal ECG at a screening visit 
• Normal serum potassium at a screening visit 
• Medically stable· 
3.2.1.2. Exclusion criteria: 
• Previously failed to attain or maintain virological suppression on a protease inhibitor-
containing regimen. 
• Known to have chronic renal, hepatic or GIT disease that may interfere with the 
pharmacokinetics of the drugs studied. 
• Known to have cardiac disease that may increase the risk for developing cardiac 
conduction abnormalities. 
• ECG changes consistent with a prolonged PR interval (>0.20s) and QT prolongation as 
identified by using a QT correction formula. QT interval with Fridericia's correction> 
480 ms. 
• Hypo or hyperkalaemia, a family history of long QT syndrome or on medication that 
may prolong the QT /QTc interval. 
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• Fasting cholesterol >7.77 mmol/L (> 300 mgJdL; grade 3 or 41), fasting triglyceride> 
8.49 mmol/L (> 750 mg/dL; grade 3 or 4) or abnormal glucose measurements at 
baseline or 6 monthly checks (routine tests as per National Guidelines). 
• Alcohol consumption in excess of 2 units/day or 14 units/week. 
• Tuberculosis (T8) will be excluded by a structured symptom questionnaire. This was 
found to be 100% sensitive in excluding T8 in patients with advanced HIV disease in 
Cape Town (Mohammed 2004). Patients with any of these validated symptoms2 will 
not be enrolled. 
• Receiving drugs other than the study medication known to potently induce or inhibit 
CYP3A4 or alter the PK of LPV; at the discretion of the PI*. 
• Receiving drugs (e.g. Oral contraceptive) other than the study drugs whose PK is 
known to be altered (with potentially important consequences) by Kaletrall *. 
• Known or suspected pregnancy*. 
• Women of child-bearing potential who are not using a recognized form of 
contraception*; An injectable progestogen-based method of contraception is 
recommended for women requiring contraception. 
*Withdrawal from the study will be considered should these criteria no longer be satisfied 
3.2.2. Study treatments: 
3.2.2.1. Formulations: 
LPV /RTV: Aluvia, Abbott 
Film-coated tablet: LPV 200 mg co-formulated with RTV 50 mg 
(not currently registered in South Africa) 
Rifampicin: Rimactanell, Sandoz 
Tablet formulation: Rifampicin 600 mg 
(SA National Registration number: H/20.2.3/68-69). 
Patients will continue their regular treatment including dual NRTI backbone and other 
medications as prescribed and supplied by their regular health care provider. 
3.2.2.2. Study treatment schedule: 
DAY -5 to DAY 1: 400 mg LPV/100 mg RTV 12 hourly 
DAY 2 to DAY 8 (7 days): 400 mg LPV/100 mg RTV 12 hourly AND rifampicin 600 mg daily 
DAY 9 to DAY 15 (7 days): 600 mg LPV/150 mg RTV 12 hourly AND rifampicin 600 mg daily 
DAY 16 to DAY 22 (7 days): 800 mg LPV/200 mg RTV 12 hourly AND rifampicin 600 mg daily 
DAY 23: Resume standard of care treatment (with 400 mg LPV/100 mg RTV 12 hourly) 
1 Division of AIDS table for grading the severity of adult and pediatric adverse events (DAIDS AE grading table); 
December 2004. 
2 Weight loss> 2.5% in 4 weeks; cough> 2 weeks; nightsweats > 2 weeks; fever> 2 weeks. 
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The treatment durations are based on the assumptions that the inducing effect of rifampicin 
will take more-or-Iess 6 days to reach a maximum and the same time to wane. 
3.2.2.3. Treatment procurement and storage: 
It is anticipated that Aluviae will be registered in South Africa at the time of the study. It will 
be procured through an authorized commercial supplier. 
Rimactanee (Sandoz; SA National Registration number: H/20.2.3/68-69) will be procured 
through an authorized commercial supplier. 
The drugs will be stored at room temperature in a locked area with access restricted to 
designated study personnel. 
An inventory of receipt and disposition of all study drugs will be kept by the study 
pharmacist. 
3.2.2.4. Treatment packaging and labeling: 
The treatments will be packed within the Division of Clinical Pharmacology, UCT, by the 
study pharmacist. Separate packages will be prepared for each participant containing 
rifampicin and lopinavir/ritonavir, respectively. The study treatment will be packaged for 
weekly dispensing at the study visits on Day -5, Day 8, Day 15 and Day 22 (see study 
schedule - 4.1). Each package of dispensed medication will be labelled with the study 
number, the individual study participant's ID, the study days that the medication is to be 
taken, the generic and trade names of the products (manufacturer) with batch numbers and 
expiry dates, the investigators name (contact number), and "for study use only; keep in a 
safe place out of reach of children". 
3.2.2.5. Study treatment dispensing, administration and adherence: 
The study pharmacist will dispense the of study medication and keep records thereof. 
Patients will be given a week's supply of study medication to take at home on Day -5, Day 1, 
Day 8, and Day 15. Together with the medication the participant will be given a self-report 
treatment card to record all doses and drug taking times for the study treatment dispensed. 
Patients will also be requested to bring the remaining study treatment and all their other 
medicines to the ward for PK sampling admissions. 
On the days of pharmacokinetic sampling, the dose administration will be carefully observed 
by the investigators / designated assistant and a mouth check performed. The exact time of 
dose administration on PK days will be recorded in the CRF. 
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3.2.3. Pharmacokinetic (PKj assessment: 
PK sampling schedule (DAYS 1, 8,15 and 22) 
Scheduled time after drug dosing for blood sampling 
1. pre-dose -0.5 to 0 h (4 ml) 
2. 1.5 h ±1 min (4 ml) 
3. 2h ±1 min (4 ml) 
4. 2.5 h ±lmin (4 ml) 
5. 3h ±lmin (4 ml) 
6. 4h ±lmin (4 ml) 
7. 5h ±lmin (4 ml) 
s. 6h ±lmin (4 ml) 
9. Sh ±lmin (4 ml) 
10. 12 h +lmin (12 ml) 
total volume=4S ml 
n=24 
The exact (to the minute) times of sampling must be recorded in the study documents. If 
samples are deviate from the scheduled time, the reason should be noted in the CRF. 
Intensive samples should be drawn at the times (after treatment administration) indicated 
in Table 2. Pre-dose samples should be taken before the lopinavir/ritonavir dose on the 
morning of PK sampling. 
Sample labelling: Each sample will be labelled with the participant's study code, the 
sampling occasion (1 for PK1; 2 for PK2; or 3 for PK3) and the number of the sample (1 [pre-
dose] to 10 [at 12 h]). 
Eg. A04K - 1 - 7 will be used to label the i h (5-hour) sample taken at the 
PKl (DAY 1) assessment from participant A04. 
E.g. A23K - 3 -1 will be used to label the pre-dose sample taken at PK3 (DAY 
22) from participant A23. 
3.2.4. Determination 0/ drug concentrations: 
LC-MS/MS: Validated liquid chromatography - tandem mass spectroscopy (LC-MS/MS) 
methods will be used to determine LPV and RTV concentrations in the plasma samples in 
the Division of Pharmacology's laboratory, which is IS017025 accredited for this purpose. 
Concentrations below the limits of quantification will be reported as such. 
Plasma (LPV, RTV): 4 ml blood samples will be collected in heparinzed tubes. Within a 
maximum of 1 hour from the time of sampling, the blood specimens will be centrifuged to 
separate the plasma (10 minutes at 3000 rpm). Blood samples will be kept on melting ice 
prior to separation. From each sample, 2 x 0.25 ml aliquots of plasma will be transferred to 
into duplicate labelled polypropylene tubes and for stored at -S02C in the laboratory 
(Division of Clinical Pharmacology, UCT) until drug concentration determination. The label 
51 
University of  Cape Town
on each polypropylene storage tube will be identical to the label on the blood sample (see 
above) - and include the subject number, sampling occasion, and the sampling time. 
The results of LPV concentrations taken at PKl will be analysed within 2 weeks of collection 
and will be made available to the attending clinician. 
3.2.5. Safety monitoring: 
Adverse events (AEs) will be recorded at screening and on DAY 1, DAY 8, DAY 15, DAY 22 and 
DAY 29. A standardized assessment form will be used. 
ALT and total serum bilirubin will be monitored at screening and then 3 x weekly from the 
day before rifampicin is started until the end of the study period (screening, DAYS 1,4,6, 8, 
11, 13, 15, 18, 20, 22, 25 and 28). 
AEs will be graded according to the US Division of AIDS table for grading the severity of adult 
and paediatric adverse events (2004) and managed in accordance with the National 
Treatment Guidelines. In the event of a grade 3 or 4 AE thought to be related to the study 
intervention, the subject will be immediately withdrawn from the study and the DSMB 
informed. In the event of unexplained abnormal laboratory test values, the tests should be 
repeated immediately. After the initial AE/serious adverse event (SAE) report, the 
investigator should take all appropriate measures to ensure the safety of the patient until 
resolution or until consolidation ofthe patient's condition. 
SAEs will be reported to the Data Safety and Monitoring Board, the Research Ethics 
Committee and to the SA Medicines Control Council within 2 working days. 
The study will be stopped should 2 or more of the first 5 participants experience a SAE, or if 
3 participants (of the enrolled cohort) experience a SAE. 
3.2.6. Other laboratory tests: 
Haematology, chemistry and viral loads will be performed by standard operating procedures 
in the laboratories ofthe NHLS (National Health Laboratory Services). 
3.2.7. Data and recording and reporting: 
• All data will be recorded in the study specific case record form of each participant . 
• Double data entry will be used to transcribe the data for analysis into an electronic data 
base, except in the case of data that is generated electronically (e.g. LC-MS/MS results). 
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3.2.8. PK analysis: 
e Plasma PK data will be analysed using NCA to determine the following PK measures for 
lPV and RlV: 
Cmin (pre-dose sample concentration) 
C12 (concentration 12 h after observed dose) 
Cmax (peak plasma concentration) 
Tmax (the time to reach Cmax after drug ingestion) 
AUC(0-12) (the area under the concentration-time curve from 
0-12 hours after drug ingestion) 
Half -life 
NCA will be performed using the software package WlnNonlin (Pharsight Corporation, US). Drug 
concentrations below the limit of quantification will be treated as 'missing data'. 
3.2.9. Statistics: 
eThe proportions of trough and 12 h concentrations < lower limit of the recommended 
range (1 mg/l) will reported for PK1, 2, 3 and 4, respectively. Comparisons between the PK 
assessments will be made using Chi-2 test. 
eThe lPV and RlV PK measures generated by NCA from the data in intensively sampled 
patients with and without T8 treatment will be compared (using paired t-tests or equivalent 
nonparametric analyses for skewed data). The geometric mean ratios (90% confidence 
intervals) will be used to compare the Cmax and AUC(0-12) at PK2, PK3 and PK4, 
respectively, with PK1. Regression analyses will be used to identify potential significant 
covariate factors that might affect lPV or RlV concentrations. 
3.2.10. Sample size justification: 
The sample size approximates that usually employed for drug interaction studies of this 
nature. It should be sufficient to generate reliable estimates of the geometric mean ratios of 
the drug concentrations at PK2, PK3 and PK4, respectively, compared to lPV and RlV 
concentrations at PK1. 
3.3. SELECTED ETHICAL AND REGULATORY ASPECTS 
3.3.1. Informed consent: 
The investigator or a designated study team member will fully explain the nature, conditions 
and consequences of the study. A competent translator, familiar with the study will assist in 
the informed consent process when necessary. Subject information and consent documents 
will be available in Xhosa, Afrikaans and English. A witness independent of the study will 
countersign the consent documents of illiterate patients. Each participant will be given a 
copy of the signed consent document. No patient will be enrolled prior to or without their 
written informed consent. 
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3.3.2. Data management and storage: 
Individual source document files for study related source documents (screening notes, 
adverse events reports, blood test result reports, adherence questionnaire documents etc.) 
will be kept at the study site. In addition, a case record form (CRF) will be compiled for each 
participant for collection of subject specific details, study-related blood test results (apart 
from drug concentrations), drug dosing details and the exact times of PK sampling. The raw 
data relating to the drug concentrations will be kept in a study specific document. All study 
related documents will be stored for at least 10 years following study completion. A 
database will be populated with the relevant data using a system of double data entry 
(except for data imported electronically from the mass spectrometer). The duplicate plasma 
samples will be kept at -802C until one year after study completion. 
3.3.3. Compensation jor participation: 
Each participant will be compensated to cover travel costs and inconvenience on a pro-rata 
basis: For each intensive sampling admission (2 nights and a day) R310; and for each short 
study-specific visit, an amount of RSO. 
3.3.4. Withdrawal: 
Participants are fr~e to withdraw from the study at any stage, without prejudice to them or 
affecting their rights to care in any way. 
Withdrawal will be indicated in the event of Grade 3 or 4 adverse events related to the 
study intervention. 
Participation in the clinical trial may be discontinued should the attending clinician deem it 
in the best interest of the patient, if there is poor compliance with visits or non-adherence 
to study medication (see also footnote to exclusion criteria: II * Withdrawal from the study 
will be considered should these criteria no longer be satisfied.") 
For each patient withdrawn from the study, a CRF must be completed at the last visit 
performed. The investigator should make every effort to re-contact and to identify the 
reason why the patient failed to attend the visit and to determine his/her health status. 
3.3.5. Insurance: 
The University of Cape Town is the sponsor of the study and the study will be conducted 
under the auspices of the University. The University's insurance poliCies covering all persons 
participating in Clinical Trials research apply; compensation will be paid in accordance with 
the policies, when on the balance of probabilities, the injury was attributable to the 
administration of a medicinal product or trial procedure provided for by the protocol that 
would not have occurred but for the inclusion of the patient in the trial. The Guidelines for 
Good Clinical Practice in the conduct of Clinical Trials in human participants in South Africa 
(Department of Health 2000) will be followed. The insurance will cover the costs of any 
medical care required for study-related events, the affected participants will receive free 
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medical care (through the public or private sectors) for the treatment of the adverse event 
until its resolution. In addition, the University of Cape Town subscribes to insurance policies 
which include professional liability (policy number 20062796-05) and personal accident 
(policy number: 148901/C0206) which also apply to researcher and research participants 
involved in research conducted under the auspices of the University. 
3.3.6. Ethical and regulatory considerations: 
The risks and inconveniences of the study will be fully explained to each participant. No 
subject will be enrolled in the study before they have been fully informed about the study 
verbally and by means of a subject information document, with the aid of a translator if 
necessary, and signed consent has been obtained on the study specific consent form. 
Safety monitoring will limit harm amongst participants. The DSMB will be fully informed of 
any grade 3 or 4 adverse events, and will act to stop the study should they deem the risks 
greater than the potential benefit of the study. 
The study documents will be submitted to the Medicines Control Council (MCq of South 
Africa and to the Research Ethics Committee ofthe University of Cape Town. Approval ofthe 
protocol and any amendments will be obtained prior to implementation. 
The study will be conducted in accordance with the Declaration of Helsinki 2008, 
international guidelines for Good Clinical Practice (/CH 1997) and according to national 
guidelines of Good Clinical Practice [National Department of Health 2006] 
55 
University of  Cape Town
CLINICAL PROCEDURES 
4. 1. Study schedule: 
Note: Enrolment and screening will take place from DAY-30 to DAY-6. The relevant 
procedures are not included in the table above but are described in section 4.2, below. 
4.2. Enrolment (DAY -30 to DAY -6): 
4.2.1. Potentially eligible patients will be enrolled after written informed consent has been 
obtained. 
4.2.2. A log will be kept of all enrolled patients. The date of enrollment, the date of 
screening, the participant's study code, and the date of study completion/withdrawal (as 
appropriate). The reasons for withdrawal/ non participation will also be documented in the 
study log. 
4.2.3 Data collection at enrolment visit (after written informed consent has been obtained). 
• date of birth, sex 
• weight, height 
• WHO stage on starting HAART 
• routine baseline tests (routine tests on starting Kaletrae-based HAART in accordance 
with National ARV Treatment Guidelines): viral load, CD4+ cell count, ALT, FBC, 
glucose, triglycerides and cholesterol. 
• results of last routine (6 monthly) measurements of viral load, CD4+ cell count, ALT, 
FBC, glucose, triglycerides and cholesterol, if applicable. 
• adverse events, other antiretroviral drugs and concomitant medicines form 
• electrocardiogram (ECG) 
• Viral load (VL) - if the most recent VL was sent> 12 weeks before enrolment 
• ALT if the most recent ALT test was> 1 week before enrolment 
• 
• 
Serum potassium will be done within 1 week of enrolment 
HBVsAg and HCV Ab - if not done within the 12 weeks before enrolment 
4.2.4. A week's supply of the TABLET formulation (Aluviae) will be dispensed to the 
participant to take from DAY-S to DAY1 (at PK1). Together with the medication the 
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participant will be given a self-report treatment card to record all doses and drug taking 
times for the study treatment dispensed. Participants whose enrolment visit occurs prior to 
DAY -5 will be contacted by te~ephone on DAY-6, to remind them to switch from their 
standard Kaletrae to the tablet formulation; alternatively an appointment will be made for 
them to attend the study site to collect the tablet formulation on DAY -7 or DAY -6. 
4.2.5. On DAY -6 or DAY -5, participants will be reminded to contact the study doctor 
immediately, should he/she experience any new symptoms or exacerbation of symptoms 
during the study period. He/she will be asked to inform any other health care providers they 
might encounter during the study, of their participation, and to urge the health care 
provider to contact the study doctor should they be concerned that any of signs or 
symptoms of the patient may be related to the study or if they wish to alter the patient's 
medication in any way. 
4.4. PK sampling admissions (PK1, PK2, PK3, PK4): 
4.4.1 Participant reminder: 
The study nurse/coordinator will contact participants during the week prior to the PK 
assessment visits to final arrangements to ensure that the participant arrives at the study 
ward (J51 Old Main Building, Groote Schuur Hospital) at about 19hOO on the evening prior 
to the PK sampling days. The study nurse/coordinator will also remind the participant to 
bring with him/her any outstanding study treatments, his/her regular medication and 
his/her self-report treatment card. 
4.4.2. Deferment ofsamplinq: 
PK sampling will be deferred and another PK assessment day schedules if: 
1} The participant vomited after taking his/her ARV treatment the that morning, has acute 
diarrhea, or is medically unstable 
OR 
2} If the participant has been less than 100% adherent to treatment during the previous 3 
days (as documented on the patient's self-reported treatment record). 
4.4.3. Admission procedures and refreshments: 
Participants will be admitted to the ward. An adverse events form will be filled out for each 
participant and his/her blood pressure, pulse and temperature recorded. 
After a light standardized meal. Participants will fast overnight until 2 hours after the 
morning treatment administration, but water will be allowed freely except for the hour 
before and the hour after the morning treatment administration. 
A light standardized breakfast will be served 2 hours after treatment administration, and 
further light standardized refreshments will be provided until discharge the following 
morning. Alcohol, grapefruit juice, caffeine and black pepper will be avoided from admission 
until 12 h after dose administration. 
Patients will have the choice of going home after the 12 h blood sample, or staying 
overnight in the study ward until the next morning. 
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4.3.4. Blood sampling: 
A cannula will be inserted into a suitable arm vein for obtaining 4 ml venous blood samples 
the times indicated in section 3.2.3. Lithium/heparin blood collection tubes will be used. 
Plasma samples will be prepared from samples at all 10 sampling times (section 3.2.4). 
The exact times (to the nearest minute) of blood sampling will be noted in the CRF. 
4.3.5. Dose administration:: 
Immediately (within 30 minutes) after the pre-dose sampling, the study treatment will be 
given under the careful observation of a member of the study team (section 3.2.2.5). The 
exact time that the treatment is taken will be recorded in the case record form by the 
investigator or designated assistant. 
4.3.6. Data collection at PK sampling visits: 
• The previous week's study treatment doses and times (the self-reported treatment card 
will be collected) 
• Adverse events and concomitant medication form will be completed 
• ALT·, total bilirubin, (clotted tube; ± 4 ml) 
• FBC (EDTA tube; ± 4 ml) 
• At PK1: creatinine, albumin and C-reactive protein (clotted tube; ± 4 ml) 
* ALT and bilirubin results will be obtained before the evening dose of study treatments. 
4.5. Additional safety data: 
In addition to the measurements on PK sampling days (Days 1, 8, 15 and 22), ALT will be 
measured on Days 4, 6, 11, 13, 18, 20, 25 and 28. Asymptomatic participants with ALT 
elevations > 1.5 x the upper limit of the normal range will be asked to present for ALT 
measurements every second day and will be contacted telephonically on a daily basis until 
resolution to below 1.5 x the upper limit of normal. Should patients be symptomatic, they 
will be requested to present urgently at the study facility or any other appropriate facility 
for evaluation. 
Participants with adverse events will be closely monitored until resolution. Grade 3 or 4 
adverse events will necessitate withdrawal of the study treatments. 
An ECG investigation will be repeated at Day 15 (before increasing the dose to double the 
dose of Aluvia e) and at Day 22 (to determine ECG changes on double dose Aluvia \ This will 
indicate ECG changes with the dose escalation. Not only will this address any safety 
e 
concerns, but will add valuable safety information to Aluvia . 
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PARTICIPANT INFORMATION LEAFLET and INFORMED CONSENT 
DATE OF FIRST INFORMED CONSENT DISCUSSION: D D / D D / D D D D (dd/mm/wyy) 
INTRODUCTION: 
You are invited to take part in the research study, entitled: 
The pharmacokinetics of lopinavir in South African HIV-infected volunteers receiving rifampicin with adjusted 
doses of LOPINAVIR/ritonavir (600/150 mg and 800/200 mg). (APK.DDK study) 
RESEARCH INSTITUTION: 
Division of Clinical Pharmacology, K-floor Old Main Building, Groote Schuur Hospital, Observatory. 
Tel: 021406 6008 
Fax: 021 448 1989 
INVESTIGATORS and STUDY STAFF: 
Dr Eric Decloedt 
Dr Helen Mcilieron 
Professor Gary Maartens 
Professor Pete Smith 
Ms Marque Venter (Study Coordinator) 
Tel:0214066353 
Tel: 021406 6292 
Tel: 021406 6008 
Tel: 021406 6289 
Tel: 021 406 6659 
Cell: 0834198851 
Cell: 084 219 0667 
Cell: 074 333 8978 
Person conducting Informed consent Interview: ................................................................................................... .. 
Contact details: Tel:............................ Cell: .......................... .. 
Before you agree to take part you need to understand why the research is being done and what it will involve. 
Please read this information leaflet carefully and ask us if anything is not clear or if you need further 
information. It is important that you have enough time to decide; please don't agree to take part until you are 
satisfied that you fully understand what will happen, the potential benefits and the risks. 
What ;s the purpose of the research? Tuberculosis (TB) is an infection that commonly causes serious illness, 
and people with HIV-infection are particularly vulnerable to becoming ill with TB. Some HIV-infected people 
who get TB will need treatment for both HIV and TB at the same time. Unfortunately, one of the drugs used to 
treat TB (rifampicin) decreases the amount of some of the antiretroviral drugs in the body, such that the 
antiretroviral treatment does not work (e.g. lopinavir which is in Kaletrae /Aluvia). Using higher doses of the 
antiretroviral drugs when they are given with rifampicin might overcome this. This study will measure the 
amount of lopinavir in the body when the usual doses are given, without and with rifampicin, and when 1.5 and 
2 times the usual dose of Kaletrae / Aluvia is given with rifampicin. In this way the research will help to define 
the right dose of Kaletrae / Aluvia to use in patients who need TB treatment at the same time. 
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Why have you been invited ta take part? We are looking for 24 people who are established on antiretroviral 
treatment including KaletraID/Aluvia. They must be doing well on their treatment (undetectable viral load), be 
medically stable, and not taking certain other medications. Furthermore people who have problems with their 
liver, kidneys or intestine may not take part, and pregnant women or women at risk of becoming pregnant 
during the study may not take part. 
What are your options? You do not have to take part. The decision to take part, or not to take part, is yours. If 
you decide to take part, you will be asked to sign that you consent to take part. You will be given a copy of this 
information leaflet to keep. If you decide to take part you are still free to change you mind at any stage; you 
can withdraw before or during the study. Withdrawing from the study will not affect the standard of medical 
care that you receive. 
What will happen to you /f you take part? After signing your consent to take part, the study staff will check 
your medical records, ask you some questions and they may take a few blood tests to check your liver, to check 
for hepatitis B infection and to measure your viral load. They will also do an electrocardiogram (ECG) test to 
check that your heart has normal electrical activity. If these tests are all fine a study time will be scheduled. The 
study will last 34 days (see schedule on page 6). 
Study treatments: During the study period your KaletraID will be replaced with a study issued product (Aluvia) 
which contains the same active ingredients as KaletraID. 
• After 1 week of Aluvia in the usual doses, you will be asked to add take the TB drug rifampicin once a day. 
After a further week, the dose of Aluvia will be increased to 1.S times the usual dose and a week after that, 
the dose will be increased to 2 times the usual dose for a week. All the study drugs will then be stopped 
and you will resume your usual treatment with Kaletra ID. Except for KaletraID, you should continue to take 
all your medicines as usual throughout the study. 
• You will be given a "treatment card" to fill in the times that you take each drug dose during the study 
period. 
Hospital stays: On 4 occasions you will be admitted to the study ward, for measurement of the amount of the 
study drugs in your blood. 
• Each admission will last from a Friday evening to Saturday evening (1 night and one day). If it is difficult for 
you to get home on the Saturday evening, you can be accommodated until the Sunday morning. 
• During the admission you will be provided with food and refreshments, you may not have any other food 
or drinks. After a meal on the Friday evening you will be allowed only water until about 10 am the following 
morning, when you will be given a light breakfast. 
• On the Saturday morning a cannula (a flexible plastic needle like those used for to give fluids to 
hospitalized patients) will be placed into one of your arm veins. It will be used for taking blood samples 10 
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times during the day. The total amount of blood taken on each day wi" be less than 60 millilitres (12 
teaspoons). 
Safety monitoring: To monitor the safety of the study treatments we wi" take regular blood samples to test 
your liver. You will need to come to the study facility at least once a week (Monday or Tuesday) for 4 weeks 
and once at the end of the study (Thursday or Friday) for a blood sample to be taken. Furthermore, we will 
repeat the ECG test at 2 study visits, to ensure that the medication is not affecting your heart. 
What are the risks a/taking part? You will be taking rifampicin and extra lopinavirjritonavir (in Aluvia). These 
extra drugs are of no benefit to you and they might cause bad effects. Moreover, giving the combination of 
these drugs together might increase the risk of them having bad effects. 
• Bad effects of rifampicin include: nausea, vomiting, anorexia, abdominal discomfort, diarrhea, rash, 
drowsiness and headache. Rare but more serious effects are liver damage confusion, fever, skin reactions, 
damage to the blood cells and damage to the kidneys. Rifampicin stains urine, tears and other body fluids a 
reddish-brown to orange. You should not wear contact lenses during the study as they might become 
stained. 
• Bad effects that occur commonly with lopinavirjritonavir are diarrhoea, nausea and vomiting. Less 
commonly it causes an unusual fat distribution. A"ergic reactions, blood-sugar abnormalities and damage 
to the liver or pancreas are rare. Recently some patients receiving high doses of lopinavirjritonavir were 
noted to have ECG test abnormalities, indicating an effect of lopinavirjritonavir on the electrical activity of 
the heart. 
• When given together lopinavirjritonavir and rifampicin may cause an increased risk of liver damage: 
Studies in volunteers who were given rifampicin for a few days before Kaletra~ was added found that there 
is a high risk of liver damage. We think that this study is safer (patients with HIV-infection and TB have 
been given the treatments with a low risk of bad consequences) and we think that taking Kaletra~ before 
we start rifampicin is a safer approach. However, liver damage remains a serious concern, so we will 
monitor your liver regularly. 
• The study doctor will tell you if any new information that might affect your decision to take part becomes 
available. 
• The blood-taking process may cause discomfort or bruising, but these will be minimized because 
experienced health professionals will take the blood samples. 
• The amount of lopinavir in your blood may be less than optimal for up to 2 weeks. There is a small 
possibility this could cause the HIV-virus to become resistant to one of more of the drugs used to fight HIV-
infection. However, this risk is very slight as the lopinavir concentrations will only be reduced for a short 
time and the HIV in your blood is currently we" controlled. 
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What i/ something goes wrong? If you experience a change in your condition or any problem that might be 
caused by taking part, please contact the study doctor (or any of the other investigators listed on the first page) 
WITHOUT DELAY. 
If you see any medical professionals outside of the study during the study period, please inform them that you 
are taking part in the study. Please ask the medical professional to contact us urgently if they are concerned 
that you might be experiencing problems from the study treatments or if they wish to change any of your 
medication in any way. 
An insurance policy has been taken out to compensate you for reasonable medical expenses related to injury 
or illness which result from taking part in the study (Internationally accepted guidelines will be used: those laid 
down by the Association of the British Pharmaceutical Industry [ABPI Guidelines], and Guidelines for Good 
Clinical Practice in the Conduct of Clinical Trials in Human Participants in South Africa). Compensation will be 
paid where the injury probably resulted from a drug given to you as part of the study protocol, or any test or 
procedure you received as part of the study. Payment would be without legal commitment. We would not be 
bound by these guidelines to pay compensation where the injury resulted from a drug or procedure outside 
the study protocol, or ifthe protocol was not followed. 
What are the possible benefits 0/ taking part? You will not benefit. The results of the study will benefit future 
patients who need treatment for TB and HIV at the same time. We will inform your doctor of the lopinavir 
measurements taken at the first admission. This information might help your doctor to adjust your Kaletrae 
dose appropriately. However, you are unlikely to have abnormal measurements of lopinavir if you have been 
taking your treatment as prescribed. 
Will your privacy be protected? Yes, as far as is possible. Your medical records will be seen some of the 
researchers, and by authorized persons checking to see that the research is being carried out correctly. They 
may also be seen by representatives of the regulatory authority or the responsible ethics committee who may 
inspect the study records. All these people are obliged to maintain your confidentiality. Your identity will not 
be disclosed in any publication of the research findings. 
What will we use your blood lor? Apart from checking that it is safe for you to take part and to monitor your 
safety during the study, we will use your blood to measure the amounts of the drugs/ medicines in your 
blood. 
What will happen to the blood we take from you? The samples used to measure the drugs will be destroyed 1 
year after the study is finished. The samples will not be used for any purposes other than those stated in this 
document. 
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Will you be compensoted for your travel costs, time and inconvenience? Yes, you will be given an amount of 
RSO for short visits and R310 for admissions to compensate you for your time, the inconvenience and travel 
costs. 
What will happen with the results 0/ the research? The results of the study will be published so that they are 
available to the medical profession throughout the world. No patients will be identified individually. 
What organizations are supporting the study? The study is financed by the European and Developing 
Countries Clinical Trials Partnership (EDCTP) and the South African Department of Health. It is supported and 
organized by the University of Cape Town. 
What 1/ you have complaints about the study? If you want any information regarding your rights as a research 
participant, or have complaints regarding this research, you may contact Prof. Marc Blockman, the Chairperson 
of the Research Ethics Committee at the University of Cape Town (021 406 6492). After you have consulted 
your doctor or the ethics committee and they have not provided you with answers to your satisfaction, you 
should write to: The Registrar, South African Medicines Control Council (MCq, Department of Health, Private 
Bag X 828, PRETORIA 0001. 
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INFORMED CONSENT FORM 
....................................................... (STUDY DOCTOR/DESIGNATED STUDY TEAM MEMBER) has provided me with a copy of 
the Participant Information Leaflet regarding the study, liThe pharmacokinetics of lopinavir in South African 
HIV-infected volunteers receiving rifampicin with adjusted doses of LOPINAVIR/ritonavir (600/150 mg and 
800/200 mg)." 
and has fully explained to me the nature, risks, benefits and purpose of the study. 
• I have been given the opportunity to ask any questions concerning the research study procedures, the 
potential benefits and risks. 
• It has been explained to me that I am free to withdraw from the study at any time, without any 
disadvantage to future care. 
• I understand everything that has been explained to me and I consent to take part in this research study. 
PARTICIPANT: 
Print name Signature / Thumbprint Date 
STUDY DOCTOR / DESIGNATED STUDY TEAM MEMBER: 
Print name Signature Date 
TRANSLATOR / PERSON EXPLAINING INFORMED CONSENT: 
Print name Signature Date 
WITNESS: 
Print name Signature Date 
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PARTCIPANT SCREENING AND ENROLMENT INFORMATION 
i Study Volunte<tr 
i SCI"(IMtng # 
EUGIBILITY ASSESSMENT 
Has inforlned consent been sio;lned ~ yolun(~e' ",ior (Q ~twy entry? 
... ...................... F +. , y~s '" 
, Has the vollinteer been documefltfld to ue HIV·infoc\ed hy p<::<; iti.e HIV.afltiuody te~P , no 
00 
, 
00 
t il 
1
00 
" 
00 
,,' y~s 00 
In yoor or"ni<J<l, is tM r . (ient medic. liy stabld yes "0 
, , ,., 
" 
renal, hep~k or GIT Jisease th. ! may interfere with 
• 
, 
• 8 49 InInO~.'L? jes ," 
• ", stino r'asm. gll.<:Ose ~ 
" 4 Does the .00unl00< consume in excess 012 un its/d.y or 14 unitslweek alcaml'; ,.> 0" 
5 Has tuberculosis (TB) been exduded? y~s 00 
, , 
" 
yes 
'" 
It; , 
,., 00 
8 Is the volunt~e< known C<" , uS!>"ct"d to he pre~nanj? jes ,'" 
jes 
'''' 
" 
iii 
V~"i"" I, dal~22,OU()()(J Po!g<! 1 01 7 
University of  Cape Town
PARTCIPANT SCREENING AND ENROLMENT INFORMATION 
~_~_~,,"':...",.V"J.:""-;'·c·c'l="==~=,I="='c'=''',,~~LJ I,. _,1 _______ _ 
SCREENING VISIT DATE: .. _.1_. _ .. '20., .• __ 
----------
Inlconod C(jnselll 
COIl~e-nI ~i gr>ed pri'" to any study-related procedures 00"," peITormed? 
Date siWtOO; ..... , _ ..• " .• ".120 •.• ," 
sructy Volunteer DemooraDJ:Jig 
... ,1.,., •.. • . 119 Date 0/ binl1 
~, M<lle l Femole 
Black l White i Caloured l Asian i oIher: 
GenerallnlortTJati"n: 
ConlIacepilon: 
I! female, is "'" usin ~ cootmceptioo; 
I! yes: what type 0/ contraception is OOtl\! used? 
Alcohol: 
Do yw us~ alcoho(/ 
It yeo 
Type 01 ..!cohol W.,.,.l\Jeerl. pirits.1othef' 
Units pe< week? 
Do you binge drir.k? 
If yes, how m~ny unH. per epi "od~ 
Smelling. 
Smoking cla~"'ioatio" l Ne.';;-~-;':'-;;;~\ --------F:~~-~:~--C --["smoker ~ 
Drog aOOst/, 
Do you use recreational drugs? 
If yes, what 00 you useihow ofterL~asl use? 
Clinical rn'als: 
Have yw taken pan in any other clinic~1 triols rui"," Ihe i<l81 2 IT">nlhs" 
II yes, provide detlJils 0/ Ih~ tri~ 1 ~s well . s th~ ~Iudy druy U~M 
Ye~ i No 
Yes i No 
Yes! No 
Yes l No 
Yes 1 No 
Yes i No 
NO~:r -------------------------
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cPiiAiiR"TilC:iilPiiA;rN~T.SNCRE_~N[_~N~~~":.~~ ~~: ':C:OC'LMC-_EONC--TC::L~~_eO-r£:";~.~CT:;I CJ~. _ .. ,_, ___ ., ___ A~CeK'.'DD,,"KC-'"'""'"''-
Genergl medic!!! hi§J2[~ 
Allergies 
Do y(~J i"'/e an, a ll ef~ i es to 'l1 ... ~ ici r;es? 
If Y'''. ",,,,oily 
Contra ind icatior>li to rNa mpi<;in 
Do you have porphyria? 
Have yoo used rifampicin iTS trealrneni) t..>1" e7 
I(yes: 
Did you develop a s ki n reaction or ~ rash ~ccompenied by a fe~ef?: 
Did you develop live, toxicity or jaundice? 
Eleborate' 
Adverse e~ents due to looinavir!ritonavir; 
Did you experience any adverse events or side-effects COl lopinaviriri~vir? 
EI~bo<~If" 
---' .....• -
Nons 
Pt.1J" 3 of J 
Yes/No 
Yes i No 
Yes i No 
Yes '" No 
Yes l No 
University of  Cape Town
H""e yOLl ~"er .uffered fram prallierns with y0\1' 
SyMem 
Head & Neck 
...... _- ------
i D~sCrrpliO/1 
·······t· 
. Yes No 
--- ._ .. _.- .................... , .. 
I Yes 
I 
I Eyes 
: Ears, nose. throat/mouth 
-----
Thyroid 
--
Heart 1--- -_ .. 
Yes No 
G" .tro; n le.1 i r>iIf Yes No 
Liver Yes No 
Urogerlita l tract ,-, ~ 
_. 
-- ----- --------- ----t--
Musculoskeletal 
, ,,, 
'0 
---------
Central """'OLlS system ,,, '0 
'000 ,,, "0 
------------- --------
S~in ,,, "0 
APK.DDK-study .. 
~~~-----.--.-.--
~ D~te Rea.on ,topp<1d 
Failure Toxicity d4T AZT EFVINVP 
EFViNVP Failure Taxicity 
Failu re Toxici ty 
dH i\ZT 
~--+--t- 1-
Failure Taxicity 
1 Failure Toxicity 
WHO 
Slagi"!) wh en .tarf,"!) HAART' 
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'P,A,R"T,C"IP"AN"",TCS,C~ROE~E~N~'~N~G~A~N~DgEgN@R~O~L"M"E;N"T4IN'FCOFR""MA",T,'O"N\==r=T=r_cA'PO'''_DgK'S.t~~~ 
"I ~"",""v·,,";,,"=·=,=,,1 =,,1 ~II~NIT~IAL~S~L--,_ f] 
! 
Exctudlng TB 
Did yoo 10058 w",ght in the I~st 4 w~""'s? 
II yeo, what wa s th ~ w!!i ght b~lore? __ " 
Whalisyoorweightoow? __ '" 
H~.e yoo beM cou~h;fl!l toe more tM "n 2 weeks? 
H~.e you b",," havinolev...-IOf more than 2 weeks? 
OF 
OF 
H~ve yoo been havirl\l ni~htsweats for mc.re than 2 weeKs?' 
MedicElicn 
---~-
What -
Yeo I No 
dress/pa", " i~e boofoce? 
dl1lsslp"'" s i~e 00l"? 
y~s I No 
Yes" No 
Yes " No 
m8,jjcation did Why did yO<! When did you Ar~ you stol I! no, wil8n did you 
yoo t~ke in the 
laSl3 mooths? 
I 
take it? stan laKitlQ it? taKing it? 
,,' 
,,, 
, .. 
Y .. 
y" 
1 y" 
y" 
,-, 
--------- -- -------
-
5uryk<ll hislOly,' 
Have yoo had any surgical r,,"ocedures in th e I~st ye..-' 
If yes, p'Qvide details' 
Pi>9" 5 of7 
,-, 
", 
stop taking it? 
- ----
No 
-
--.--
No 
-t -
No ! 
-
No 
-----
No 
---
No 
No 
No 
--- --- ---
No 
------------
No 
Yes I No 
Dose l/Sed 
--, 
I 
I 
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PAftTCIPANT SCREENING AND ENROLMENT INFORMATION 
Physical examination 
I 
Body $Y$tem 
I Stu<1y Volunteer 
S<:r..rn!lO} It I I I INITIALS 
Height Or!ol temperature 
em c C 
Notdone 
I] 
Supine BP 
mmHo 
Supine pul$" 
bprn i 
-----j 
I Geoor. 1 appearance 
Head and neck 
---------+----------1 
Eyes, ears. 00"", 
f"C"'"~"~m"w"'C" __ ~ _______ +--_________________________ ~ 
Ca'dioy~ scular 
Pulrnooary 
AWoo\,m 
. ----+----------1 
------ -----------1 
--------
Urogonil . 1 r--~""";,;'"";~;'""~,·;"';, ============~-----== ----- ----------------
Neurologcal 
Skin 
Olh"r 
Commerll~ 
Special jnVl!sti!latiOr]S: 
CXR done? 
II yes, 
Dale 
~~ 
Reponed by 
SUQ(lestiVQ 01 PTa 
II y"" provide delails' 
-----+------------1 
Yes i No 
,.,.1,. , •....•. , 120 __ ._ 
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PARTCIPANT SCREENING AND ENROLMENT INFORMATION 
r--'-~-
Blood test D~t8 
HI\! ELISA 
a"s<'/ino /t>sis don" 0" s!"rlinf} ~1f>avir·b"stW HAART 
Vira' lead i , ------- -----, CD4+ 0,,11 couni i , 
, AC' ! , 
'" 
, 
-------------~--
-- -- [--
Random plucose , 
F~sting QUe"",, , 
-- - ---- --- ------ -------
Tri~lyoerid .. s , 
-----
COOIe,i"",1 , 
Test:; di;YI~-on las"! 6 "'oolllly tr}l1lin" VISrI ' 
- --
Virallood 
----------
CD4+ cell CQu,1I 
AL 1" 
---~--
,eo 
Ra<ldom ~ Iucos .. 
F~sti~ ~1\lC()ISQ 
--- - ------ ------- -- ----- ----- ------
Tri~lyo...-id .. s 
---------
CoolestefOl c--- ---------HBV~' 
HCV Ab' 
, 
Rapeat test if resul t i. m"", tho n 12 w9<lks old 
' Rep"all"S! if rasult is more thun 1 week old 
------------
PATIENT INCLUDED IN STUDY, YES/NO 
IF YES' PARTICIPANT ID / Enrol"",nt # D ____ _ 
IF NO: REASON _ 
FORM COMPLETED BY-
NAMf'- ___________ S/GNATURE 
SlutiyRol€! DATt' 
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PKVISIT 
ADMISSION DATE: _ .... _ .. 1._ .. _ .. _ ... , 2009 
Act1",."..,e 
Pi~ coont dome Yes i No 
Treatroont card checked Yes i No 
Ct>eck list lor new treatm ent of AEs completed Yes' No 
yttal $igns 
LI·_-_""'_ ... _"'_,"-'-I_'_ ....... __ ·-t 
Time of Friday evenir>;J Aluviu~ dose (~e·PK ""mplir>;J dase) 
Time of dose oIlsefVed 0 I obtainedlrom vofunteer rnstory D 
APK.DDK-STUDY 
TIME: ._ .. _ .. h _ .. 
p<!te: 
.Blood samples to be taken from yolun\eer.~fte'~m]llfating ()IJ PK sampling day: 
PiJi/~ lof I PK .<DUlce OOcjjn,.",t 
University of  Cape Town
DATE:,. , .• , .. I •...•...•.. 12009 ., , ' ,'.U 
. "'." • c • TlME: •...•.. , h •.. , 
.............. __ ._-----
CheGi< list fOf new tre~tm .. nt ~ nd A.E', completed? Yes,' No 
Vital siMS 
. ______ ·c 
__ '__ mm", 
I oyestig ator aig n.!ll1r.~; 
""" 
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ADVERSE EVENl RECORD 
Date 
I-/ 20()9 Yes I No 
- , , . " " " 2009 
""'''''' 
Yes I No c----.-.-... _ .. 
, -------------~ ..'-~""'-'-'.''"''+------ ------
,~ 
__ I 2009 Yes/ND 
" ,." ... ,/2009 ""'fe" Yes / No 
-
--,'-,--''".,."''''"' ,.,'''--'';---t_----------
-----
i~ 
" . ,,/ . ,, _ ,/2009 ! ""'I<" Yes/No c-- ----------
~"" .. '" ... y 
~ 1-----
Yes / No 
",' 2009 f' """",,''----t_-
1----------t~;';'":":'.·.·.'.'~~J------ -
~" •• ,.'----t_j 
AOdO",," ...,fe" 
__ 12009 
__ " 20()9 '_"e_"'-___ t_-I Yes / ND 
.. ",' "".,,,,,/20()9 
-------I-'"'.'".'~"".-",.'--"'-I-+--------
~;~;;;:::::-~otDly - Yes,' No 
-
Fo"'" uo "" 
r""~"'~ """""" 
e',"'" 
fo"'" "e'" 
I""*"_~ 00:1""", 
-
F" ",", Up on 
."."'''~ om",," 
""',,' 
Now "'" .. '" O'f~O' 
FoIo.o u~ at1 
I"""""-~~ 
-
-
""~ '", ...... onL 
Fo _",,"" 
" .. """-"" ,~ 
~,"v .... ~ .. ", 
F,*"" "" "" ~"";:,'" _ee>o 
.-
... ~ " " ",," 0 """,, 
rolowl\loo 
", .. ,,,",_ .. 
c,,,. 
N ... 00:1".'" 0 ___ 
Fojow"" on 
~rov"". :>lve,,., 
-
_ .
M,j.""' ;>;)fet,_t--I _________ j"""""-____ , _ 
'" / "" . ,,/2009 
"---- -
~ 
Silioty 
..... aJ ',6fSC """ " 
f ,,;:,w L\l on 
I """""",' ""v",," 
- " 
Yes / No 
Yes / No 
Yes / No 
r 
Ye,,I No 
Yes / No 
y",,INo 
, 
-
Yes / No 
i 
YeslNo 
Yes / No 
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APKDDK 
ADVERSE EVENT ASSESSMENT FORM 
PARTICIPANT'S STUDY ID D DATE I dd I mml 2009 
Name of person completing form 
section 1 
(A) Does the participant report any problems with taking the medication? 
If YES, describe: 
(8) Does the patient associate the problemls with particular medicine/s? 
If YES, describe: 
Section 2 
Do any findings on history or examination meet the definition of an adverse event (AE)? 
An AE is any untoward medical occurrence which does not necessarily have a causal relationship with this trial treatment. It can be any 
unfavoureble and unintended sign (inel an abnonnallaboretol)' finding). symptom or disease temporally associated with /he use of the study 
drug. whether or not related. 
If YES, please describe on page 2. Grade using the DAiDS system in the study file. 
If AE is grade 3 or 4. /he pallicipant must be withdrawn from the study and /he DSMB informed." /he AE is serious (results in death. is life 
threataning. requires hospitalisation or prolongation of a hospital edmission. is medicaUy important/necessitates change in ARV regimen). 
contact PI (/hus REC. MCC) asap; FUI out SAE fonn 
Section 3 
Are any laboratory results abnormal? 
IF YES, please record on page 3. Use the DAIDS grading system in the study file 
If AE is grade 3 or 4. /he pat/icipant must be withdrawn from /he study and /he DSMB infonned. If the AE is serious (results in death. is life 
threatening. requires hospitalisation or prolongation of a hospital edmission. is medically important/necessitates change in ARV regimen). 
contact PI (thus REC. MCC) asap; Fill out SAE ronn 
Notes: 
Version 2.0 Dated 1910612009 
APKDDK 
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APK.DDK 
ADVERSE EVENT ASSESSMENT FORM - page 2 
PARTICIPANTS STUDY 10 
AE 1 description 
(use DAiDS categories 
W applicable) 
o DATE I dd I mm I 2009 
when did it start? I did 1m 1m Iy I y I duration .... 1 ____ ..... 1 / I ongoing I 
please grade the event - use DAIDS system in study file 
does it meet the definition of serious? 
is it associated with any particular medicine/s? ~ 
which drug/s? 
[][]][])[]J 
[Y]I]] 
probably I possibly [§J 
I 
Action Dnone Dincreased observation Dhospitalization Dmedication (as below) 
Treatment plan 
nochange D drugs started D drugs stopped D reason: 
drug: ~I I------I 
AE 2 description 
(use DAIDS categories 
if applicable) 
when did it start? I d I dim 1m Ix I y I duration .... 1 ____ .... 1 / I ongOing I 
please grade the event - use DAIDS system in study file 
does it meet the definition of serious? 
is it associated with any particular medicine/s? 
which drug/s? 
[][]][])[]J 
[Y]I]] 
probably I .... 1 -pos-s"""ib""'ly"'l [§J 
I 
Action Dnone Dincreased observation D hospitalization Dmedication (as below) 
Treatment plan 
nochange D 
drug: 
drugs started D drugs stopped 
Please photocopy more sheets If more AE's 
Notes: 
Version 2.0 Dated 19/0612009 
D reason 
APK.DDK 
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APKDDK 
ADVERSE EVENT ASSESSMENT FORM· page 3 
PARTICIPANT'S STUDY ID D DATE dd I mml 2009 
Section 3 
Please report any abnormal laboratory results 
Please grade the AE using the DAIDS system in the study file 
Please specify the date the test was taken 
TEST: RESULT: GRADE: 
[] [II 
relation to drug: Iffi:J Iprobably IpoSSibly [§:] 
2 [] [II 
relation to drug: Iffi:J Iprobably IposSiblY [§:] 
31 [] [II 
relation to drug: ~ IprObably IposSibly [§:] 
41 [] [II 
relation to drug: Iffi:J IprObablY IposSibly [§:] 
5 1 [] [II 
relation to drug: Iffi:J IprobablY IpOSSibly [§:] 
6 1 [] [II 
relation to drug: Iffi:J Iprobably lpossibly [§:] 
71 [] [II 
relation to drug: Iffi:J Iprobably IposSibly [§:] 
DATE otTEST: 
[]] III Idldlmlmlyly 
which drug/s: 1 
[]] III Idldlmlml:d~ 
which drug/s: 1 
[]] III Idldlmlml~l~ 
which drug/s: 1 
[]] III Idldlmlrnl~l~ 
which drug/s: 1 
[]] III IdldlrnlmlYI~ 
which drug/s: 1 
[]] III Idldlmlmhly 
which drug/s: 1 
[]] III 1 dl dlrnlrnl ~I ~ 
which drug/s: 
ACTIONS: Dnone Dincreased observation Dhospitalization Dmedication (as below) 
TREATMENT PLAN: 
nochange D 
drug: 
Notes: 
drugs started D drugs stopped D reason 
~ 11-----
Version 2.0 Dated 19/0612009 
APKDDK 
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APKDDK PK umpling r""ord Participant II) liiTTI 
PK SAMPLING VISIT Date of PK_ sampling: -09 
itl 
" 
AILJvia" (400/1 OOmg) __ i tablets administered Time of dose: 
Observed by: Signature' 
Comments 
~ nrrl - ----, I 0 ------- - - 01 
----, II"IT] I I 0 - 02 ,~ : -- - __ .J 
0 
-- -
- 03 
.2J [ I I I I :--.JTI 
~ I I I lJ ~------T II 0 -04 ' I -- -
0 
-- -
- 05 =::0 IITT 
".", I I I 
-06 ='J W. - UlJ 0 
-- - ----- -
0 - 07 CD ITI J I I I 
0 -08 U] I I [LJU! 
0 -09 U] ,----, I I I LJ 
-- -
0 - 10 LiJ LLI _.-
, , 
NOTES' 
Th is form shou ld be fiIIgd ill duplicate 
University of  Cape Town
Appendix 3 
Ethics approval letter 
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Appendix 4 
Instructions for authors: 
Antimicrobial Agents and Chemotherapy 
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ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 
2011 INSTRUCTIONS TO AUmORS· 
SCOPE 
Antimicrobial Agents and Chemotherapy (AAC) is an 
interdisciplinary journal devoted to the dissemination of 
knowledge relating to all aspects of antimicrobial and 
antiparasitic agents and chemotherapy. Within the cir-
cumscriptions set forth below, any report involving stud-
ies of or with antimicrobial, antiviral (including antiret-
roviral), antifungal, or antiparasitic agents as these 
relate to human disease is within the purview of AAC. 
Studies involving animal models, pharmacological char-
acterization, and clinical trials are appropriate for con-
sideration. 
ASM publishes a number of different journals cover-
ing various aspects of the field of microbiology. Each 
journal has a prescribed scope that must be considered 
in determining the most appropriate journal for each 
manuscript. The following guidelines may be of assis-
tance. 
(i) Papers which describe the use of antimicrobial 
agents as tools for elucidating the basic biological pro-
cesses of bacteria are considered more appropriate for 
the Journal of Bacteriology. 
(ii) Manuscripts that (a) describe the use of antimi-
crobial or antiparasitic agents as tools in the isolation, 
identification, or epidemiology of microorganisms asso-
ciated with disease; (b) are concerned with quality con-
trol procedures for diffusion, elution, or dilution tests for 
determining susceptibilities to antimicrobial agents in 
clinical laboratories; and (c) deal with applications of 
commercially prepared tests or kits to assays performed 
in clinical laboratories to measure the activities of estab-
lished antimicrobial agents or their concentrations in 
body fluids are considered more appropriate for the 
Journal of Clinical Microbiology. Manuscripts concerned 
with the development or modification of assay methods 
(e.g., plasma antimicrobial concentrations and high-
throughput screening techniques, etc.) and validation of 
their sensitivity and specificity with a sufficiently large 
number of determinations or compounds are considered 
appropriate for AAC. 
(iii) Manuscripts describing new or novel methods or 
improvements in media and culture conditions will not 
be considered for publication in AAC unless these meth-
ods are applied to the study of problems related to the 
production or activity of antimicrobial agents. Such 
manuscripts are more appropriate for Applied and En-
vironmental Microbiology or the Journal of Clinical Mi-
crobiology . 
(iv) Manuscripts dealing with properties of unpuri-
fied natural products, with entities that are primarily 
·Instructions to Authors are published annually In the January issue. 
A separate html version, which is updated throughout the year, is at 
http://aac.asm.org/lI1isc/ifora.dtl. 
antitumor agents, or with immunomodulatory agents 
that are not antimicrobial agcnts arc not appropriate 
for AAC. 
(v) Manuscripts dealing with novel small molecular 
antimicrobials must provide at least some data show-
ing that the proposed new agents or scaffolds have the 
potential to become therapeutic agents. Appropriate 
demonstrations will vary but generally should be some 
combination of data on physical properties (solubility, 
protein binding, log P [logarithm of the ratio of the 
concentrations of un-ionized solute in solvents]). 
pharmacological properties (Cac02 predictions of bio-
availability, pharmacokinetics in an animal species), 
or tolerability (mammalian cell toxicity, likelihood of 
hepatic metabolism, potential for receptor interac-
tions, potential for human ERG liability). Initial pre-
sentations of compounds are not expected to address 
all these areas but rather to show an appropriate ini-
tial subset. For example, the first publication of a 
novel compound or compound series might address 
selected physical properties plus mammalian cell tox-
icity. Subsequent publications are expected to add 
progressively to the proof of the agent's therapeutic 
potential. 
(vi) Biochemical analyses for ~-lactamases that deter-
mine kinetic parameters (e.g., Km , kcat) must be per-
formed on purified enzyme preparations. The enzyme 
must be in its native form, without any leader sequences 
or fusions used for purification (e.g., His tag). The de-
termination of relative rates of hydrolysis may be per-
formed on crude extracts. 
(vii) Authors of papers describing enzymological stud-
ies should review the standards of the STRENDA Com-
mission for information required for adequate descrip-
tion of experimental conditions and for reporting 
enzyme activity data (http://www.beilstein-institut.de/en 
/projekte/strendalguidelines/). 
(viii) A manuscript limited to the nucleic acid se-
quence of a gene encoding an antibiotic target, receptor, 
or resistance mechanism may be submitted as a short-
form paper (see "Short-Form Papers") or a New-Data 
Letter to the Editor (see "Letters to the Editor"), de-
pending on its length. Formatting instructions for nu-
cleic acid sequences are given below (see "Presentation 
of Nucleic Acid Sequences"). Repetition of sequences 
already in a database should be avoided. 
Questions about these guidelines may be directed to 
the editor in chief of the journal being considered. 
If transfer to another ASMjournal is recommended 
by an editor, the corresponding author will be con-
tacted. 
Note that a manuscript rejected by one ASM journal 
on scientific gronnds or on the basis of its general suit-
ability for publication is considered rejected by all other 
ASM journals. 
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2 2011 AAC INSTRUCTIONS TO AUTHORS 
EDITORIAL POLICY 
Use of Microbiological Infonnation 
The Council Policy Committee (CPC) of the Ameri-
can Society for Microbiology affirms the long-standing 
position of the Society that microbiologists will work for 
the proper and beneficent application of science and will 
call to the attention of the public or the appropriate 
authorities misuses of microbiology or of information 
derived from microbiology. ASM members are obligated 
to discourage any use of microbiology contrary to the 
welfare of humankind, including the use of microbes as 
biological weapons. Bioterrorism violates the fundamen-
tal principles expressed in the Code of Ethics of the 
Society and is abhorrent to ASM and its members. 
ASM recognizes that there are valid concerns regard-
ing the publication of information in scientific journals 
that could be put to inappropriate use as described in the 
CPC resolution mentioned above. Members of the ASM 
Publications Board will evaluate the rare manuscript 
that might raise such issues during the review process. 
However, as indicated elsewhere in these Instructions, 
research articles must contain sufficient detail, and ma-
terial/information must be made available, to permit the 
work to be repeated by others. Supply of materials 
should be in accordance with laws and regulations gov-
erning the shipment, transfer, possession, and use of 
biological materials and must be for legitimate, bona fide 
research needs. Links to, and information regarding, 
these laws and regulations can be found at http://www 
.asm.org/ under the Public Policy tab. We ask that au-
thors pay particular attention to the NSAR Select 
Agentfl'oxin list on the CDC website http://www 
.selectagents.gov/index.html and the NSABB criteria for 
identifying dual use research of concern in the report 
"Proposed Framework for the Oversight of Dual Use 
Life Sciences Research: Strategies for Minimizing the 
Potential Misuse of Research Information" on the Of-
fice of Biotechnology Activities website http://oba.od.nih 
.gov/biosecurity/pdf/Framework%20for%20transmittal 
%200807_Sept07.pdf (p. 17-22). 
Ethical Guidelines 
ASM requirements for submitted manuscripts are 
consistent with the Uniform Requirements for Manu-
scripts Submitted to Biomedical Journals, as last up-
dated by the International Committee of Medical Jour-
nal Editors in April 2010 (http://www.icmje.org). 
Authors are expected to adhere to the highest ethical 
standards. The following sections of these Instructions 
include detailed information about ASM's ethical stan-
dards. Failure to comply with the policies described in 
these Instructions may result in a letter of reprimand, a 
suspension of publishing privileges in ASM journals, 
andlor notification of the authors' institutions. Authors em-
ployed by companies whose policies do not permit them to 
comply with ASM policies may be sanctioned as individuals 
andlor ASM may refuse to consider manuscripts having 
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authors from such companies. The ASM Publications 
Board wishes to clarify the following in particular. 
Plagiarism. Misappropriating another person's intel-
lectual property constitutes plagiarism. This includes 
copying sentences or paragraphs verbatim (or almost 
verbatim) from someone else's work, even if the orig-
inal work is cited in the references. The NIH ORI 
publication "Avoiding Plagiarism, Self-Plagiarism, and 
Other Questionable Writing Practices: a Guide to 
Ethical Writing" (http://orLdhhs.gov/education/products 
/plagiarisrn/) can help authors identify questionable writ-
ing practices. 
Plagiarism is not limited to the text; it can involve any 
part of the manuscript, including figures and tables, in 
which material is copied from another publication with-
out permission and attribution. An author may not reuse 
his or her own previously published work without attri-
bution; this is considered self-plagiarism. 
Fabrication, manipulation, and falsification of data. 
As a member of the Committee on Publication Ethics 
(COPE), ASM encourages authors to consult COPE's 
"Guidelines on Good Publication Practice" (http: 
//publicationethics.org/static/t 999/1 999pdft 3.pdf). Fab-
rication, manipulation, and falsification of data consti-
tute misconduct. As defined by the U.S. Department of 
Health and Human Services, fabrication is "making up 
data or results and recording or reporting them," and 
falsification is "manipulating research materials, equip-
ment, or processes, or changing or omitting data or re-
sults such that the research is not accurately represented 
in the research record" (42 Code of Federal Regula-
tions, §93.103). All sources and methods used to obtain 
and analyze data, including any electronic preprocessing, 
should be fully disclosed; detailed explanations should 
be provided for any exclusions. 
Primary publication. Manuscripts submitted to the 
journal must represent reports of original research, and 
the original data must be available for review by the 
editor if necessary. 
By submission of a manuscript to the journal, the 
authors guarantee that they have the authority to publish 
the work and that the manuscript, or one with substan-
tially the same content, was not published previously, is 
not being considered or published elsewhere, and was 
not rejected on scientific grounds by another ASM jour-
nal. It is incumbent upon the author to acknowledge any 
prior publication, including hislher own articles, of the 
data contained in a manuscript submitted to an ASM 
journal. A copy of the relevant work should be submitted 
with the paper as supplemental material. Whether the 
material constitutes the substance of a paper and there-
fore renders the manuscript unacceptable for publica-
tion is an editorial decision. 
In brief, a paper is not acceptable for submission to an 
ASM journal if it, or its substance, has been publishedl 
posted in: 
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• A serial, periodical, or book 
• A conference report or symposium proceedings 
• A technical bulletin or company white paper 
• A non personal website 
• Any other retrievable source 
The following do not preclude submission to, or pub-
lication by, an ASM journal, as long as the posted data 
do not constitute the substance of a submission: 
• Posting of a method/protocol on a nonpersonal 
website 
• Posting of a limited amount of original data on a 
personaVuniversity/corporate website or web-
sites of small collaborative groups working on a 
problem 
• Posting of unpublished sequence data on the In-
ternet (the URL where the sequence is posted 
should be included in the text) 
• Preliminary disclosures of research findings as 
meeting posters. webcast as meeting presenta-
tions, or published in abstract form as adjuncts to 
a meeting, e.g., part of a program 
• Posting of theses and dissertations on a personall 
university-hosted website 
Availability of materials. By publishing in the journal, 
the authors agree that, subject to requirements or limi-
tations imposed by laws or governmental regulations of 
the United States, any DNAs, viruses, microbial strains, 
mutant animal strains. cell lines, antibodies, and similar 
materials described in the article are available from a 
national collection or will be made available in a timely 
fashion, at reasonable cost, and in limited quantities to 
members of the scientific community for noncommercial 
purposes. The authors guarantee that they have the author-
ity to comply with this policy either directly or by means of 
material transfer agreements through the owner. 
Similarly, the authors agree to make available com-
puter programs, originating in the authors' laboratory, 
that are the only means of confirming the conclusions 
reported in the article but that are not available com-
mercially. The program(s) and suitable documentation 
regarding its (their) use may be provided by any of the 
following means: (i) as a program transmitted via the 
Internet, (ii) as an Internet server-based tool, or (iii) as 
a compiled or assembled form on a suitable medium 
(e.g., magnetic or optical). It is expected that the mate-
rial will be provided in a timely fashion and at reason-
able cost to members of the scientific community for 
noncommercial purposes. The authors guarantee that 
they have the authority to comply with this policy either 
directly or by means of material transfer agreements 
through the Owner. 
Pennissions. The corresponding author is responsible 
for obtaining permission from both the original author 
and the original publisher (i.e., the copyright owner) to 
reproduce or modify figures and tables and to reproduce 
text (in whole or in part) from previous publications. 
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Permission(s) must be obtained no later than the 
modification stage. The original signed permission(s) 
must be identified as to the relevant item in the ASM 
manuscript (e.g., "permissions for Fig. 1 in AACO0123-
11") and submitted to the ASM production editor on 
request. In addition, a statement indicating that the ma-
terial is being reprinted with permission must be in-
cluded in the relevant figure legend or table footnote of 
the manuscript. Reprinted text must be enclosed in quo-
tation marks, and the permission statement must be 
included as running text or indicated parenthetically. 
It is expected that the authors will provide written 
assurance that permission to cite unpublished data or 
personal communications has been granted. 
For supplemental material intended for posting by 
ASM (see "Supplemental Material"), if the authors of 
the AAC manuscript are not also the owners of the 
supplemental material, the corresponding author must 
send to ASM signed permission from the copyright 
owner that allows posting of the material, as a supple-
ment to the article, by ASM. The corresponding author 
is also responsible for incorporating in the supplemental 
material any copyright notices required by the owner. 
Authorship. All authors of a manuscript must have 
agreed to its submission and are responsible for its con-
tent (initial submission and any subsequent versions), 
including appropriate citations and acknowledgments, 
and must also have agreed that the corresponding au-
thor has the authority to act on their behalf in all matters 
pertaining to publication of the manuscript. The corre-
sponding author is responsible for obtaining such agree-
ments and for informing the coauthors of the manu-
script's status throughout the submission, review, and 
publication process. Submitting a paper before all coau-
thors have read and approved it is considered an ethical 
violation, as is failure to credit someone who qualifies as 
a coauthor; however, ASM does not itself investigate or 
attempt to resolve authorship disputes. 
An author is one who made a substantial contribution 
to the overall design and execution of the experiments; 
therefore, ASM considers all authors responsible for 
the entire paper. Individuals who provided assistance, 
e.g., supplied strains or reagents or critiqued the paper, 
need not be listed as authors but may be recognized in 
the Acknowledgments section. 
A study group, surveillance team, working group, con-
sortium, or the like (e.g., the Active Bacterial Core Sur-
veillance Team) may be listed as a coauthor in the byline 
if its contributing members satisfy the requirements for 
authorship and accountability as described in these In-
structions. The names (and institutional affiliations if 
desired) of the contributing members only may be given 
in a footnote linked to the study group name in the 
byline or as a separate paragraph in the Acknowledg-
ments section. 
If the contributing members of the group associated 
with the work do not fulfill the criteria of substantial 
contribution to and responsibility for the paper, the 
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group may not be listed in the author byline. Instead, it 
and the names of its contributing members may be listed 
in the Acknowledgments section. 
All authors must agree to the order in which their 
names are listed in the byline. Statements regarding 
equal contributions by two or more authors (e.g., X.I. 
and Y.S. contributed equally to ... ) are permitted as 
footnotes to bylines and must be agreed to by all of the 
authors. Other statements of attribution may be in-
cluded in the Acknowledgments section. 
A change in authorship (order of listing, addition or 
deletion of a name, or corresponding author designa-
tion) after submission of the manuscript will be imple-
mented only after receipt of signed statements of agree-
ment from all parties involved. 
Disputes about authorship may delay or prevent re-
view and/or publication of the manuscript. Should the 
individuals involved be unable to reach an accord, re-
view and/or publication of the manuscript can proceed 
only after the matter is investigated and resolved by the 
authors' institution(s) and an official report of such and 
signed statements of agreement are provided to ASM. 
Conflict of interest. All authors are expected to dis-
close, in the manuscript submittal letter, any commercial 
affiliations as well as consultancies, stock or equity in-
terests, and patent-licensing arrangements that could be 
considered to pose a conflict of interest regarding the 
submitted manuscript. (Inclusion of a company name in 
the author address lines of the manuscript does not 
constitute disclosure.) Details of the disclosure to the 
editor will remain confidential. However, it is the re-
sponsibility of authors to provide, in the Acknowledg-
ments section, a general statement disclosing financial or 
other relationships that are relevant to the study. Exam-
ples of potentially conflicting interests that should be 
disclosed include relationships that might detract from 
an author'S objectivity in presentation of study results 
and interests whose value would be enhanced by the 
results presented. All funding sources for the project, 
institutional and corporate, should be credited in the 
Acknowledgments section, as described below. In addi-
tion, if a manuscript concerns a commercial product, the 
manufacturer's name must be indicated in the Materials 
and Methods section or elsewhere in the text, as appro-
priate, in an obvious manner. 
Copyright 
To maintain and protect the Society's ownership and 
rights and to continue to afford scientists the opportunity 
to publish in high-quality journals, ASM requires the 
corresponding author to sign a copyright transfer agree-
ment on behalf of all the authors on acceptance. Unless 
this agreement is executed (without changes and/or ad-
denda), ASM will not publish the article. 
In the copyright transfer agreement signed by an au-
thor, ASM grants to that author (and coauthors) the 
right to repUblish discrete portions of hislher (their) 
article in any other publication (print, CD-ROM, and 
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other electronic forms) of which he/she is (they are) the 
author(s) or editor(s), on the condition that appropriate 
credit is given to the original ASM publication. This 
republication right also extends to posting on a host 
computer to which there is access via the Internet. Ex-
cept as indicated below, significant portions of the article 
may not be reprinted/posted without ASM's prior writ-
ten permission, however, as this would constitute dupli-
cate publication. 
Authors may post their own published articles on their 
personal or university-hosted (but not corporate, gov-
ernment, or similar) websites without ASM's prior writ-
ten permission provided that appropriate credit is given 
(i.e., the copyright lines shown at the top of the first page 
of the PDF version). 
The copyright transfer agreement asks that authors 
who were U.S. government employees and who wrote 
the article as part of their employment duties be identi-
fied. This is because works authored solely by such U.S. 
government employees are not subject to copyright pro-
tection, so there is no copyright to be transferred. The 
other provisions of the copyright transfer agreement, 
such as author representations of originality and author-
ity to enter into the agreement, apply to U.S. govern-
ment employee-authors as well as to other authors. 
Copyright for supplemental material (see "Supple-
mental Material") remains with the author, but a li-
cense permitting the posting by ASM will be sent, 
along with the article copyright transfer agreement, to 
the corresponding author for signing at the accep-
tance stage. If the author of the article is not also the 
copyright owner of the supplemental material, the 
corresponding author must send to ASM signed per-
mission from the owner that allows posting of the 
material, as a supplement to the article, by ASM. The 
corresponding author is also responsible for incorpo-
rating into the supplemental material any copyright 
notices required by the owner. 
Funding Agency Repositories 
The National Institutes of Health (NIH) requests 
that its grantee and intramural authors provide copies 
of their accepted manuscripts to PubMed Central 
(PMC) for posting in the PMC Public Access Repos-
itory. However, AAC authors are automatically in 
compliance with this policy and need take no action 
themselves. For the past several years, ASM has de-
posited in PubMed Central all publications from all 
ASM journals. Further, ASM policy is that all primary 
research articles are made available to everyone, free, 
6 months after publication through PubMed Central, 
HighWire, and international PubMed Central-like re-
positories. By having initiated these policies, ASM is 
in full compliance with NIH policy. For more infor-
mation, see http://publicaccess.nih.gov/. ASM also al-
lows AAC authors whose work was supported by sim-
ilar funding agencies that have public access 
requirements like those of the NIH (e.g., the Well-
come Trust) to post their accepted manuscripts in 
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publicly accessible electronic repositories maintained 
by those funding agencies. If a funding agency does 
not itself maintain such a site, then ASM allows the 
author to fulfill that requirement by depositing the 
manuscript (not the typeset article) in an appropriate 
institutional or subject-based open repository estab-
lished by a government or noncommercial entity. 
Since ASM makes the final, typeset articles from its 
primary-research journals available free of charge on the 
ASM Journals and PMC websites 6 months after final 
publication, ASM recommends that when submitting the 
accepted manuscript to PMC or a similar public access 
site, the author specify that the posting release date for 
the manuscript be no earlier than 6 months after pub-
lication of the typeset article by ASM. 
Use of Human Subjects or Animals in Research 
The use of human subjects or other animals for re-
search purposes is regulated by the federal government 
and individual institutions. Manuscripts containing in-
formation related to human or animal use should clearly 
state that the research has complied with all relevant 
federal guidelines and institutional policies. Copies of 
these guidelines and policy statements must be available 
for review by the editor if necessary. 
Patient Identification 
When isolates are derived from patients in clinical 
studies, do not identify them by using the patients' ini-
tials, even as part of a strain designation. Change the 
initials to numerals or use randomly chosen letters. Do 
not give hospital unit numbers; if a designation is 
needed, use only the last two digits of the unit. (Note: 
established designations of some viruses and cell lines, 
although they consist of initials, are acceptable [e.g., JC 
virus, BK virus, and HeLa cells].) 
Nucleotide and Amino Acid Sequences 
Newly determined nucleotide and/or amino acid se-
quence data must be deposited and GenBanklEMBU 
DDBJ accession numbers must be included in the manu-
script no later than the modification stage of the review 
process. It is expected that the sequence data will be 
released to the public no later than the publication (on-
line posting) date of the accepted manuscript. The ac-
cession numbers should be included in a separate para-
graph at the end of the Materials and Methods section 
for full-length papers or at the end of the text for short-
form papers. If conclusions in a manuscript are based on 
the analysis of sequences and a GenBank/EMBUDDBJ 
accession number is not provided at the time of the 
review, authors should provide the sequence data as 
supplemental material. . 
It is expected that. when previously published se-
quence accession numbers are cited in a manuscript, the 
original citations (e.g., journal articles) will be included 
in the References section when possible or reasonable. 
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Authors are also expected to do elementary searches 
and comparisons of nucleotide and amino acid se-
quences against the sequences in standard databases 
(e.g.. GenBank) immediately before manuscripts are 
submitted and again at the proof stage. 
Analyses should specify the database, and the date of 
each analysis should be indicated as, e.g., January 2011. 
If relevant, the version of the software used should be 
specified. 
See "Presentation of Nucleic Acid Sequences" for nu-
cleic acid sequence formatting instructions. 
The URLs of the databases mentioned above are as 
follows: DNA Data Bank of Japan (DDBJ), http://www 
.ddbj.nig.ac.jp/; EMBL Nucleotide Sequence Database, 
http://www.ebLac.uk!embl/; and GenBank, National 
Center for Biotechnology Information, http://www.ncbi 
.nlm.nih.gov/. 
Proper Use of Locus Tags as Systematic Identifiers 
for Genes 
To comply with recommendations from the Interna-
tional Nucleotide Sequence Database (INSD) Collabo-
rators and to avoid conflicts in gene identification, re-
searchers should implement the following two 
fundamental guidelines as standards for utilization of 
locus tags in genome analysis, annotation, submission, 
reporting, and publication. (i) Locus tag prefixes are 
systematic gene identifiers for all of the replicons of a 
genome and as such should be associated with a single 
genome project submission. (ii) New genome projects 
must be registered with INSD, and new locus tag pre-
fixes must be assigned in cooperation with INSD to 
ensure that they conform to the agreed-upon criteria. 
Locus tag prefixes that are currently in use may be 
searched at the NCBI locus tag database (http://www 
.ncbi.nlm.nih.gov/gcnomes/lItp.cgi). 
Structural Determinations 
Coordinates for new structures of macromolecules de-
termined by X-ray crystallography or cryo-electron mi-
croscopy must be deposited in the Protein Data Bank 
and assigned identification codes must be included in the 
manuscript no later than the modification stage of the 
review process. It is expected that the coordinates will be 
released to the public no later than the publication (on-
line posting) date of the accepted manuscript. Authors 
are encouraged to send coordinates with their original 
submission, however, so that reviewers can examine 
them along with the manuscript. The accession num-
ber( s) should be listed in a separate paragraph at the end 
of the Materials and Methods section for full-length 
papers or at the end of the text for short-form papers. 
The URLs for coordinate deposition are hUp://rcsb 
-deposit.rutgers.edu/ and http://pdbdep.protein.osaka-u 
.ac.jp/cn/. 
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Microarray Data 
The entire set of supporting micro array data must be 
deposited in the appropriate public database (e.g., GEO, 
ArrayExpress, or CIBEX) and the assigned accession 
number(s) must be included in the manuscript no later 
than the modification stage of the review process. It is 
expected that the data will be released to the public no 
later than the publication (online posting) date of the 
accepted manuscript. Authors are encouraged to send 
the relevant data with their original submission, how-
ever, so that reviewers can examine them along with the 
manuscript. The accession number(s) should be listed in 
a separate paragraph at the end of the Materials and 
Methods section for full-length papers or at the end of 
the text for short-form papers. 
The URLs of the databases mentioned above are as 
follows: Gene Expression Omnibus (GEO), http://www 
.ncbi.nlm.nih.gov/projects/geo/; ArrayExpress, http: 
//www.ebi.ac.uk/microarray-as/ae/; and Center for Infor-
mation Biology Gene Expression Database (CIBEX), 
http://cibex.nig.ac.jp/index.jsp. 
Culture Deposition 
AAC expects authors to deposit strains used in thera-
peutic activity assessments and .studies .of me~hanisms ~f 
action, resistance, and cross-resIstance m publicly accessI-
ble culture collections and to refer to the collections and 
strain numbers in the text. Since the authenticity of sub-
cultures of culture collection specimens that are distributed 
by individuals cannot be ensured, authors should indicate 
laboratory strain designations and donor sources as well as 
original culture collection identification numbers. 
MycoBaok 
New scientific names of fungi along with key nomen-
clatural and descriptive material must be deposited in 
MycoBank (http://www.myco~ank.org). and the assign.ed 
accession number(s) must be mcluded m the manuscnpt 
no later than the modification stage of the review pro-
cess. It is expected that the data will be released to the 
public no later than the publication (online posting) date 
of the accepted manuscript. Authors are encouraged to 
send the relevant data with their original submission, 
however, so that reviewers can examine them along with 
the manuscript. The accession number(s) should be 
listed in a separate paragraph at the end of the Materials 
and Methods section for full-length papers and at the 
end of the text for short-form papers. 
Supplemental Material 
Supplemental material intended for posting by ASM 
should be restricted primarily to large or complex data sets 
or results that cannot readily be displayed in printed form 
because of space or technical limitations. Such material 
may include data from micro array, structural, biochemi~, 
or video imaging analyses. In such cases, the manuscrtpt 
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submitted for review should include a distillation of the 
results so that the principal conclusions are fully supported 
without referral to the supplemental material. 
Supplemental material intended for posting by ASM 
must be uploaded as a separate Supplemental Material 
file(s) in the manuscript submission and peer review 
system and will be reviewed along with the manuscript. 
The maximum size permitted for an individual file is 8 
MB (20 MB for movie files). If your file exceeds this size, 
you must use the file compression utility WinZip to 
reduce the file size. The decision to publish (i.e., post 
online only) the material with the article if it is accepted 
will be made by the editor. ASM will post no more than 
10 individual supplemental files with an individual arti-
cle. It is possible that a manuscript will be accepted but 
that the supplemental material will not be. 
To ensure broad access, supplemental files should be 
submitted in the following standard formats: 
(i) Text. Word, RTF, or PDF files. 
(iI) Figures. TIFF, EPS, high-resolution PDF, JPEG, 
or GIF format. Supplemental figures should not be em-
bedded in the manuscript text. 
(iii) Tables. Word, RTF, or PDF files. 
(Iv) Data sets. Excel (.xIs), RTF, TXT, or PDF files. 
(v) Movies. Audio Video Interleave (.avi), QuickTime 
(.mov), or MPEG files. All movies should be submitted 
at the desired reproduction size and length. 
Unlike the manuscript, supplemental material will not 
be edited by the ASM Journals staff and proofs will not 
be made available. References related to supplemental 
material only should not be listed in the References 
section of an article; instead, include them with the sup-
plemental material hosted by ASM or posted on a per-
sonaVinstitutional website. 
Supplemental material will always remain associated 
with its article and is not subject to any modifications after 
publication. 
Material that has been pUblished previously (print or 
online) is not acceptable for posting as supplemental ma-
terial. Instead, the appropriate reference(s) to the original 
publication should be made in the manuscript text. 
Copyright for the supplemental material remains with 
the author, but a license permitting the posting by ASM 
must be signed by the corresponding author. If you are 
not the copyright owner, you must provide to ASM 
signed permission from the owner that allows posting of 
the material, as a supplement to your article, by ASM. 
You are responsible for including in the supplemental 
material any copyright notices required by the owner. 
See also "Publication Fees." 
Warranties and Exclusions 
Articles published in this journal represent the opin-
ions of the authors and do not necessarily represent the 
opinions of ASM. ASM does not warrant the fitness or 
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suitability, for any purpose, of any methodology, kit. 
product, or device described or identified in an article. 
The use of trade names is for identification purposes 
only and does not constitute endorsement by ASM. 
SUBMISSION, REVIEW, AND PUBLICATION 
PROCESSES 
Submission Process 
All submissions to AAC must be made electronically. 
In 2011, the ASM journals are switching from Rapid 
Review to the eJ ournalPress (eJP) manuscript submis-
sion and peer review system. Journals will be transi-
tioned one by one over the course of several months, and 
the exact timing for AAC has not been determined. 
When the transition occurs, only new manuscript sub-
missions will be made through the eJP system. If you are 
returning a modified manuscript and made the original 
submission in Rapid Review, please use Rapid Review. 
For up-to-date information about where to submit your 
manuscript, please refer to the separate html version of 
Instructions to Authors, http://aac.asm.org!misc/ifora 
.dtl, which is updated throughout the year. 
Review Process 
All manuscripts are considered to be confidential and 
are reviewed by the editors, members of the editorial 
board, or qualified ad hoc reviewers. To expedite the 
review process, authors must recommend at least three 
reviewers who have expertise in the field, who are not 
members of their institution(s), who have not recently 
been associated with their laboratory(ies), and who 
could not otherwise be considered to pose a conflict of 
interest regarding the submitted manuscript. At least 
one recommended reviewer must be a member of the 
journal's editorial board. Please provide, where indi-
cated on the submission form, contact information for 
suggested reviewers who are not editorial board mem-
bers. 
Copies of in-press and submitted manuscripts tbat 
are important for judgment of the present manuscript 
sbould be included as supplemental material to facili-
tate tbe review. 
When a manuscript is submitted to the journal, it is 
given a control number (e.g., AACOO047-11 version 1) 
and assigned to one of the editors. (Always refer to tbis 
control number in communications witb the editor and 
the Journals Department.) It is the responsibility of the 
corresponding author to inform the coauthors of the 
manuscript's status throughout the submission, review, 
and publication processes. The reviewers operate under 
strict guidelines set forth in "Guidelines for Reviewers" 
(http://www.journals.asm.org!misc/reviewguide.dtl) and 
are expected to complete their reviews expeditiously. 
The corresponding author is notified, generally within 4 
to 6 weeks after submission, of the editor's decision to 
accept, reject, or require modification. When modification 
is requested, the corresponding author must either submit 
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the modified version within 2 months or withdraw the 
manuscript. A point-by-point response to the reviews must 
be provided with the revised manuscript, and a compare 
copy of the manuscript (without figures) should be in-
cluded as supplemental material if the editor requested 
one. 
Manuscripts that have been rejected, or withdrawn 
after being returned for modification, may be resubmit-
ted to the same ASM journal if the major criticisms have 
been addressed. A manuscript rejected by one ASM 
journal on scientific grounds or on the basis of its general 
suitability for publication is considered rejected by all 
other ASM journals; however, a manuscript rejected 
solely on the basis of scope may be "resubmitted" to a 
more appropriate ASM journal. A manuscript is consid-
ered a resubmission no matter bow much (or little) it 
di.ers from tbe rejected or witbdrawn manuscript and 
regardless of bow mucb time bas passed. 
For all resubmissions (to the same or a different journal, 
irrespective of the extent of the revisions, and irrespective 
of the amount of time between rejection and resubmis-
sion), the cover letter must state that the manuscript is a 
resubmission, and the former manuscript control number 
must be provided. A point-by-point response to the re-
view(s) and a compare copy of the revised manuscript 
showing the changes must be included as supplemental 
material. Manuscripts resubmitted to the same journal are 
normally handled by the original editor. 
Rejected manuscripts may be resubmitted only once 
unless permission has been obtained from the original 
editor or from the editor in chief. 
Notification of Acceptance 
When an editor has decided that a manuscript is ac-
ceptable for publication on the basis of scientific merit, 
the author and the Journals Department are notified. A 
PDF version of the accepted manuscript is posted online 
as soon as possible (see "AAC Accepts"). 
The text files undergo an automated preediting, 
cleanup, and tagging process specific to the particular 
article type, and the illustrations are examined. If all files 
have been prepared according to the criteria set forth in 
these Instructions and those in the online manuscript 
submission system, the acceptance procedure will be 
completed successfully. H there are problems that would 
cause extensive corrections to be made at the copyedit-
ing stage or if the files are not acceptable for production, 
ASM Journals staff will contact the corresponding au-
thor. Once all the material intended for publication has 
been determined to be adequate, the manuscript is 
scheduled for the next available issue. The editorial staff 
of the ASM Journals Department completes the editing 
of the manuscript to bring it into conformity with pre-
scribed standards. 
AAC Accepts 
For its primary-research journals, ASM posts online 
PDF versions of manuscripts that have been peer re-
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viewed and accepted but not yet copyedited. This feature 
is called "~ournal acronym] Accepts" (e.g., AAC Ac-
cepts) and is accessible from the Journals website. The 
manuscripts are published online as soon as possible 
after acceptance, on a weekly basis, before the co-
pyedited, typeset articles are published. They are posted 
"as is" (Le., as submitted by the authors at the modifi-
cation stage) and do not reflect ASM editorial changes. 
No corrections/changes to the PDF manuscripts are ac-
cepted. Accordingly, there likely will be differences be-
tween the AAC Accepts manuscripts and the final, type-
set articles. The manuscripts remain listed on the AAC 
Accepts page until the final, typeset articles are posted. 
At that point, the manuscripts are removed from the 
AAC Accepts page. The manuscripts are under subscrip-
tion access control until 6 months after the typeset arti-
cles are posted, when free access is provided to everyone 
(subject to the applicable ASM license terms and con-
ditions). Supplemental material intended, and accepted, 
for publication is not posted until publication of the 
final, typeset article. 
Instructions on how to cite such manuscripts may be 
found in "References." 
Page Proofs 
Page proofs, together with a query sheet and instruc-
tions for handling proofs, will be made available to the 
corresponding author electronically via a PDF file that 
can be accessed through a unique password. Since cor-
responding authors will be notified of the availability of 
their PDF proofs, instructed how to access information 
about page charges, reprints, and color figure charges (if 
applicable), and assigned their unique password via e-
mail, an e-mail address must be supplied in the corre-
spondent footnote. Failure to do so may result in a delay 
in publication. The PDF page proofs must be printed 
out, and corrections must be written on the hard copy. 
Queries must be answered on the query page or on a 
separate sheet of paper, and any changes related to the 
queries must be indicated on the proofs. Note that the 
copy editor does not query at every instance where a 
change has been made. Queries are written only to re-
quest necessary information or clarification of an un-
clear passage or to draw attention to edits that may have 
altered the sense. It is the author's responsibility to read 
the entire text, tables, and figure legends, not just items 
queried. As soon as the page proofs are corrected and 
signed by the person who proofread them (within 48 h), 
they should be mailed or sent by a courier service such 
as FedEx, not faxed or sent as an e-mail attachment, to 
the ASM Journals Department, 1752 N St., N.W., Wash-
ington, DC 20036-2904. 
The proof stage is not the time to make extensive 
corrections, additions, or deletions. Figures as they ap-
pear in the proofs are for validation of content and 
placement, not quality of reproduction or color accu-
racy. Print output of figures in the PDF page proofs will 
be of lower quality than the same figures viewed on a 
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monitor. Please avoid making changes to figures based 
on quality of color or reproduction in proof. 
Important new information that has become available 
between acceptance of the manuscript and receipt of the 
proofs may be inserted as an addendum in proof with the 
permission of the editor. If references to unpublished 
data or personal communications are added, it is ex-
pected that written assurance granting permission for 
the citation will be included. Limit changes to correc-
tions of spelling errors, incorrect data, and grammatical 
errors and updated information for references to articles 
that have been submitted or are in press. If URLs have 
been provided in the article, recheck the sites to ensure 
that the addresses are still accurate and the material that 
you expect the reader to find is indeed there. 
Questions about late proofs and problems in the 
proofs should be directed to the ASM Journals Depart-
ment (e-mail, nlin@asmusa.org; telephone, 202-942-
9231). Questions about accessing or viewing your PDF 
proofs should be directed to Katie Gay of Cadmus Com-
munications at 804-261-3155 or gayk@cadmus.com. 
PDF Files 
A corresponding author who has included an e-mail 
address in his/her "corresponding author" footnote will 
have limited access (10 downloads, total) to the PDF file of 
hislher published article. An e-mail alert will automatically 
be sent to him/her on the day the issue is posted. It will 
provide a URL, which will be required to obtain access, 
and instructions. An article may be viewed, printed, or 
stored, provided that it is for the author's own use. 
Should coauthors or colleagues be interested in view-
ing the paper for their own use, the corresponding au-
thor may provide them with the URL; a copy of the 
article may not be forwarded electronically. However, 
they must be made aware of the terms and conditions of 
the ASM copyright. (For details, go to http://www 
.journals.asm.orglmisc/terms.dtl.) Note that each such 
download will count toward the corresponding author's 
total of 10. After 10 downloads, access will be denied 
and can be obtained only through a subscription to the 
journal (either individual or institutional) or after the 
standard access control has been lifted (Le., 6 months 
after publication). 
Publication Fees 
Page charges. Authors whose research was supported 
by grants, special funds (including departmental and in-
stitutional), or contracts (including governmental) or 
whose research was done as part of their official duties 
(government or corporate, etc.) are required to pay page 
charges (based on the number of typeset pages, includ-
ing illustrations, in the article). 
For a corresponding author who is an ASM member, 
page charges are currently $67 per page for the first 
eight pages and $125 per page for each page in excess of 
eight (subject to change without notice). To obtain the 
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member rate, the corresponding author must be an ASM 
member. 
For a nonmember corresponding author, page 
charges are currently $80 per page for the first eight 
pages and $250 for each page in excess of eight (subject 
to change without notice). A corresponding author who 
is not an ASM member may join ASM to obtain the 
member rate. 
If the research was not supported by any of the means 
described above, a request to waive the charges may be 
sent to the Journals Department, ASM, 1752 N St., 
N.W., Washington, DC 20036-2904, USA (fax, 202-942-
9355; e-mail, aluckey@asmusa.org). The request must 
include the manuscript control number assigned by 
ASM and indicate how the work was supported. Waivers 
apply only to page charges; responsibility for color charges 
and other publication fees remains with the author. 
Minireviews, Commentaries, and Comment Letters to 
the Editor are not subject to page charges. New-Data 
Letters to the Editor are subject to page charges. 
Color charges. The cost of pUblishing in color must be 
borne by the author. 
For a corresponding author who is an ASM member, 
color charges are currently $170 per color figure (subject 
to change without notice). 
For a nonmember corresponding author, color charges 
are currently $375 per color figure (subject to change with-
out notice). A corresponding author who is not an ASM 
member may join ASM to obtain the member rate. 
Minireviews, Commentaries, and Comment Letters to 
the Editor are not subject to color charges. New-Data 
Letters to the Editor are subject to color figure charges. 
Reprints. Reprints (in multiples of 100) may be pur-
chased by all coauthors. In the proof notification e-mail, 
the corresponding author will be instructed how to ac-
cess information about reprints. 
The corresponding authors of Minireviews and Com-
mentaries may receive 100 free reprints of their contri-
bution; additional reprints (in multiples of 100) may be 
purchased if desired. As for regular articles, the corre-
sponding author will be instructed, in the proof notifi-
cation e-mail, how to access information about reprints. 
Supplemental material fee. Authors are charged a flat 
fee for posting supplemental material as an adjunct to 
their published article. For 2011, the fee is $190. (Ex-
ceptions: No fee is charged for supplemental material 
associated with Minireviews or Commentaries.) 
Optional open access fee. Author-paid optional open 
access (OOA) is now available for all article types. The 
2011 fee is $2,000. This fee is in addition to any page 
charges, color charges, or supplemental material charges 
and permits immediate public access to both the prelim-
inary "Accepts" version and the copyedited, typeset ver-
sion published in the online journal. This option is in 
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addition to the open access already provided through 
NIH's PubMed Central repository; all primary research 
published in ASM journals is freely available through 
PubMed Central 6 months after publication. 
ORGANIZATION AND FORMAT 
Editorial Style 
The editorial style of ASM journals conforms to the 
ASM Style Manual for Journals (American Society for 
Microbiology, 2011, in-house document) and How To 
Write and Publish a Scientific Paper, 6th ed. (Greenwood 
Press, Westport, cr, 2006), as interpreted and modified by 
the editors and the ASM Journals Department. 
The editors and the Journals Department reselVe the 
privilege of editing manuscripts to conform with the 
stylistic conventions set forth in the aforesaid publica-
tions and in these Instructions. 
On receipt at ASM, an accepted manuscript under-
goes an automated preediting, cleanup, and tagging pro-
cess specific to the particular article type. To optimize 
this process, manuscripts must be supplied in the correct 
format and with the appropriate sections and headings. 
Type every portion of the manuscript double-spaced 
(a minimum of 6 mm between lines), including figure 
legends, table footnotes, and references. and number all 
pages in sequence, including the abstract, figure leg-
ends, and tables. Place the last two items after the 
References section. Manuscript pages must have line 
numbers; manuscripts without line numbers may be 
editorially rejected by the editor, with a suggestion of 
resubmission after line numbers are added. The font 
size should be no smaller than 12 points. It is recom-
mended that the following sets of characters be easily 
distinguishable in the manuscript: the numeral zero 
(0) and the letter "oh" (0); the numeral one (1), the 
letter "el" (I), and the letter "eye" (I); and a multipli-
cation sign (X) and the letter "ex" (x). Do not create 
symbols as graphics or use special fonts that are ex-
ternal to your word processing program; use the "in-
sert symbol" function. Set the page size to 81f2 by 11 
inches (ca. 21.6 by 28 cm). Italicize any words that 
should appear in italics, and indicate paragraph lead-
ins in boldface type. 
Authors who are unsure of proper English usage 
should have their manuscripts checked by someone pro-
ficient in the English language. 
Manuscripts may be editorially rejected, without re-
view, on the basis of poor English or lack of conformity 
to the standards set forth in these Instructions. 
FuIl.Length Papers 
Full-length papers should include the elements de-
scribed in this section. 
Title, running title, and byline. Each manuscript 
should present the results of an independent, cohesive 
study; thus, numbered series titles are not permitted. 
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Exercise care in composing a title. Avoid the main title/ 
subtitle arrangement. complete sentences, and unneces-
sary articles. On the title page, include the title, the 
running title (not to exceed 54 characters and spaces), 
the name of each author, the addressees) of the institu-
tion(s) at which the work was performed, each author's 
affiliation, and a footnote indicating the present ad-
dress of any author no longer at the institution where 
the work was performed. Place an asterisk after the 
name of the author to whom inquiries regarding the 
paper should be directed (see "Correspondent foot-
note," below). 
Study group in byline. A study group, surveillance 
team, working group, consortium, or the like (e.g., the 
Active Bacterial Core Surveillance Team) may be listed 
as a coauthor in the byline if its contributing members 
satisfy the requirements for authorship and accountabil-
ity as described in these Instructions. The names (and 
institutional affiliations if desired) of the contributing 
members may be given in a footnote keyed to the study 
group name in the byline or as a separate paragraph in 
Acknowledgments. 
If the contributing members of the group associated 
with the work do not fulfill the criteria of substantial 
contribution to and responsibility for the paper, the 
group may not be listed in the author byline. Instead, it 
and the names of its contributing members may be listed 
in the Acknowledgments section. 
Correspondent footnote. The complete mailing ad-
dress, a single telephone number, a single fax number, 
and a single e-mail address for the corresponding author 
should be included on the title page of the manuscript. 
This information will be published in the article as a 
footnote to facilitate communication, and the e-mail ad-
dress will be used to notify the corresponding author of 
the availability of proofs and, later, of the PDF file of the 
published article. No more than two authors may be 
designated corresponding authors. 
Abstract. Limit the abstract to 250 words or fewer 
and concisely summarize the basic content of the paper 
without presenting extensive experimental details. Avoid 
abbreviations and references, and do not include dia-
grams. When it is essential to include a reference, use 
the same format as shown for the References section but 
omit the article title. Conclude the abstract with a sum-
mary statement. Because the abstract will be published 
separately by abstracting services, it must be complete 
and understandable without reference to the text. 
Introduction. The introduction should supply suffi-
cient background information to allow the reader to 
understand and evaluate the results of the present study 
without referring to previous publications on the topic. 
The introduction should also provide the hypothesis that 
was addressed or the rationale for the study. References 
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should be chosen carefully to provide the most salient 
background rather than an exhaustive review of the topic. 
Case Report. The Case Report section, placed after 
the introduction and before Materials and Methods, is 
optional and gives relevant clinical information about 
one or more patients. 
Materials and Methods. The Materials and Methods 
section should include sufficient technical information to 
allow the experiments to be repeated. When centrifuga-
tion conditions are critical, give enough information to 
enable another investigator to repeat the procedure: make 
of centrifuge, model of rotor, temperature, time at maxi-
mum speed, and centrifugal force (X g rather than revolu-
tions per minute). For commonly used materials and meth-
ods (e.g., media and protein concentration 
determinations), a simple reference is sufficient. If several 
alternative methods are commonly used, it is helpful to 
identify the method briefly as well as to cite the reference. 
For example, it is preferable to state "cells were broken by 
ultrasonic treatment as previously described (9)" rather 
than "cells were broken as previously described (9)." This 
allows the reader to assess the method without constant 
reference to previous publications. Describe new methods 
completely, and give sources of unusual chemicals, equip-
ment, or microbial strains. When large numbers of micro-
bial strains or mutants are used in a study, include tables 
identifying the immediate sources (i.e., sources from whom 
the strains were obtained) and properties of the strains, 
mutants, bacteriophages, and plasmids, etc. 
A method or strain, etc., used in only one of several 
experiments reported in the paper may be described in the 
Results section or very briefly (one or two sentences) in a 
table footnote or figure legend. It is expected that the 
sources from whom the strains were obtained will be iden-
tified. 
Results. In the Results section, include the rationale 
or design of the experiments as well as the results; re-
serve extensive interpretation of the results for the Dis-
cussion section. Present the results as concisely as pos-
sible in one of the following: text, table(s), or figure(s). 
Avoid extensive use of graphs to present data that might 
be more concisely or more quantitatively presented in 
the text or tables. Limit photographs (particularly pho-
tomicrographs and electron micrographs) to those that 
are absolutely necessary to show the experimental find-
ings. Number figures and tables in the order in which 
they are cited in the text, and be sure that all figures and 
tables are cited. 
Discussion. The Discussion should provide an inter-
pretation of the results in relation to previously pub-
lished work and to the experimental system at hand and 
should not contain extensive repetition of the Results 
section or reiteration of the introduction. In short pa-
pers, the Results and Discussion sections may be com-
bined. 
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Acknowledgments. The source of any financial sup-
port received for the work being published must be in-
dicated in the Acknowledgments section. (It will be as-
sumed that the absence of such an acknowledgment is a 
statement by the authors that no support was received.) 
The usual format is as follows: "This work was supported 
by Public Health Service grant CA-01234 from the Na-
tional Cancer Institute." 
Recognition of personal assistance should be given as 
a separate paragraph, as should any statements disclaim-
ing endorsement or approval of the views reflected in the 
paper or of a product mentioned therein. 
Appendixes. Appendixes that contain additional ma-
terial to aid the reader are permitted. Titles, authors, 
and reference sections that are distinct from those of the 
primary article are not allowed. If it is not feasible to list 
the author(s) of the appendix in the byline or the Ac-
knowledgments section of the primary article, rewrite 
the appendix so that it can be considered for publication as 
an independent article, either full-length or short-form 
style. Equations, tables, and figures should be labeled with 
the letter "A" preceding the numeral to distinguish them 
from those cited in the main body of the text. 
References. (i) References listed in the References 
section. The References section must include all jour-
nal articles (both print and online), books and book 
chapters (both print and online), patents, theses and 
dissertations, published conference proceedings, meet-
ing abstracts from published abstract books or journal 
supplements, letters (to the editor), and company pub-
lications, as well as in-press journal articles, book chap-
ters, and books (publication title must be given). As we 
use the citation-name reference style, arrange the cita-
tions in alphabetical order (letter by letter, ignoring 
spaces and punctuation) by first-author surname and 
number consecutively. Provide the names of all the au-
thors for each reference. All listed references must be 
cited parenthetically by number in the text. Since title 
and byline information that is downloaded from 
PubMed does not always show accents, italics, or special 
characters, authors should refer to the PDF files or hard-
copy versions of the articles and incorporate the neces-
sary corrections in the submitted manuscript. Abbreviate 
journal names according to the PubMed Journals Data-
base (National Library of Medicine, National Institutes 
of Health; available at http://www.ncbi.nlm.nih.gov/sites 
/entrez'ldb=joumals), the primary source for ASM style, 
but use periods on abbreviated words. 
Follow the styles shown in the examples below for 
print references. 
1. Alexander, T. W., et al. 2008. Effect of subtherapeu-
tic administration of antibiotics on the prevalence of 
antibiotic-resistant Escherichia coli bacteria in feed-
lot cattle. Appl. Environ. Microbiol. 74:4405-4416. 
2. Cox, C. S., B. R. Brown, and J. C. Smith. J. Gen. 
Genet., in press.· {Article title is optiona~' journal title 
is mandatory.} 
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3. da Costa, M. S., M. F. Nobre, and F. A. Rainey. 
2001. Genus I. Thermus Brock and Freeze 1969, 
295,AL emend. Nobre, Triiper and da Costa 1996b, 
605, p. 404-414. In D. R. Boone, R. W. Castenholz, 
and G. M. Garrity (ed.), Bergey's manual of system-
atic bacteriology, 2nd ed., vol. 1. Springer, New 
York, NY. 
4. Elder, B. L., and S. E. Sharp. 2003. Cumitech 39, 
Competency assessment in the clinical laboratory. 
Coordinating ed., S. E. Sharp. ASM Press, Washing-
ton, DC. 
5. Falagas, M. E., and S. K. Kasiakou. 2006. Use of 
international units when dosing colistin will help 
decrease confusion related to various formulations 
of the drug around the world. Antimicrob. Agents 
Chemother. 50:2274-2275. (Letter.) {"Letter" or 
"Letter to the editor" is allowed but not required at the 
end of such an entry.} 
6. Fitzgerald, G., and D. Shaw. In A. E. Waters (ed.), 
ainical microbiology, in press. EFH Publishing Co., 
Boston, MA.· {Chapter title is optional.} 
7. Forman, M. S., and A. Valsamakis. 2003. Specimen 
collection, transport, and processing: virology, p. 
1227-1241. In P. R. Murray, E. J. Baron, M. A. 
Pfaller, J. H. Jorgensen, and R. H. Yolken (ed.), 
Manual of clinical microbiology, 8th ed. ASM Press, 
Washington, DC. 
8. Garcia, C. 0., et al. 1996. Detection of salmonella 
DNA in synovial membrane and synovial fluid from 
Latin American patients. Arthritis Rheum. 39(Suppl.): 
S185. {Meeting abstract published in journal supple-
ment.} 
9. Green, P. N., D. Hood, and C. S. Dow. 1984. Taxo-
nomic status of some methylotrophic bacteria, p. 
251-254. In R. L. Crawford and R. S. Hanson (ed.), 
Microbial growth on C1 compounds. Proceedings of 
the 4th International Symposium. American Society 
for Microbiology, Washington, DC. 
10. Odell, J. C. April 1970. Process for batch culturing. 
U.S. patent 484,363,770. {Include the name of the 
patented item/process if possible; the patent number is 
mandatory .} 
11. O'Malley, D. R. 1998. Ph.D. thesis. University of 
California, Los Angeles, CA. {Title is optional.} 
12. Rotimi, V. 0., N. O. Salako, E. M. Mohaddas, and 
L. P. Philip. 2005. Abstr. 45th Intersci. Conf. Anti-
microb. Agents Chemother., abstr. D-1658. {Ab-
stract title is optional.} 
13. Smith, D., C. Johnson, M. Maier, and J. J. Maurer. 
2005. Distribution of fimbrial, phage and plasmid 
associated virulence genes among poultry Salmo-
nella enterica serovars, abstr. P-038, p. 445. Abstr. 
105th Gen. Meet. Am. Soc. Microbiol. American 
Society for Microbiology, Washington, DC. {Ab-
stract title is optional.} 
14. Stratagene. 2006. Yeast DNA isolation system: in-
struction manual. Stratagene, La Jolla, CA. {Use the 
company name as the author if none is provided for a 
company publication.} 
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* A reference to an in-press ASM publication should state 
the control number (e.g., AAOJ0577-11) if it is a journal 
article or the name of the publication if it is a book. 
Online references must provide essentially the same 
information that print references do. For onlinejournal 
articles, posting or revision dates may replace the year of 
publication, and a DOlor URL may be provided in 
addition to or in lieu of volume and page numbers. Some 
examples follow. 
1. Charlier, D., and N. Glansdorft'. September 2004, 
posting date. Chapter 3.6.1.10, Biosynthesis of argi-
nine and polyamines. In R. Curtiss III et al. (ed.), 
EcoSal-Escherichia coli and Salmonella: cellular and 
molecular biology. ASM Press, Washington, DC. 
http://www.ecosaI.org!. {Note that each chapter has its 
own posting date.} 
2. Dionne, M. S., and D. S. Schneider. 2002. Screening 
the fruitfty immune system. Genome BioI. 3: 
REVIEWS1010. http://genomebiology.com/2002/3/4 
/reviews/lOlO. 
3. Smith, F. X., H. J. Merianos, A. T. Brunger, and 
D. M. Engelman. 2001. Polar residues drive associa-
tion of polyleucine transmembrane helices. Proc. 
Natl. Acad. Sci. U. S. A. 98:2250-2255. doi:10.1073 
/pnas.041593698. 
4. Winnick, S., D. O. Lucas, A. L. Hartman, and D. Toll. 
2005. How do you improve compliance? Pediatrics 
115:e718--e724. 
Note: a posting or accession date is required for any 
online reference that is periodically updated or changed. 
(ii) References cited in the text. References to un-
published data, manuscripts submitted for publication, 
unpublished conference presentations (e.g., a report or 
poster that has not appeared in published conference 
proceedings), personal communications, patent applica-
tions and patents pending, computer software, data-
bases, and websites should be made parenthetically in 
the text as follows. 
· .. similar results (R. B. Layton and C. C. Weath-
ers, unpublished data). 
· .. system was used (J. L. McInerney, A. F. 
Holden, and P. N. Brighton, submitted for pub-
lication). 
· .. as described previously (M. G. Gordon and 
F. L. Rattner, presented at the Fourth Sympo-
sium on Food Microbiology, Overton, IL, 13 to 
15 June 1989). {For non published abstracts and 
posters, etc.} 
· .. this new process (Y. R. Smoll, 20 June 1999, Aus-
tralian Patent Office). {For non-U.S. patent appli-
cations, give the date of publication of the applica-
tion.} 
· .. available in the GenBank database (http://www 
.ncbi.nlm.nih.gov/genbanklindex.html). 
· .. using ABC software (version 2.2; Department 
ANTIMIC'ROB. AGENTS CIIEMOnIER. 
of Microbiology, State University [http://www 
.state.micro.edu D. 
URLs for companies that produce any of the products 
mentioned in your study or for products being sold may 
not be included in the article. However, company URLs 
that permit access to scientific data related to the study 
or to shareware used in the study are permitted. 
(iii) References related to supplemental material. Ref-
erences that are related only to supplemental material 
hosted by ASM or posted on a personal/institutional 
website should not be listed in the References section of 
an article; include them with the supplemental material 
itself. 
(iv) Referencing ASM Accepts (publish-ahead-of-
print) manuscripts. Citations of ASM Accepts manu-
scripts should look like the following example. 
Wang, G. G., M. P. Pasillas, and M. P. Kamps. 15 
May 2006. Persistent transactivation by Meis1 re-
places Hox function in myeloid leukemogenesis 
models: evidence for co-occupancy of Meis1-Pbx 
and Hox-Pbx complexes on promoters of leukemia-
associated genes. Mol. Cell. Bioi. doi:1O.1128 
/MCB.00586-06. 
Other journals may use different styles for their pub-
lish-ahead-of-print manuscripts. but citation entries 
must include the following information: author name(s), 
posting date. title, journal title, and volume and page 
numbers and/or DOl. The following is an example: 
Zhou, F. X., H. J. Merianos, A. T. Brunger, and 
D. M. Engelman. 13 February 2001. posting date. 
Polar residues drive association of polyleucine 
transmembrane helices. Proc. Natl. Acad. Sci. 
U. S. A. doi:10.1073/pnas.041593698. 
Short-Form Papers 
The short-form format is intended for the presenta-
tion of brief observations that do not warrant full-length 
papers. Submit short-form papers in the same way as 
full-length papers. They receive the same review, they 
are not published more rapidly than full-length papers, 
and they are not considered preliminary communica-
tions. 
The title, running title (not to exceed 54 characters 
and spaces), byline, and correspondent footnote should 
be prepared as for a full-length paper. Each short-form 
paper must have an abstract of no more than 75 words. 
Do not use section headings in the body of the paper; 
combine methods, results, and discussion in a single 
section. Paragraph lead-ins are permissible. The text 
should be kept to a minimum and if possible should not 
exceed 1,000 words; the number of figures and tables 
should also be kept to a minimum. Materials and meth-
ods should be described in the text, not in figure legends 
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or table footnotes. Present acknowledgments as in full-
length papers, but do not use a heading. The References 
section is identical to that of full-length papers. 
Minireviews 
Minireviews are brief (limit of six printed pages ex-
clusive of references) biographical profiles, historical 
perspectives, or summaries of developments in fast-mov-
ing areas of chemotherapy. They must be based on pub-
lished articles; they are not outlets for unpublished data. 
They may address any subject within the scope of AAC. 
For example, subject matter may range from structure-
activity correlates among a group of semisynthetic ceph-
alosporins to the comparative efficacies of new and old 
drugs in the prevention or treatment of diseases of mi-
crobial origin in humans. 
Minireviews may be either solicited or proffered by 
authors responding to a recognized need. Irrespective of 
origin, Minireviews are subject to review and should be 
submitted via the online manuscript submission and 
peer review system. The cover letter should state 
whether the article was solicited and by whom. 
Minireviews must have abstracts. Limit the abstract 
to 250 words or fewer. The body of the Minireview may 
have section headings and/or paragraph lead-ins. 
Author biographies. At the editor's invitation, corre-
sponding authors of Minireviews may submit brief bio-
graphical sketches (limit, 150 words) of each contribut-
ing author, to be published at the end of the article. If 
the editor asks you to submit a modified manuscript, you 
should submit biographical text and photos with your 
modification. 
Commentaries 
Commentaries are invited communications concern-
ing topics relevant to the readership of AAC and are 
intended to engender discussion. Reviews of the litera-
ture, methods and other how-to papers, and responses 
targetcd at a specific published paper arc not appropri-
ate. Commentaries are subject to review. 
The length may not exceed four printed pages, and the 
format is like that of a Minireview (see above) except 
that Commentaries do not have abstracts. (In the sub-
mission form, use "NA" or "Not Applicable" in the 
space provided for the abstract.) 
Letters to the Editor 
Two types of Letters to the Editor may be submitted. 
The first type (Comment Letter) is intended for com-
ments on final, typeset articles published in the journal 
(not on publish-ahead-of-print manuscripts) and must 
cite published references to support the writer's argu-
ment. The second type (New-Data Letter) may report 
new, concise findings that are not appropriate for pub-
lication as full-length or short-form papers. 
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Letters may be no more than 500 words long and must 
be typed double-spaced. Refer to a recently published 
Letter for correct formatting. Note that authors and 
affiliations are listed at the foot of the Letter. Provide 
only the primary, affiliation for each author. 
All Letters to the Editor must be submitted electron-
ically, and the type of Letter (New Data or Comment) 
must be selected from the drop-down list in the submis-
sion form. For Letters commenting on published arti-
cles, the cover letter should state the volume and issue in 
which the article was published, the title of the article, 
and the last name of the first author. In the Abstract 
section of the submission form, put "Not Applicable." 
Letters to the Editor do not have abstracts. Both types of 
Letter must have a title, which must appear on the 
manuscript and on the submission form. Figures and 
tables should be kept to a minimum. 
If the Letter is related to a published article, it will be 
sent to the editor who handled the article in question. If 
the editor believes that publication is warranted, he/she 
will solicit a reply from the corresponding author of the 
article and give approval for publication. 
New-Data Letters will be assigned to an editor accord-
ing to subject matter and will be reviewed by that editor 
and/or a reviewer. 
Please note that some indexing/abstracting services do 
not include Letters to the Editor in their databases. 
Errata 
The Erratum section provides a means of correcting 
errors that occurred during the writing, typing, editing, 
or publication (e.g., a misspelling, a dropped word or 
line, or mislabeling in a figure) of a published article. 
Submit Errata via the online manuscript submission and 
peer review system (see "Submission, Review, and Pub-
lication Processes"). In the Abstract section of the sub-
mission form (a required field), put "Not Applicable." 
Upload the text of your Erratum as a Microsoft Word 
file. Please see a recent issue for correct formatting. 
Authors' Corrections 
The Author's Correction section provides a means of 
correcting errors of omission (e.g., author names or ci-
tations) and errors of a scientific nature that do not alter 
the overall basic results or conclusions of a published 
article (e.g., an incorrect unit of measurement or order 
of magnitude used throughout, contamination of one of 
numerous cultures, or misidentification of a mutant 
strain, causing erroneous data for only a [noncritical] 
portion of the study). Note that the addition of new data 
is not permitted. 
For corrections of a scientific nature or issues involv-
ing authorship, including contributions and use or own-
ership of data and/or materials, all disputing parties 
must agree, in writing, to publication of the Correction. 
For omission of an author's name, letters must be signed 
by the authors of the article and the author whose name 
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was omitted. The editor who handled the article will be 
consulted if necessary. 
Submit an Author's Correction via the online manu-
script submission and peer review system (see 
"Submission, Review, and Publication Processes"). 
Select Erratum as the manuscript type; there is no sep-
arate selection for an Author's Correction, but your Cor-
rection will be published as such if appropriate. In the 
Abstract section of the submission form (a required 
field), put "Not Applicable." Upload the text of your 
Author's Correction as a Microsoft Word file. Please see 
a recent issue for correct formatting. Signed letters of 
agreement must be supplied as supplemental material 
(scanned PDF files). 
Retractions 
Retractions are reserved for major errors or breaches 
of ethics that, for example, may call into question the 
source of the data or the validity of the results and 
conclusions of an article. Submit Retractions via the 
online manuscript submission and peer review system 
(see "Submission, Review. and Publication Processes"). 
In the Abstract section of the submission form (a re-
quired field), put "Not Applicable." Upload the text of 
your Retraction as a Microsoft Word file. Letters of 
agreement signed by all of the authors must be supplied 
as supplemental material (scanned PDF files). The Re-
traction will be assigned to the editor in chief of the 
journal, and the editor who handled the paper and the 
chairperson of the ASM Publications Board will be con-
sulted. If all parties agree to the publication and content 
of the Retraction, it will be sent to the Journals Depart-
ment for publication. 
ILLUSTRATIONS AND TABLES 
DIustrations 
Image manipulation. Computer-generated images 
may be processed only minimally. Processing (e.g., 
changing contrast, brightness, or color balance) is ac-
ceptable only if applied to all parts of the image, as well 
as to the controls, equally, and descriptions of all such 
adjustments and the tools used (both hardware and soft-
ware) must be provided in the manuscript. Unprocessed 
data and files must be retained by the authors and be 
provided to the editor on request. 
File types -8Ild formats. Illustrations may be contin-
uous-tone images, line drawings, or composites. Color 
graphics may be submitted, but the cost of printing in 
color must be borne by the author. Suggestions about 
how to reduce costs and ensure accurate color reproduc-
tion are given below. 
On initial submission, illustrations should be supplied 
as PDF files, with the legend on the same page, to assist 
review. At the modification stage, production quality dig-
ital files must be provided, along with text files for the 
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legends. The legends are copyedited and typeset for final 
publication, not included as part of the figure itself. All 
graphics submitted with modified manuscripts must be bit-
map, grayscale, or in the RGB (preferred) or CMYK. color 
mode. See "Color illustrations." Halftone images (thale 
with various densities or shades) must be grayscale, not 
bitmap. AAC accepts TIFF or EPS files but discourages 
PowerPoint for either black-and-white or color images. 
For instructions on creating acceptable EPS and TIFF 
files, refer to the Cadmus digital art website, http://art 
.cadmus.eom/da/index.jsp. PowerPoint requires users to 
pay close attention to the fonts used in their images (see 
the section on fonts below). If instructions for fonts are 
not followed exactly, images prepared for publication 
are subject to missing characters, improperly converted 
characters, or shifting/obscuring of elements or text in 
the figure. For proper font use in PowerPoint images, 
refer to the Cadmus digital art website, http://arLcadmus 
.com/da/instructions/ppt_disclaimcr.jsp. 
We strongly recommend that before returning their 
modified manuscripts, authors check the acceptability 
of their digital images for production by running their 
files through Rapid Inspector, a tool provided at the 
following URL: hUp://rapidinspector.cadmus.com 
/Rapidlnspector/zmw/index.jsp. Rapid Inspector is an 
easy-to-use, Web-based application that identifies file 
characteristics that may render the image unusable for 
production. 
If you require additional information, please send an 
e-mail inquirytodigitalart@cadmus.com. 
Minimum resolution. It is extremely important that a 
high enough file resolution is used. All separate images 
that you import into a figure file must be at the correct 
resolution before they are placed. (For instance, placing 
a 72-dpi image in a 300-dpi EPS file will not result in the 
placed image meeting the minimum requirements for 
file resolution.) Note, however, that the higher the res-
olution, the larger the file and the longer the upload 
time. Publication quality will not be improved by using a 
resolution higher than the minimum. Minimum resolu-
tions are as follows: 
300 dpi for grayscale and color 
600 dpi for combination art (lettering and images) 
1,200 dpi for line art 
Size. All graphics should be submitted at their in-
tended publication size; that is, the image uploaded 
should be 100% of its print dimensions so that no re-
duction or enlargement is necessary. Resolution must be 
at the required level at the submitted size. Include only 
the significant portion of an illustration. White space 
must be cropped from the image, and excess space be-
tween panel labels and the image must be eliminated. 
Maximum width for a I-column figure: 35/16 inches 
(ca. 8.4 em) 
Maximum width for a 2-column figure: 6% inches 
(ca. 17.4 cm) 
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Minimum width for a 2-column figure: 41,4 inches 
(10.8 cm) 
Maximum height: 91/16 inches (23.0 cm) 
Contrast. lllustrations must contain sufficient con-
trast to be viewed easily on a monitor or on the printed 
page. 
Labeling and assembly. All final lettering and label-
ing must be incorporated into the figures. On initial 
submission, illustrations should be provided as PDF 
files, with the legend beneath each image, to assist re-
view. At the modification stage, production quality dig-
ital figure files must be provided, along with text files for 
the legends. Put the figure number well outside the 
boundaries of the image itself. (Numbering may need to be 
changed at the copyediting stage.) Each figure must be 
uploaded as a separate file, and any multipanel figures 
must be assembled into one file; i.e., rather than uploading 
a separate file for each panel in a figure, assemble all 
panels in one piece and supply them as one file. 
Fonts. To avoid font problems, set all type in one of the 
following fonts: Arial, Helvetica. Times Roman, European 
PI, Mathematical PI, or Symbol. Courier may be used but 
should be limited to nucleotide or amino acid sequences in 
which a nonproportional (monospace) font is required. All 
fonts other than these must be converted to paths (or 
outlines) in the application with which they were created. 
Compression. When figure files are uploaded to the 
manuscript submission and peer review system, they may 
be compressed with WinZip. 
Color illustrations. Color costs must be borne by the 
author. See "Publication Fees." All figures submitted in 
color will be processed as color. Adherence to the fol-
lowing guidelines will help to minimize costs and to 
ensure color reproduction that is as accurate as possible. 
The online version is considered the version of record 
for AAC and all other ASM journals. To maximize on-
line reproduction, color illustrations should be supplied 
in the RGB color mode, as either (i) RGB TIFF images 
with a resolution of at least 300 pixels per inch (raster 
files, consisting of pixels) or (ii) lllustrator-compatible 
EPS files with RGB color elements (vector files, consist-
ing of lines, fonts, fills, and images). CMYK files are also 
accepted. Other than in color space, CMYK files must 
meet the same production criteria as RGB files. The 
RGB color space is the native color space of computer 
monitors and of most of the equipment and software 
used to capture scientific data, and it can display a wider 
range of colors (especially bright fluorescent hues) than 
the CMYK (cyan, magenta, yellow, black) color space 
used by print devices that put ink (or toner) on paper. 
For the print version (and reprints), ASM's print pro-
vider will automatically create CMYK versions of color 
illustrations from the supplied RGB versions. Color in 
the print journal may not match that in the online jour-
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nal of record because of the smaller range of colors 
capable of being reproduced by CMYK inks on a print-
ing press. For additional information on RGB versus 
CMYK color, refer to the Cadmus digital art site, http: 
Ilartcadmus.comldaiguidelines_rgb.jsp. 
Drawings 
Submit graphs, charts, complicated chemical or mathe-
matical formulas, diagrams, and other drawings as finished 
products not requiring additional artwork or typesetting. 
All elements, including letters, numbers, and symbols, must 
be easily readable, and both axes of a graph must be la-
beled. Keep in mind that the journal is published both in 
print and online and that the same electronic files submit-
ted by the authors are used to produce both. 
When creating line art, please use the following guide-
lines: 
(i) All art must be submitted at its intended publica-
tion size. For acceptable dimensions, see "Size," above. 
(ii) Avoid using screens (i.e., shading) in line art. It 
can be difficult and time-consuming to reproduce these 
images without moire patterns. Various pattern back-
grounds are preferable to screens as long as the patterns 
are not imported from another application. If you must 
use images containing screens, 
(a) Generate the image at line screens of 85 lines per 
inch or less. 
(b) When applying multiple shades of gray, differen-
tiate the gray levels by at least 20%. 
(c) Never use levels of gray below 5% or above 95% as 
they are likely to fade out or become totally black when 
output. 
(iii) Use thick, solid lines that are no finer than 1 point 
in thickness. 
(iv) No type should be smaller than 6 points at the 
final publication size. 
(v) Avoid layering type directly over shaded or tex-
tured areas. 
(vi) Avoid the use of reversed type (white lettering on 
a black background). 
(vii) Avoid heavy letters, which tend to close up, and 
unusual symbols, which the printer may not be able to 
reproduce in the legend. 
(viii) If colors are used, avoid using similar shades of 
the same color and avoid very light colors. 
In figure ordinate and abscissa scales (as well as table 
column headings), avoid the ambiguous use of numbers 
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with exponents. Usually, it is preferable to use the 
Systeme International d'Unites (SI) ~bols (fJ. for 10-6, 
m for 10-3, k for 103, and M for 10 , etc.). A complete 
listing of SI symbols can be found in the International 
Union of Pure and Applied Chemistry (IUPAC) publi-
cation Quantities, Units and Symbols in Physical Chemis-
try (RSC Publishing, Cambridge, United Kingdom, 
2007); an abbreviated list is available at http://old.iupac 
.org/reports/1993lhomann/indcx.hlml. Thus, a represen-
tation of 20,000 cpm on a figure ordinate should be 
made by the number 20 accompanied by the label kcpm. 
When powers of 10 must be used, the journal requires 
that the exponent power be associated with the number 
shown. In representing 20,000 cells per ml, the numeral 
on the ordinate should be "2" and the label should be 
"Hf cells per ml" (not "cells per ml X 10-4,,). Likewise, 
an enzyme activity of 0.06 U/ml might be shown as 6 
accompanied by the label "10-2 U/ml." The preferred 
designation is 60 mU/ml (milliunits per milliliter). 
Presentation of Nucleic Acid Sequences 
Long nucleic acid sequences must be presented as 
figures in the following format to conserve space. Print 
the sequence in lines of approximately 100 to 120 nucle-
otides in a nonproportional (monospace) font that is 
easily legible when published with a line length of 6 
inches (ca. 15.2 em). If possible, lines of nucleic acid 
sequence should be further subdivided into blocks of 10 
or 20 nucleotides by spaces within the sequence or by 
marks above it. Uppercase and lowercase letters may be 
used to designate the exon-intron structure or tran-
scribed regions, etc., if the lowercase letters remain leg-
ible at a 6-inch (ca. 15.2-cm) line length. Number the 
sequence line by line; place numerals representing the 
first base of each line to the left of the lines. Minimize 
spacing between lines of sequence, leaving room only for 
annotation of the sequence. Annotation may include 
boldface, underlining, brackets, and boxes, etc. Encoded 
amino acid sequences may be presented, if necessary, 
immediately above or below the first nucleotide of each 
codon, by using the single-letter amino acid symbols. 
Comparisons of multiple nucleic acid sequences should 
conform as nearly as possible to the same format. 
Figure Legends 
On initial submission, to assist review, the legend should 
be incorporated in the image file and appear beneath the 
figure. At the modification stage, figure legends must be 
provided as text files separate from the image file. 
Legends should provide enough information so that 
the figure is understandable without frequent reference 
to the text. However, detailed experimental methods 
must be described in the Materials and Methods section, 
not in a figure legend. A method that is unique to one of 
several experiments may be set forth in a legend only if 
the description is very brief (one or tWo sentences). 
Define all symbols used in the figure and define all 
abbreviations that are not used in the text. 
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TABLE 1. Distribution of protein and ATPase in fractions of 
dialyzed membranes· 
ATPase 
Membrane Fraction 
U/mg of protein Total U 
Control Depleted membrane 0.036 2.3 
Concentrated supernatant 0.134 4.82 
El treated Depleted membrane 0.034 1.98 
Concentrated supernatant 0.11 4.6 
• Specific activities of ATPase of nondepleted membranes from control and 
treated bacteria were 0.21 and 0.20, respectively. 
Tables 
Tables that contain artwork, chemical structures, or 
shading must be submitted as illustrations in an accept-
able format at the modification stage. The preferred 
format for regular tables is Microsoft Word; however, 
WordPerfect and Acrobat PDF are also acceptable. 
Note that a straight Excel file is not currently an accept-
able format. Excel files must be either embedded in a 
Word or WordPerfect document or converted to PDF 
before being uploaded. If your modified manuscript 
contains PDF tables and is being submitted in Rapid 
Review, select "for reviewing purposes only" at the be-
ginning of the file upload process. 
Tables should be formatted as follows. Arrange the 
data so that columns of like material read down, not 
across. The headings should be sufficiently clear so that 
the meaning of the data is understandable without ref-
erence to the text. See the "Abbreviations" section of 
these Instructions for those that should be used in tables. 
Explanatory footnotes are acceptable, but more-exten-
sive table "legends" are not. Footnotes should not in-
clude detailed descriptions of the experiment. Tables 
must include enough information to warrant table for-
mat; those with fewer than six pieces of data will be 
incorporated into the text by the copy editor. Table 1 is 
an example of a well-constructed table. 
Avoid tables (or figures) of raw data on drug suscep-
tibility, therapeutic activity, or toxicity. Such data should 
be analyzed by an approved procedure, and the results 
should be presented in tabular form. 
NOMENCLATURE 
Chemical and Biochemical Nomenclature 
The recognized authority for the names of chemical 
compounds is Chemica/Abstracts (CAS; http://www.ca.i.org/) 
and its indexes. The Merck Index, 14th ed. (Merck & Co., 
Inc., Whitehouse Station, NJ, 2006), is also an excellent 
source. For guidelines to the use of biochemical termi-
nology, consult Biochemical Nomenclature and Related 
Documents (Portland Press, London, United Kingdom, 
1992), available at http://www.chem.qmul.ac.uk/iupac 
/biblioglwhite.html, and the instructions to authors of 
the Journal of Biological Chemistry and the Archives of 
Biochemistry and Biophysics (first issues of each year). 
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Molecular weight should not be expressed in daltons; 
molecular weight is a unitless ratio. Molecular mass is 
expressed in daltons. 
For enzymes, use the recommended (trivial) name as 
assigned by the Nomenclature Committee of the Inter-
national Union of Biochemistry (IUB) as described in 
Enzyme Nomenclature (Academic Press, Inc., New York, 
NY, 1992) and its supplements and at http://www.chcm 
.qmul.ac.uk/iubmb/cnzymc/. If a nonrecommended 
name is used, place the proper (trivial) name in paren-
theses at first use in the abstract and text. Use the EC 
number when one has been assigned. Authors of papers 
describing enzymological studies should review the stan-
dards of the S1RENDA Commission for information re-
quired for adequate description of experimental conditions 
and for reporting enzyme activity data (hup://www.bcilstcin 
-institllLdc/cn/projckte/strcnda/guidelincs/). 
Nomenclature of Microorganisms 
Binary names, consisting of a generic name and a 
specific epithet (e.g., Escherichia coli), must be used for 
all microorganisms. Names of categories at or above the 
genus level may be used alone, but specific and subspe-
cific epithets may not. A specific epithet must be pre-
ceded by a generic name, written out in full the first time 
it is used in a paper. Thereafter, the generic name should 
be abbreviated to the initial capital letter (e.g., E. coli), 
provided there can be no confusion with other genera 
used in the paper. Names of all taxa (kingdoms, phyla, 
classes, orders, families, genera, species, and subspecies) 
are printed in italics and should be italicized in the 
manuscript; strain designations and numbers are not. 
Vernacular (common) names should be in lowercase 
roman type (e.g., streptococcus, brucella). For Salmo-
nella, genus, species, and subspecies names should be 
rendered in standard form: Salmonella enterica at first 
use, S. enterica thereafter; Salmonella enterica subsp. ari-
zonae at first use, S. enterica subsp. arizonae thereafter. 
Names of serovars should be in roman type with the first 
letter capitalized: Salmonella enterica serovar Typhi-
murium. After the first use, the serovar may also be 
given without a species name: Salmonella Typhimurium, 
S. Typhimurium, or Salmonella serovar Typhimurium. 
For other information regarding serovar designations, 
see Antigenic Formulae of the Salmonella Serovars, 9th 
ed. (P. A. D. Grimont and F.-X. Weill, WHO Collab-
orating Centre for Reference and Research on Salmo-
nella, Institut Pasteur, Paris, France, 2007; see http://www 
.pasteur.fr/ip/portal/action/WebdrivcActionEvent/oid/Ols 
-000036-089). For a summary of the current standards 
for Salmonella nomenclature and the Kaufmann-White 
criteria, see the article by Brenner et al. (J. Clin. Micro-
bioI. 38:2465-2467, 2000), the opinion of the Judicial 
Commission of the International Committee on System-
atics of Prokaryotes (Int. J. Syst. Evol. Microbiol. 55: 
519-520, 2005), and the article by Tindall et al. (Int. J. 
Syst. Evol. Microbiol. 55:521-524, 2005). 
The spelling of bacterial names should follow the Ap-
proved Lists of Bacterial Names (Amended) & Index of the 
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Bacterial and Yeast Nomenclatural Changes (V. B. D. 
Skerman et aI., ed., American Society for Microbiol-
ogy, Washington, DC, 1989) and the validation lists 
and notification lists published in the International 
Journal of Systematic and Evolutionary Microbiology 
(formerly the International Journal of Systematic Bac-
teriology) since January 1989. In addition, two sites on 
the World Wide Web list current approved bacterial 
names: Bacterial Nomenclature Up-to-Date (hUp: 
/ /www.dsmz.dc/microorganisms/main.php?contentleft 
Jd = 14) and List of Prokaryotic Names with Standing 
in Nomenclature (http://www.bacterio.cict.frl). If there is 
reason to use a name that does not have standing in no-
menclature, the name should be enclosed in quotation 
marks in the title and at its first use in the abstract and the 
text and an appropriate statement concerning the nomen-
clatural status of the name should be made in the text. 
"Candidatus" species should always be set in quotation 
marks. 
Since the classification of fungi is not complete, it is 
the responsibility of the author to determine the ac-
cepted binomial for a given organism. Sources for these 
names include The Yeasts: a Taxonomic Study, 5th ed. 
(c. P. Kurtzman, J. W. Fell, and T. Boekhout, ed., 
Elsevier Science, Amsterdam, Netherlands, 2010), and 
Dictionary of the Fungi, 10th ed. (P. M. Kirk, P. F. Can-
non, and J. A. Stalpers, ed., CABI Publishing, Walling-
ford, Oxfordshire, United Kingdom, 2008); see also http: 
//www.spccicsfungorum.orgiNamcs/Fundic.asp. 
Names used for viruses should be those approved by 
the International Committee on Taxonomy of Viruses 
(ICTV) and reported on the ICTV Virus Taxonomy 
website (http://WWW. ictvonline.orglindex.asp). In addi-
tion, the recommendations of the ICTV regarding the 
use of species names should generally be followed: when 
the entire species is discussed as a taxonomic entity, the 
species name, as with other taxa, is italic and has the first 
letter and any proper nouns capitalized (e.g., Tobacco 
mosaic virus, Murray Valley encephalitis virus). When the 
behavior or manipulation of individual viruses is dis-
cussed, the vernacular (e.g., tobacco mosaic virus, Mur-
ray Valley encephalitis virus) should be used. If desired, 
synonyms may be added parenthetically when the name 
is first mentioned. Approved generic (or group) and 
family names may also be used. 
Microorganisms, viruses, and plasmids should be 
given designations consisting of letters and serial num-
bers. It is generally advisable to include a worker's ini-
tials or a descriptive symbol of locale or laboratory, etc., 
in the designation. Each new strain, mutant, isolate, or 
derivative should be given a new (serial) designation. 
This designation should be distinct from those of the 
genotype and phenotype, and genotypic and phenotypic 
symbols should not be included. Plasmids are named 
with a lowercase "p" followed by the designation in up-
percase letters and numbers. To avoid the use of the 
same designation as that of a widely used strain or plas-
mid, check the designation against a publication data-
base such as Medline. 
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Genetic Nomenclature 
To facilitate accurate communication, it is important 
that standard genetic nomenclature be used whenever 
possible and that deviations or proposals for new nam-
ing systems be endorsed by an appropriate authoritative 
body. Review and/or publication of submitted manu-
scripts that contain new or nonstandard nomenclature 
may be delayed by the editor or the Journals Depart-
ment so that they may be reviewed by the Genetics and 
Genomics Committee of the ASM Publications Board. 
Before submission of manuscripts, authors may di-
rect questions on genetic nomenclature to the commit-
tee's chairperson: Maria Costanzo (maria@genome. 
stanford.edu). Such a consultation should be mentioned 
in the manuscript submission letter. 
Bacteria. The genetic properties of bacteria are de-
scribed in terms of phenotypes and genotypes. The pheno-
type describes the observable properties of an organism. 
The genotype refers to the genetic constitution of an or-
ganism, usually in reference to some standard wild type. 
The guidelines that follow are based on the recommenda-
tions of Demerec et al. (Genetics 54:61-76, 1966). 
(i) Phenotype designations must be used when mutant 
loci have not been identified or mapped. They can also 
be used to identify the protein product of a gene, e.g., 
the ~mpA protein. Phenotype designations generally 
cons1st of three-letter symbols; these are not italicized, 
and the first letter of the symbol is capitalized. It is 
preferable to use Roman or Arabic numerals (instead of 
letters) to identify a series of related phenotypes. Thus, 
a s~ries of nucleic acid polymerase mutants might be 
des1gnated Poll, Po12, and Po13, etc. Wild-type charac-
teristics can be designated with a superscript plus (Pol+), 
and, _when necessary for clarity, negative superscripts 
(Pol ) can be used to designate mutant characteristics. 
Lowercase superscript letters may be used to further 
delineate phenotypes (e.g., Str for streptomycin resis-
tance). Phenotype designations should be defined. 
(ii) Genotype designations are also indicated by three-
letter locus symbols. In contrast to phenotype designations. 
these are lowercase italic (e.g., ara his rps). If several loci 
govern related functions, these are distinguished by itali-
cized capital letters following the locus symbol (e.g., araA 
araB araC). Promoter, terminator, and operator sites 
should be indicated as described by Bachmann and Low 
(Microbiol. Rev. 44:1-56, 1980): e.g., lacZp, laeAl, and 
lacZo. 
(iii) Wild-type alleles are indicated with a superscript 
plus (ara+ his+). A superscript minus is not used to 
indicate a mutant locus; thus, one refers to an ara mu-
tant rather than an ara- strain. 
(iv) Mutation sites are designated by placing serial 
isolation numbers (allele numbers) after the locus sym-
bol (e.g., araA1 araA2). If only a single such locus exists 
or if it is not known in which of several related loci the 
mutation has occurred, a hyphen is used instead of the 
capital letter (e.g., ara-23). It is essential in papers re-
porting the isolation of new mutants that allele numbers 
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be given to the mutations. For Escherichia coli there is 
a registry of such numbers: E. coli Genetic Stock Center 
(http://~gsc.b~ology.yale.edu/). For the genus Salmonella, 
the reg1stry 1S Salmonella Genetic Stock Center (http: 
//people.ucalgary.ca/-kesander/). For the genus Bacil-
lus, the registry is Bacillus Genetic Stock Center (http: 
//www.bgsc.org!). 
(v) The use of superscripts with genotypes (other 
than + to indicate wild-type alleles) should be avoided. 
Designations indicating amber mutations (Am), temper-
ature-sensitive mutations (Ts) , constitutive mutations 
(Con), cold-sensitive mutations (Cs), production of a 
hybrid protein (Hyb), and other important phenotypic 
properties should follow the allele number [e.g., 
araA230(Am) hisD21(Ts)]. All other such designations 
of phenotype must be defined at the first occurrence. If 
su~erscripts must be used, they must be approved by the 
ed1tor and defined at the first occurrence in the text. 
Subscripts may be used in two situations. Subscripts 
may be used to distinguish between genes (having the 
s~e name) .from different organisms or strains; e.g., 
hzsE . coli or hZSK _12 for the his gene of E. coli or strain 
K-12, respectively, may be used to distinguish this gene 
from the his gene in another species or strain. An ab-
breviation may also be used if it is explained. Similarly, 
a subscript is also used to distinguish between genetic 
elements that have the same name. For example, the 
promoters of the gin operon can be designated glnAPl 
and glnAP2' This form departs slightly from that recom-
mended by Bachmann and Low (e.g., desC1p). 
(vi) Deletions are indicated by the symbol t1 placed 
before the deleted gene or region, e.g., t1trpA432, 
t1(aroP-aceE)419, or t1(hisQ-hisJo )1256. Similarly, other 
symbols can be used (with appropriate definition). Thus, 
a fusion of the ara and lac operons can be shown as 
<I>(ara-lac)95. Likewise, <I>(araB'-lacZ+)96 indicates that 
the fusion results in a truncated araB gene fused to an 
intact lacZ gene, and <I>(maIE-lacZ)97(Hyb) shows that 
a hybrid protein is synthesized. An inversion is shown as 
IN(rrnD-rrnE)1. An insertion of an E. coli his gene into 
plasmid pSC101 at zero kilobases (0 kb) is shown as 
pSC101 O(Okb::K-12hisB)4. An alternative designation 
of an insertion can be used in simple cases, e.g., 
galT236::TnS. The number 236 refers to the locus of the 
ins~rti~n,. ~d if the strain carries an additional gal mu-
tatIOn, 1t 1S hsted separately. Additional examples, which 
utilize a slightly different format, can be found in the 
papers by Campbell et al. and Novick et al. cited below. 
It is important in reporting the construction of strains in 
which a mobile element was inserted and subsequently 
deleted that this fact be noted in the strain table. This 
can be done by listing the genotype of the strain used as 
an intermediate in a table footnote or by making a direct 
or parenthetical remark in the genotype, e.g., (F-), t1Mu 
cts, or mal::t1Mu cts::/ac. In setting parenthetical re-
marks within the genotype or dividing the genotype into 
constituent elements, parentheses and brackets are used 
without special meaning; brackets are used outside pa-
rentheses. To indicate the presence of an episome, pa-
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rentheses (or brackets) are used (A, F+). Reference to 
an integrated episome is indicated as described above 
for inserted elements, and an exogenote is shown as, for 
example, W311O/F'8(gal+). 
For information about genetic maps of locus symbols 
in current use, consult Berlyn (Microbiol. Mol. BioI. 
Rev. 62:814-984, 1998) for E. coli K-12, Sanderson and 
Roth (Microbiol. Rev. 52:485-532, 1988) for Salmonella 
serovar Typhimurium, Holloway et al. (Microbiol. Rev. 
43:73-102, 1979) for the genus Pseudomonas, Piggot and 
Hoch (Microbiol. Rev. 49:158-179, 1985) for Bacillus 
subtilis, Perkins et al. (Microbiol. Rev. 46:426-570, 1982) 
for Neurospora crassa, and Mortimer and Schild (Mi-
crobiol. Rev. 49:181-213, 1985) for Saccharomyces 
cerevisiae. For yeasts, Chlamydomonas spp., and sev-
eral fungal species, symbols such as those given in the 
Handbook of Microbiology, 2nd ed. (A. I. Laskin and 
H. A. Lechevalier, ed., CRC Press, Inc., Cleveland, 
OH, 1988) should be used. 
Conventions for naming genes. It is recommended 
that (entirely) new genes be given names that are mne-
monics of their function, avoiding names that are al-
ready assigned and earlier or alternative gene names, 
irrespective of the bacterium for which such assignments 
have been made. Similarly, it is recommended that, 
whenever possible, orthologous genes present in differ-
ent organisms receive the same name. When homology 
is not apparent or the function of a new gene has not 
been established. a provisional name may be given by 
one of the following methods. (i) The gene may be 
named on the basis of its map location in the style yaaA, 
analogous to the style used for recording transposon 
insertions (zef) as discussed below. A list of such names 
in use for E. coli has been published by Rudd (Microbiol. 
Mol. BioI. Rev. 62:985-1019, 1998). (ii) A provisional 
name may be given in the style described by Demerec et 
al. (e.g., usg, gene upstream of folC). Such names should 
be unique. and names such as or! or genX should not be 
used. For reference, the E. coli Genetic Stock Center's 
database includes an updated listing of E. coli gene 
names and gene products. It is accessible on the Internet 
(http://cgsc.biology.yale.edu/index.php).Alist can also 
be found in the work of Riley (Microbiol. Rev. 57:862-
952, 1993). For the genes of other bacteria, consult the 
references given above. 
For prokaryotes, gene names should not begin with 
prefixes indicating the genus and species from which the 
gene is derived. (However, subscripts may be used where 
necessary to distinguish between genes from different 
organisms or strains as described in section v of "Bacte-
ria" above.) For eukaryotes, such prefixes may be used 
for clarity when discussing genes with the same name 
from two di1Ierent organisms (e.g., ScURA3 versus 
CaURA3); the prefixes are not considered part of the 
gene name proper and are not italicized. 
Locus tags. Locus tags are systematic, unique identifi-
ers that are assigned to each gene in GenBank. All genes 
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mentioned in a manuscript should be traceable to their 
sequences by the reader, and locus tags may be used for 
this purpose in manuscripts to identify uncharacterized 
genes. In addition, authors should check GenBank to make 
sure that they are using the correct, up-to-date format for 
locus tags (e.g., uppercase versus lowercase letters and the 
presence or absence of an underscore, etc.). Locus tag 
formats vary between di1Ierent organisms and also may be 
updated for a given organism, so it is important to check 
GenBank at the time of manuscript preparation. 
"Mutant" versus ''mutation.'' Keep in mind the dis-
tinction between a mutation (an alteration of the primary 
sequence of the genetic material) and a mutant (a 
strain carrying one or more mutations). One may 
speak about the mapping of a mutation, but one can-
not map a mutant. Likewise, a mutant has no genetic 
locus, only a phenotype. 
"Homology" versus "similarity." For use of terms 
that describe relationships between genes, consult the 
articles by Theissen (Nature 415:741, 2002) and Fitch 
(Trends Genet. 16:227-231,2000). "Homology" implies 
a relationship between genes that have a common evo-
lutionary origin; partial homology is not recognized. 
When sequence comparisons are discussed, it is more 
appropriate to use the term "percent sequence similar-
ity" or "percent sequence identity," as appropriate. 
Strain designations. Do not use a genotype as a 
name (e.g., " ... subsequent use of /euC6 for transduc-
tion ... "). If a strain designation has not been chosen, 
select an appropriate word combination (e.g., "another 
strain containing the leuC6 mutation"). 
Viruses. The genetic nomenclature for viruses di1Iers 
from that for bacteria. In most instances, viruses have no 
phenotype, since they have no metabolism outside host 
cells. Therefore, distinctions between phenotype and geno-
type cannot be made. Superscripts are used to indicate 
hybrid genomes. Genetic symbols may be one, two, or 
three letters. For example, a mutant strain of A might be 
designated A Aamll int2 red114 cI857; this strain carries 
mutations in genes cI, int, and red and an amber-suppress-
ible ~am) mutation in geneA. A strain designated A att34 
imm 1 would represent a hybrid of phage A that carries the 
immunity region (imm) of phage 21 and the attachment 
(att) region of phage 434. Host DNA insertions into viruses 
should be delineated by square brackets, and the genetic 
symbols and designations for such inserted DNA should 
conform to those used for the host genome. Genetic sym-
bols for phage A can be found in reports by Szybalski and 
Szybalski (Gene 7:217-270, 1979) and Echols and Muri-
aldo (Microbiol. Rev. 42:577-591, 1978). 
Eukaryotes. FlyBase (http://flybase.org/) is the genetic 
nomenclature authority for Drosophila melanogaster. 
WormBase (http://wormbase.orgl) is the genetic nomen-
clature authority for Caenorhabditis elegans. When naming 
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genes for Aspergillus species, the nomenclature guidelines 
posted at http://www.aspergillus.org.uklindcxhome.htm 
'!secure/sequence Jnfo/nomcnclaturc .htm - main should 
be followed, and the Aspergillus Genome Database (http: 
//www.aspgd.org) should be searched to ensure that any 
new name is not already in use. For information about the 
genetic nomenclature of other eulcaryotes, see the Instruc-
tions to Authors for Eukaryotic Cell and Molecular and 
Cellular Biology. 
Transposable elements, plasmids, and restriction en-
zymes. Nomenclature of transposable elements (insertion 
sequences, transposons, and phage Mu, etc.) should 
follow the recommendations of Campbell et al. (Gene 
5:197-206, 1979), with the modifications given in sec-
tion vi of "Bacteria," above. The Internet site where 
insertion sequences of eubacteria and archae a are de-
scribed and new sequences can be recorded is http: 
//WWW-is.biotoul.fr/is.html. 
The system of designating transposon insertions at sites 
where there are no known loci, e.g., zef-123::Tn5, has 
been described by Chumley et al. (Genetics 91:639-
655, 1979). The nomenclature recommendations of 
Novick et al. (Bacteriol. Rev. 40:168-189, 1976) for 
plasmids and plasmid-specified activities, of Low 
(Bacteriol. Rev. 36:587-607, 1972) for F' factors, and 
of Roberts et al. (Nucleic Acids Res. 31:1805-1812, 
2003) for restriction enzymes, DNA methyltransferases, 
homing endonucleases, and their genes should be used 
whenever possible. The nomenclature for recombinant 
DNA molecules, constructed in vitro, follows the nomen-
clature for insertions in general. DNA inserted into recom-
binant DNA molecules should be described by using the 
gene symbols and conventions for the organism from which 
the DNA was obtained. 
Tetracycline resistance determinants. The nomen-
clature for tetracycline resistance determinants is based 
on the proposal of Levy et al. (Antimicrob. Agents Che-
mother. 43:1523-1524, 1999). The style for such deter-
minants is, e.g., Tet B; the space helps distinguish the 
determinant designation from that for phenotypes and 
proteins (TetB). The above-referenced article also gives 
the correct format for genes, proteins, and determinants 
in this family. 
ABBREVIATIONS AND CONVENTIONS 
Verb Tense 
ASM strongly recommends that for clarity you use the 
past tense to narrate particular events in the past, in-
cluding the procedures, observations, and data of the study 
that you are reporting. Use the present tense for your own 
general conclusions, the conclusions of previous research-
ers, and generally accepted facts. Thus, most of the ab-
stract, Materials and Methods, and Results will be in the 
past tense, and most of the introduction and some of the 
Discussion will be in the present tense. 
Be aware that it may be necessary to vary the tense in 
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a single sentence. For example, it is correct to say 
"White (30) demonstrated that XYZ cells grow at pH 
6.8," "Figure 2 shows that ABC cells failed to grow at 
room temperature," and "Air was removed from the 
chamber and the mice died, which proves that mice re-
quire air." In reporting statistics and calculations, it is 
correct to say "The values for the ABC cells are statis-
tically significant, indicating that the drug inhibited .... " 
For an in-depth discussion of tense in scientific writ-
ing, see p. 191-193 in How To Write and Publish a Sci-
entific Paper, 6th ed. 
Abbreviations 
General. Abbreviations should be used as an aid to 
the reader, rather than as a convenience to the author, 
and therefore their use should be limited. Abbreviations 
other than those recommended by the IUPAC-IUB 
(Biochemical Nomenclature and Related Documents, 
1992) should be used only when a case can be made for 
necessity, such as in tables and figures. 
It is often possible to use pronouns or to paraphrase a 
long word after its first use (e.g., "the drug" or "the sub-
strate"). Standard chemical symbols and trivial names or 
their symbols (folate, Ala, and Leu, etc.) may also be used. 
Define each abbreviation and introduce it in parentheses 
the first time it is used; e.g., "cultures were grown in Eagle 
minimal essential medium (MEM)." Generally, eliminate 
abbreviations that are not used at least three times in the 
text (including tables and figure legends). 
Not requiring introduction. In addition to abbrevia-
tions for Systeme International d'Unites (SI) units of 
measurement, other common units (e.g., bp, kb, and 
Da), and chemical symbols for the elements, the follow-
ing should be used without definition in the title, ab-
stract, text, figure legends, and tables: DNA (deoxyribo-
nucleic acid); cDNA (complementary DNA); RNA 
(ribonucleic acid); cRNA (complementary RNA); 
RNase (ribonuclease); DNase (deoxyribonuclease); 
rRNA (ribosomal RNA); mRNA (messenger RNA); 
tRNA (transfer RNA); AMP, ADP, ATP, dAMP, 
ddATP, and GTP, etc. (for the respective 5' phosphates 
of adenosine and other nucleosides) (add 2'-, 3'-, or 5'-
when needed for contrast); ATPase and dGTPase, etc. 
(adenosine triphosphatase and deoxyguanosine triphos-
phatase, etc.); NAD (nicotinamide adenine dinucleoti-
de); NAD+ (nicotinamide adenine dinucleotide, oxi-
dized); NADH (nicotinamide adenine dinucleotide, 
reduced); NADP (nicotinamide adenine dinucleotide 
phosphate); NADPH (nicotinamide adenine dinucle-
otide phosphate, reduced); NADP+ (nicotinamide ade-
nine dinucleotide phosphate, oxidized); poly(A) and 
poly( dT), etc. (polyadenylic acid and polydeoxythymi-
dylic acid, etc.); oligo ( dT), etc. (oligodeoxythymidylic 
acid, etc.); UV (ultraviolet); PFU (plaque-forming 
units); CFU (colony-forming units); MIC (minimal in-
hibitory concentration); Tris [tris(hydroxymethyl)amino-
methane]; DEAE (diethylaminoethyl); EDTA (ethyl-
enediaminetetraacetic acid); EGTA [ethylene glycol-
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bis(f3-aminoethyl ether)-N,N,N' ,N'-tetraacetic acid]; 
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesul-
fonic acid); PCR (polymerase chain reaction); and AIDS 
(acquired immunodeficiency syndrome). Abbreviations 
for cell lines (e.g., HeLa) also need not be defined. 
The following abbreviations should be used without 
definition in tables: 
amt (amount) 
approx (approximately) 
avg (average) 
concn (concentration) 
diarn (diameter) 
expt (experiment) 
exptl (experimental) 
ht (height) 
mo (month) 
mol wt (molecular weight) 
no. (number) 
prepn (preparation) 
SD (standard deviation) 
SE (standard error) 
SEM (standard error of the 
mean) 
sp act (specific activity) 
sp gr (specific gravity) 
temp (temperature) 
tr (trace) 
vol (volume) 
vs (versus) 
wk (weck) 
wt (weight) 
yr (year) 
Drugs and pharmaceutical agents. Should an author 
decide to abbreviate the names of antimicrobial agents 
in a manuscript, the following standard abbreviations are 
strongly recommended. 
(i) Antibacterial agents. Amikacin, AMK; amoxicil-
lin, AMX; amoxicillin-clavulanic acid, AMC; ampicillin. 
AMP; ampicillin-sulbactam, SAM; azithromycin. AZM; 
azlocillin, AZL; aztreonam, ATM; carbenicillin, CAR; 
cefaclor, CEC; cefadroxil, CFR; cefamandole, FAM; ce-
fazolin, CFZ; cefdinir. CDR; cefditoren, CON; 
cefepime, FEP; cefetamet, FET; cefixime, CFM; 
cefmetazole, CMZ; cefonicid, CID; cefoperazone, CFP; 
cefotaxime, crx; cefotetan, CIT; cefoxitin, FOX; cef-
podoxime, CPO; cefprozil, CPR; ceftazidime, CAZ; cef-
tibuten, erB; ceftizoxime, ZOX; ceftriaxone, CRO; ce-
furoxime (axetil or sodium). CXM; cephalexin, LEX; 
cephalothin, CEF; cephapirin, HAP; cephradine, RAO; 
chloramphenicol, CHL; cinoxacin. CIN; ciprofloxacin, 
CIP; clarithromycin, CLR; clinafloxacin. CLX; clinda-
mycin. CLI; colistin. CST; daptomycin. OAP; dicloxacil-
lin, OCX; dirithromycin, OTM; doxycycline. OOX; 
enoxacin, ENX; erythromycin, ER Y; fleroxacin, FLE; 
fosfomycin, FOF; gatifloxacin, GAT; gentamicin, GEN; 
grepafloxacin. GRX; imipenem, IPM; kanamycin, KAN; 
levofloxacin, LVX; linezolid, LZO; lomefloxacin. LOM; 
loracarbef. LOR; meropenem. MEM; methicillin, MET; 
mezlocillin, MEZ; minocycline, MIN; moxalactam, 
MOX; moxifloxacin, MXF; nafcillin, NAF; nalidixic 
acid, NAL; netilmicin, NET; nitrofurantoin, NIT; nor-
floxacin, NOR; ofloxacin, OFX; oxacillin, OXA; penicil-
lin, PEN; piperacillin, PIP; piperacillin-tazobactam, 
TZP; polymyxin B, PMB; quinupristin-dalfopristin 
(Synercid), 0-0; rifabutin, RFB; rifampin, RIF; rifap-
entine, RFP; sparfloxacin, SPX; spectinomycin, SPT; 
streptomycin, STR; teicoplanin, TEC; telithromycin, 
TEL; tetracycline, TET; ticarcillin, TIC; ticarcillin-cla-
vulanic acid, TIM; tigecycline, TGC; tobramycin, TOB; 
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trimethoprim, TMP; trimethoprim-sulfamethoxazole, 
SXT; trovafloxacin, TVA; and vancomycin, VAN. 
(ii) f3-Lactamase inhibitors. Clavulanic acid, CLA; 
sulbactam, SUL; and tazobactam, TZB. 
(iii) Antifungal agents. Amphotericin B, AMB; clo-
trimazole, CLT; flucytosinc, 5FC; fluconazole, FLC; 
itraconazole, ITC; ketoconazole, KTC; nystatin, NYT; 
terbinafine, TRB; and voriconazole, VRC. 
(iv) Antiviral agents. Acyclovir. ACV; cidofovir, 
COY; famciclovir, FCV; foscamet. FOS; ganciclovir, 
GCV; penciclovir, PCV; val acyclovir, VCV; and zidovu-
dine, AZT. 
The use of "nonstandard" abbreviations to designate 
names of antibiotics and other pharmaceutical agents 
generally will not be accepted, because the use of differ-
cnt abbreviations for a single agent has often caused 
confusion. If, on occasion, a nonstandardized abbrevia-
tion for a drug or pharmaceutical substance is used, it 
will be accepted under the following conditions: (i) it 
must be defined at the first use in the text, (ii) it must be 
unambiguous in meaning, and (iii) it must contribute to 
ease of assimilation by readers. 
Chemical or generic names of drugs should be used; the 
use of trade names is not permitted. Avoid the ambiguous 
term "generation" when classes of drugs are described. 
When code names or corporate proprietary numbers are to 
be used, either the chemical structure of the compound or 
a published literature reference illustrating the chemical 
structure, if known, must be provided at the first occur-
rence of the code name or number. For compounds not 
identified by generic nomenclature, all previous or concur-
rent identification numbers or appellations should be listed 
in the manuscript. 
Pharmacodynamic terminology. Pharmacodynamic 
indices (POls) must be introduced at their first occur-
rence in the text and follow guidelines set forth by 
Mouton et al. (J. Antimicrob. Chemother. 55:601-607, 
2005). In Materials and Methods, it should be clearly 
stated how the POls were derived. The most common 
indices used are the following: AUC/MIC ratio (the area 
under the concentration-time curve over 24 h in steady 
state divided by the MIC), AUIC (the area under the 
inhibitory curve; note that the AUC/MIC ratio is not equal 
to the AUIC), %T MIC (the cumulative percentage of a 24-h 
period that the drug concentration exceeds the MIC under 
steady-state pharmacokinetic conditions), CmaxfMIC ratio 
(the peak level divided by the MIC), PTA (probability of 
target attainment), and CFR (cumulative fraction of re-
sponse). aear distinction should be made between 
%T MIO which is expressed as a percentage of the dosing 
interval, and T MIO expressed in hours. It is strongly rec-
ommended that the prefix I be used with an index (e.g., 
IAUC) if the free, unbound fraction of the drug is meant. 
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IJ-Lactamases 
Studies performed to characterize a ~-lactamase or 
the interaction of a compound with a ~-lactamase (i.e., 
as a substrate, inhibitor, or inducer) should follow the 
guidelines set forth by Bush and Sykes (Antimicrob. 
Agents Chemother. 30:6-10,1986). Assays that measure 
the hydrolysis of ~-lactam antibiotics must be appropri-
ate for the substrate examined (e.g., iodometric methods 
are not appropriate quantitative assays for substrates 
whose products are unknown). Reproducibility of results 
must be shown. When referring to ~-lactamases, please 
use the functional designations defined by Bush et al. 
(Antimicrob. Agents Chemother. 39:1211-1233, 1995). 
Alternatively, if the amino acid sequence for the enzyme 
is known, the ~-lactamases may be described by molec-
ular class as initiated by Ambler (Philos. Trans. R. Soc. 
Lond. B BioI. Sci. 289:321-331, 1980). 
A database of defining amino acid alterations for 
many ~-lactamases is maintained at the Internet address 
hltp://www.lahey.orglstudies/. The managers of that site 
should be consulted about the name of a potentially 
novel ~-lactamase sequence before a new designation or 
number is proposed for publication. 
In Vitro Susceptibility Tests 
Tabulate results of determinations of minimal inhibitory 
and bactericidal concentrations according to the range of 
concentrations of each antimicrobial agent required to in-
hibit or kill the members of a species or of each group of 
microorganisms tested, as well as the corresponding con-
centrations required to inhibit 50 and 90% of the strains 
(MICso and MICw, respectively) and those required to kill 
50 and 90% of the strains (MBCso and MBCw, respec-
tively). The MICso and MIC90 reported should be the ac-
tual concentrations tested that inhibited 50 and 90%, re-
spectively, of the strains. They should not be values 
calculated from the actual data obtained. When only six to 
nine isolates of a species are tested, tabulate only the MIC 
range of each antimicrobial agent tested. 
H more than a single drug is studied, insert a column 
labeled "Test agent" between the columns listing the or-
ganisms and the columns containing the numerical data 
and record data for each agent in the same isolate order. 
Cumulative displays of MICs or MBCs in tables or figures 
are acceptable only under unusual circumstances. 
The percentage of strains susceptible and/or resistant 
to an antibiotic at its breakpoint concentration may be 
given only if an appropriate breakpoint has been ap-
proved, as by the Clinical and Laboratory Standards 
Institute, 940 W. Valley Rd., Suite 1400, Wayne, PA 
19087-1898. In the absence of approved breakpoints, 
authors cannot assign breakpoints or use breakpoints 
from related antibiotics. An exploratory analysis tabulat-
ing the percentage of strains inhibited over a range of 
concentrations is acceptable. 
Bactericidal tests must be performed with a sufficient 
inoculum (>5 X lOS CFU/ml) and subculture volume (0.01 
ml) to ensure accurate determination of the 99.9% killing 
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endpoint, as described by Pearson et al. (Antimicrob. 
Agents Chemother. 18:699--708, 1980) and Taylor et al. 
(Antimicrob. Agents Chemother. 23:142-150,1983). Inoc-
ulum size and subculture volume are also critical to studies 
of combinations of antimicrobial agents. 
Synergy is defined in two-dimensional or checker-
board tests when the fractional inhibitory concentration 
(FIC) or fractional bactericidal concentration (FBC) in-
dex (I) is ~0.5. In killing curves, synergy is defined as a 
~2-log1o decrease in CFU per milliliter between the 
combination and its most active constituent after 24 h, 
and the number of surviving organisms in the presence 
of the combination must be ~210glO CFU/mI below the 
starting inoculum. At least one of the drugs must be 
present in a concentration which does not affect the 
growth curve of the test organism when used alone. 
Antagonism is defined by a IFIC or IFBC of >4.0. 
When standard twofold-dilution schemes are used to 
determine checkerboard interactions, the inherent vari-
ability of the method casts doubt on the significance of 
interactions represented by IFICs or IFBCs of >0.5 but 
~4. Therefore, such interactions, if labeled at all, should 
be termed "indifferent." Alternatively, indices in this 
range may be described as "nonsynergistic" or "non an-
tagonistic," as appropriate. The technically imprecise 
term "additive" should be avoided as it is too easily 
misunderstood. See reports by W. R. Greco et al. (Phar-
macol. Rev. 47:331-385, 1995), F. C. Odds (J. Antimi-
crob. Chemother. 52:1, 2003), and M. D. Johnson et al. 
(Antimicrob. Agents Chemother. 48:693-715, 2004) for 
further discussion of these issues. 
For killing curve tests, the minimal, accurately count-
able number of CFU per milliliter must be stated and 
the method used for determining this number must be 
described. In the absence of any drug and with a sample 
size of 1 mI, this number is 30 (1.5 in 10glO) CFU. If 
procedures for drug inactivation or removal have not 
been performed, the author must state how drug car-
ryover effects were eliminated or quantified. For drugs 
showing an inoculum effect, mere dilution below the 
MIC obtained in standard tests is not sufficient. 
Clinical Trials 
(i) Criteria for enrollment. The methods used to find 
and enroll patients and the criteria for enrollment in a 
clinical trial should be stated. In addition, the time period 
(month/year to month/year) of the enrollment should be 
specified. It should be indicated, if appropriate, that written 
informed consent was obtained and that the trial was ap-
proved by the pertinent committee on human subjects. 
(ii) Method of randomization. Randomized, double-
blind studies are preferred. Comparisons using historical 
controls are usually regarded as questionable unless the 
differences in outcome between the groups are dramatic 
and almost certainly the result of the new intervention. 
The rationale for the choice of the control group should 
be explained. The sample size should be justified, and 
the method of randomization should be stated. 
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(iii) Criteria for determining whether a case is evalu-
able. The minimum criteria for evaluability should be 
stated explicitly. For example, it should be stated that the 
minimum criterion for evaluability was a or the combina-
tion of b and c rather than a, b, and c without designating 
which were the minimum criteria. The criteria for evalu-
ability are usually different from those for enrollment. 
(iv) Reasons for nonevaluability. State the number of 
patients in each group who were excluded from evalua-
tion and the reason(s) for each exclusion. 
(v) Criteria for assessment. Define each outcome for 
each category of assessment (e.g., "clinical outcomes 
were classified as cure, improvement, and failure; micro-
biological outcomes were classified as eradication, per-
sistence, and relapse"). The frequency and timing of 
such assessments in relation to treatment should be 
stated. Specify any changes made in the study regimen(s) 
during the trial; the results for regimens with and with-
out such modification generally should be stated sepa-
rately. The criteria (questionnaires, results of specific 
laboratory tests) for evaluation of adverse effects should 
be stated, as should the period encompassed in the as-
sessment and the time of assessment in relation to the 
time of treatment (e.g., daily during treatment). Some 
authors prefer to consider superinfections as failures of 
treatment, whereas others prefer to consider them sep-
arately or even as adverse effects. In any event, the 
manuscript should state the number of superinfections 
with each regimen and should differentiate between su-
perinfections and colonization. The duration of fol-
low-up should be mentioned. 
(vi) Statistical analyses. The type of statistical test 
should be stated and, when appropriate, the reason for 
the choice of test should be given. References should be 
given for statistical procedures other than the t test, 
chi-square test, and Wilcoxon rank sum test. The com-
parability of the treatment groups at the baseline should 
be evaluated statistically. 
For a review of some common errors associated with 
statistical analyses and reports, plus guidelines on how to 
avoid them, see the article by Olsen (Infect. Immun. 
71:6689-6692, 2003). 
For a review of basic statistical considerations for vi-
rology experiments, see the article by Richardson and 
Overbaugh (J. Virol. 79:669-676, 2005). 
(vii) Beta error. For trials which show no statistically 
significant difference between regimens, the authors 
should calculate the probability (~) of a type II error and 
the power of the study (1 - ~) to detect a specified 
clinically meaningful difference in efficacy between the 
regimens. For further details, see the article by Freiman 
et al. (N. Engl. J. Med. 299:690-694, 1978). Alterna-
tively, or in addition, the authors should indicate the 
magnitude of difference between the regimens that 
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could have been detected at a statistically significant 
level with the number of evaluable patients studied. 
For further details, see the editorial on guidelines for 
clinical trials (Antimicrob. Agents Chemother. 33:1829-
1830, 1989). 
Reporting Numerical Data 
Standard metric units are used for reporting length, 
weight, and volume. For these units and for molariW, use 
the grefixes m, ~, n, and p for 10-3, 10-6, 10- • and 
10- ,respectively. Likewise, use the prefix k for 103• 
Avoid compound prefixes such as m~ or ~~. Use ~glml 
or ~glg in place of the ambiguous ppm. Units of tem-
perature are presented as follows: 37°C or 324 K. 
When fractions are used to express units such as en-
zymatic activities, it is preferable to use whole units, such 
as g or min, in the denominator instead of fractional or 
multiple units, such as ~g or 10 min. For example, 
"pmol/min" is preferable to "nmol/lO min," and 
"~mol/g" is preferable to "nmol/~g." It is also preferable 
that an unambiguous form such as exponential notation 
be used; for example, "~mol g-l min-1" is preferable to 
"~mol/glmin." Always report numerical data in the ap-
propriate SI units. 
Representation of data as accurate to more than two 
significant figures must be justified by presentation of 
appropriate statistical analyses. 
For a review of some common errors associated with 
statistical analyses and reports, plus guidelines on how to 
avoid them, see the article by Olsen (Infect. Immun. 
71:6689-6692, 2003). 
For a review of basic statistical considerations for vi-
rology experiments, see the article by Richardson and 
Overbaugh (J. Virol. 79:669-676, 2005). 
Isotopically Labeled Compounds 
For simple molecules. labelin§ is indicated in the 
chemical formula (e.g., 14C02, -H20, and H2"S04)' 
Brackets are not used when the isotopic symbol is at-
tached to the name of a compound that in its natural 
state does not contain the element (e.g., 32S_ATP) or to 
a word that is not a specific chemical name (e.g., 1311_ 
labeled protein, 14C-amino acids, and 3H-ligands). 
For specific chemicals, the symbol for the isotope in-
troduced is placed in square brackets directly preceding 
the part of the name that describes the labeled entity. 
Note that configuration symbols and modifiers precede 
the isotopic symbol. The following examples illustrate 
correct usage: 
[14C]urea 
L-[methyl-14C]methionine 
[2,3-~H]serine 
[a-14C]Jysine 
[-y_~2P}A TP 
UDp_[U_14C]g1ucose 
E. coli [32p}DNA 
fructose 1,6-[1-~2P)bisphosphate 
AAC follows the same conventions for isotopic label-
ing as the Journal of Biological Chemistry, and more-
detailed information can be found in the instructions to 
authors of that journal (first issue of each year). 
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